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ABSTRACT 
 
 
 Hematological malignances of the B cells affect almost 130,000 people in the 
United States every year of which approximately 44,000 lose their lives. Therapies for B 
cell malignancies such as doxorubicin, have limitations due to dose related adverse 
effects such as neutropenia and cardiomyopathy. AD 198 is a novel PKC-delta activating 
agent that has cytotoxic superiority over doxorubicin by being able to circumvent 
resistance mechanisms developed by the cancer cells towards doxorubicin and being 
cadioprotective from the damage caused to cardiomyocytes by doxorubicin. Targeted 
delivery of AD 198 is crucial to moderate the non-specific interactions of the 
chemotherapeutic agent with healthy cells. The objective of this work was to design, 
develop and evaluate AD 198 loaded liposomal formulations for targeted delivery to 
CD22 overexpressing B cell cancers. Liposomes were prepared by the classical Bangham 
method followed by size reduction by extrusion. Anti-CD22 Fab’ were generated and 
conjugated to the long circulating AD 198 liposomes by thioether bonds. Physico-
chemical parameters of the CD22 targeted liposomal formulation such as size, zeta-
potential, drug encapsulation, drug release and drug targeting were optimized to 
maximize efficacy and stability of the nanoparticles. In vitro studies established that 
uptake of the targeted liposomes was via an endocytotic pathway independent of the 
conventional proteins involved in clathrin and caveolae dependent endocytosis. Uptake 
was preferentially higher in CD22 overexpressing malignant B cells (Daudi) compared to 
cells devoid of CD22 (Jurkat). Intracellular localization of the targeted liposomes was 
observed to be in endolysosomes which suggests that drug release was via lysosomal 
enzymatic breakdown of the liposomal structure which would release encapsulated AD 
198. Cytotoxicity was also observed to be higher in Daudi cells compared to Jurkat cells 
whereas free solution AD 198 had comparable cytotoxicity in both cell types. The 
mechanism of cell death was deduced to be apoptosis by the activation of apoptotic 
proteins such as caspase-3, and by the inhibition of oncoproteins such as c-myc. Stability 
of the dispersed liposomal formulation was inadequate for long term storage. To address 
this concern, lyophilized formulations were developed and optimized to maximize long 
term storage as displayed by short term stability studies. It was determined that targeted 
drug delivery with liposomal AD 198 was more potent and specific compared to other 
untargeted formulations.  
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CHAPTER 1.    INTRODUCTION* 
 
 
1.1. Statement of the Problem 
 
 Cancers are tissue/organ specific and may manifest as solid tumours such as 
breast cancer or lung cancer or can be circulating as in hematopoietic malignancies. B 
cell malignancies are characterized as hematopoietic malignancies (Harris et al., 2000, 
Mittal et al., 2014). Hematopoietic malignancies mostly occur due to uncontrolled 
proliferation of the leukocytes. These include the leukemias and lymphomas (Swerdllow 
et al., 2008). One of the main causes for the development of B cell malignancies are 
genetic abnormalities. Various genes are over expressed such as cell cycle control genes, 
cell cycle checkpoint genes and DNA synthesis and replication genes. As an example, the 
gene Ki67 is commonly used to determine the extent of proliferation of the malignancy 
(Alizadeh et al., 2000). In the United States, B cell malignancies are the most common 
cause of cancer in children at birth and up to 19 years of age. Approximately 130,000 
people in the United States are expected to be diagnosed with a B cell malignancy in the 
year 2015, of which about 44,000 will lose the battle against this lethal disease. (The 
Leukemia and Lymphoma Society, 2014, Delarue et al., 2013) 
 
 Depending on the type of cancer, chemotherapy is often considered to be a 
debilitating aspect of therapeutic intervention. The stage of progression of the tumour 
determines the treatment options and can range from surgery to chemotherapy and/or 
radiation (Brannon-Peppas and Blanchette, 2004, Love et al., 1989). Although the type 
and stage of cancer dictates the treatment options, chemotherapy is the primary treatment 
option for haematological malignancies. Limitations of solution chemotherapy include 
lack of cell specificity, development of resistance mechanisms and debilitating adverse 
effects such as loss of function of healthy tissue, nausea, vomiting and tiredness (Zhang 
et al., 2007, Sahoo et al., 2007).  
 
 To this end, the past decade has seen significant advancements in the field of 
nanotechnology and has provided researchers with the means to overcome some of these 
limitations and develop superior drug delivery systems. One type of nanoparticles are 
liposomes, that are nanosized vesicles with unilamellar or multilamellar phospholipid 
bilayers that surround aqueous compartments. Figure 1.1 illustrates the most important 
components of a liposome. Depending on the physicochemical characteristics of the 
therapeutic molecules, they can be encapsulated either in the bilayer or in the aqueous 
core of the liposome. These specialized nanoparticulate carrier systems can be designed 
to deliver a range of therapeutic entities ranging from small molecule drugs to peptides, 
proteins and nucleic acids.  
 
 They can be made to target specific cancer cells thus increasing drug efficacy and 
------------------- 
*Adapted with permission. Mittal, N. K., Bhattacharjee, H., Mandal, B., Balabathula, P., 
Thoma, L. A. & Wood, G. C. (2014). Targeted liposomal drug delivery systems for the 
treatment of B cell malignancies. J Drug Target, 22, 372-86.  
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Figure 1.1. Components of unilamellar liposomal drug formulations 
 
Notes. Hydrophilic drugs are encapsulated in the aqueous core, whereas hydrophobic 
drugs are incorporated into the lipid bilayer (Zamboni, 2005, Molema, 2001). The bilayer 
is principally composed of a phospholipid such as phosphatidylcholine. Cholesterol 
molecules impart some degree of rigidity to the bilayer thus increasing bilayer stability, 
mDSPE-PEG2000 (methoxy-distearoyl phosphatidylethanolamine – polyethylene glycol 
2000) molecules make the liposome surface more hydrophilic which aid in escape from 
removal by the immune cells, mal-DSPE-PEG2000 (1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000]) serves as an anchor 
where the targeting ligands can be conjugated, and the targeting ligand can be any 
molecule that can be specific for a particular cancer tissue. The targeting ligands shown 
here are half-antibody molecules and Fab´ (antigen binding fragment) of the antibody. 
These systems are modified to make them more compatible with the type and or 
physiology of the targeted tissue (Davis et al., 2008).  
 3 
reducing the non-specific actions of the drug, which eventually reduces the adverse 
effects (Bharali and Mousa, 2010).  Liposomes aim at achieving selectivity towards the 
malignant cells by harnessing the targeting ability of several cell surface markers which 
are over-expressed exclusively in certain malignant cells. CD19, CD20, CD22 and CD74 
are a few of the markers over-expressed on malignant B cells (Sapra and Allen, 2002).  
 
 Another significant feature of these systems is their ability to overcome multi-
drug resistance (MDR) which is a major problem in chemotherapy (Thierry et al., 1993). 
One of the mechanisms for MDR is via P-glycoprotein (P-gp), an efflux pump, which 
drives the therapeutic molecules out of the cancer cells. Nanoparticles such as liposomes 
are designed to utilize the enhanced permeability and retention (EPR) effect to exit the 
blood vessels in the tumour and target the surface receptors on tumour cells. Figure 1.2 
shows how the liposomes then enter the cells by endocytosis without being recognized by 
P-gp producing a longer activity at the cancerous cell (Brigger et al., 2002). 
 
 The treatment of blood malignancies employing targeted particulate drug delivery 
systems still presents unique challenges and considerable research has been focused 
towards the development of targeted liposomal formulations for B cell leukemias and 
lymphomas. A number of studies have demonstrated the advantages of targeted liposomal 
systems encapsulating doxorubicin or vincristine (Mayer et al., 1994, Rodriguez et al., 
2009, Sapra et al., 2004, Sarris et al., 2000). In this study, liposomal encapsulation of 
newer anti-neoplastic agents which are superior to doxorubicin are considered. N-
benzyladriamycin-14-valerate (AD 198) is a newer lipophilic anthracycline, which is 
superior to doxorubicin (DOX) in murine cancer models and has novel biochemical 
pathways and pharmacological properties (He et al., 2005). It has been shown that the 
cells that had developed (multiple drug resistance) MDR toward DOX, were sensitive to 
AD 198 (Cai et al., 2010, Edwards et al., 2013, Ganapathi et al., 1989). The 
cardiotoxicity manifested by DOX is also absent in AD 198 and that was one of the 
rationales for AD 198 development. While the pharmacological and biochemical 
superiority of AD 198 over DOX has been proven by Ganapathi et al (Ganapathi et al., 
1989), its usefulness in targeted drug delivery was yet to be determined. In the present 
study an AD 198 loaded targeted liposomal system for B cell malignancies has been 
developed.  
 
 
1.1.1. The drug – AD 198 
 
 Figure 1.3 shows the structure of N-benzyladriamycin-14-valerate or AD 198, a 
protein kinase C (PKC) activating agent that demonstrates cytotoxic superiority over 
doxorubicin (Hofmann et al., 2007). It does so by circumventing multiple mechanisms of 
drug resistance to which doxorubicin is susceptible. The mechanism of action of AD 198 
(Figure 1.4) induced cell death is entirely different from that of doxorubicin. 
Doxorubicin functions by preferential binding to chromosomal DNA of intact cells 
(Momparler et al., 1976).  
 
 Conversely, AD 198 functionality does not depend on binding to DNA. It 
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Figure 1.2. Nanoparticles can overcome surface efflux pump mediated drug 
resistance 
 
Notes. Nanoparticles are designed to utilize the EPR effect to exit blood vessels in the 
tumor, to target surface receptors on tumor cells, and to enter tumor cells by endocytosis 
before releasing their drug payloads. This method of delivery allows for high intracellular 
drug concentrations that can overcome efflux-pump mediated drug resistance (Davis et 
al., 2008)  
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Figure 1.3. Structure of N-benzyladriamycin-14-valerate (AD 198) 
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Figure 1.4. AD 198 mechanisms of action 
 
Notes: AD 198 actions are not very well defined. Information known is that AD 198 
binds to PKC, thus activating the holoenzyme. This activation is sufficient to produce 
pro-apoptotic effects. Later the catalytic segment (CS) dissociates from the PKC-δ. The 
CS activates at least three downstream molecules. One is PLS3 (phospholipid scramblase 
3) which depolarizes the mitochondria releasing cytochrome c (Cyt C). Cyt C has two 
effects, one is to release Ca+2 ions from the endoplasmic reticulum and second to 
activate caspases (primarily caspase 3). Caspase 3 eventually results in apoptosis. The 
second molecule activated by CS is PLS1 (phospholipoid scramblase 1) which 
depolarizes the cell membrane that causes the cell to undergo apoptosis. However, AD 
198 is also cytotoxic in cells that do not express PLS1 such as HL60 cells. The CS also 
phosphorylates Rad9, which in turn depolarizes the nuclear membrane also resulting in 
apoptosis.  
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functions by the activation of a PKC-δ induced cascade of apoptotic mechanisms (He et 
al., 2005, Lothstein et al., 2006). AD 198 does not display the cardiotoxic property of 
doxorubicin. Moreover, it is cardioprotective to the cardiomyocytes from the damage 
caused by doxorubicin therapy (Cai et al., 2010). Previously it was known that the 
cardiotoxicity of doxorubicin is due to the generation of reactive oxygen species (ROS) 
from the semi-quinone ring. Although the same ring is also present in AD 198 structure, 
Hofmann et al hypothesized that the cardioprotective nature of AD 198 was due to its 
ability to activate PKC-ε (Hofmann et al., 2007). PKC-ε is a key component of protective 
ischemic preconditioning which prevents cardiac damage (Murry et al., 1986). Recent 
studies have now proven that the cardiotoxicity of doxorubicin is due to its activity as a 
poison to topoisomerase II beta (TOP2B). Zhang et al (Zhang et al., 2012) have shown 
that the deletion of TOP2B in mice prevents doxorubicin mediated cardiotoxicity.  
 
 Nevertheless, AD 198 is no wonder drug with all advantages and no limitations. 
Recently, an unpublished drug evaluation study of solution AD 198 in dogs conducted by 
Paradox Pharmaceuticals Inc. shows that AD 198 has adverse effects such as neutropenia 
and thrombocytopenia similar to other chemotherapeutic drugs. Figures 1.5 – 1.8 are 
results from this study that indicate that there was some level of liver and kidney injury 
after solution AD 198 therapy. As specified earlier, these injuries are due to interactions 
of the drug with non-target or healthy tissues. Development of a targeted long circulating 
liposomal AD 198 drug delivery system will impart specificity to the drug action thus 
increasing efficacy and reducing adverse effects.  
 
 
1.1.2. The disease – B cell malignancies 
 
 B cell malignancies are characterized as hematopoietic malignancies (Harris et al., 
2000). Hematopoietic malignancies mostly occur due to the uncontrolled proliferation of 
the leukocytes, which include the leukemias and lymphomas. B cell malignancies can be 
categorized into two broad classes – precursor B cell neoplasms, which include B cell 
lymphomas and leukemias, and the mature B cell neoplasms (Swerdllow et al., 2008, 
Harris et al., 2000). Table 1.1 summarizes the classification of B cell neoplasms. Both 
lymphomas and leukemias are often included in the same classification, as both solid and 
circulating phases as present in lymphoid neoplasms. For example, B cell chronic 
lymphocytic leukemia (CLL) and B cell small lymphocytic lymphoma (SLL) are 
different manifestations of neoplasm of the same cell. The distinction between the two 
being that CLL is primarily circulating whereas SLL presents itself at the lymph nodes. B 
cell malignancies can either be indolent or rapidly proliferating. CLL and follicular 
lymphoma (FL) are rather indolent (Alizadeh et al., 2000) compared to the other types of 
B cell malignancies. This is derived primarily due to the observation that they manifest as 
clusters in proximity to the resting B cells.  
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Figure 1.5. Mean change in neutrophil count after solution AD 198 treatment 
(n=3) 
 
Notes. Mean drop in white blood cells (WBC’s), mainly neutrophils was approximately 
40% on day 7 after treatment with solution AD 198 (unpublished drug evaluation study 
of solution AD 198 in dogs conducted by Paradox Pharmaceuticals Inc). Error bars 
represent standard deviation around the mean.  
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Figure 1.6. Alanine transaminase (ALT) levels after AD 198 treatment (n=3) 
 
Notes. ALT levels measure liver health and change in these levels indicate liver 
damage/disease. In this figure we can see a drop in ALT levels by almost 50% after 
solution AD 198 treatment (unpublished drug evaluation study of solution AD 198 in 
dogs conducted by Paradox Pharmaceuticals Inc). Error bars represent standard 
deviation around the mean.  
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Figure 1.7. Mean change in alkaline phosphatase levels after solution AD 198 
treatment (n=3) 
 
Notes. Alkaline phosphatase levels are also indicative of liver health. Typically, increased 
levels of alkaline phosphatase denote diseases of the liver/ liver damage.  In this study, 
alkaline phosphatase levels rose almost 4 times the normal range (unpublished drug 
evaluation study of solution AD 198 in dogs conducted by Paradox Pharmaceuticals Inc). 
Error bars represent standard deviation around the mean.  
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Figure 1.8. Mean blood urea nitrogen (BUN) after solution AD 198 treatment 
(n=3) 
 
Notes. BUN is indicative of renal health. If diet is kept approximately the same, increased 
levels of BUN indicate lower excretion by kidneys indicating kidney damage. Post 
solution AD 198 treatment BUN levels were higher by 60% of the normal levels 
(unpublished drug evaluation study of solution AD 198 in dogs conducted by Paradox 
Pharmaceuticals Inc). Error bars represent standard deviation around the mean. 
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Table 1.1. Types of B cell neoplasms 
 
  
Precursor B cell neoplasm Mature (peripheral) B cell neoplasms 
Precursor B-lymphoblastic 
leukemia/lymphoma 
(precursor B cell acute 
lymphoblastic leukemia) 
B cell chronic lymphocytic /small lymphocytic 
lymphoma 
B cell prolymphocytic leukemia 
Lymphoplasmacytic lymphoma 
Splenic marginal zone B cell lymphoma (+/- villous 
lymphocytes) 
Hairy cell leukemia 
Plasma cell myeloma/plasmacytoma 
Extranodal marginal zone B cell lymphoma of MALT 
type 
Nodal marginal zone B cell lymphoma (+/- 
monocytoid B cells) 
Follicular lymphoma 
Mantle-cell lymphoma 
Diffuse large B cell lymphoma 
Mediastinal large B cell lymphoma 
Primary effusion lymphoma 
Burkitt’s lymphoma/Burkitt cell leukemia 
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1.1.3. Therapies for B cell malignancies 
 
 Currently available therapies for haematological malignancies of the B cells can 
be divided into conventional, advanced and experimental therapies. These therapies are 
currently in use, those which are used by a few patients today and those in which most 
are currently under clinical trials. Conventional therapies include treatment options like  
chemotherapy, bone marrow transplantation (BMT) and radiation therapy (Leonard, 
1998).  
 
 Chemotherapy is a treatment modality, employing anti-neoplastic drug’s 
administered either parenterally, or orally to eradicate malignant cells.  
Combinations of two or three chemotherapeutic agents are common treatment regimens, 
with CHOP being the standard (Leonard, 1998). CHOP therapy consists of 
cyclophosphamide, hydroxydaunorubicin (doxorubicin), Oncovin® (vincristine) and 
prednisone. For an overview of the most currently used chemotherapeutic drugs the 
reader is advised to read a report by the Leukemia and Lymphoma Society (The 
Leukemia and Lymphoma Society, 2014). Chemotherapeutic agents function by 
truncating the growth and division of cancer cells that have a much higher rate of 
development compared to normal tissues. However, the non-specific nature of these 
treatments, result in loss of healthy tissue. This property is seen to cause considerable 
adverse effects which are due to the inherent toxicity of the chemotherapeutic agents 
(Mackey et al., 2012, Soultati et al., 2012, Marchese et al., 2011). In recent years attempts 
have been focused on eradicating these adverse effects using the application of 
nanoparticulate drug delivery systems.  
 
 Advanced therapies include biological therapies such as cytokines, monoclonal 
antibodies (Gupta and Kanodia, 2002, Cheson and Leonard, 2008) and antibody drug 
conjugates (ADC’s)(Carter and Senter, 2008, Senter, 2009), whereas experimental 
therapies include approaches that are based on sophisticated drug delivery platforms 
(mainly targeted nanoparticles such as liposomes) that directly and indirectly show 
promise of effectively treating blood malignancies. Nanoparticles such as liposomes can 
also be made to target specific tissues by immobilizing target specific molecules on their 
surface (Torchilin, 1994). One such class of molecules are antibodies and antibody 
conjugated liposomes are often referred to as immunoliposomes.  
 
 In the following sections emphasis has been given specifically on liposomal 
systems developed for B cell malignancies. Types of targeting, barriers to delivery of 
liposomes to B cell malignancies, specific approaches in active targeting to malignant B 
cells, the impact of liposomal construct design and selections of targeting agents are 
extensively discussed.  
 
 
1.2. Nanoparticle Targeting 
 
 Most research activities initiated and studied employing targeted drug delivery 
systems are associated with solid tumours. A mechanistic understanding of nanoparticle 
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targeting to malignant tissues can be explained by two well-studied phenomenon; 1) 
passive targeting and 2) active targeting (Danhier et al., 2010). These processes have 
been extensively discussed in the literature and the reader is directed to multiple reviews 
for a comprehensive study of these phenomenon (Hirsjärvi et al., 2011, Byrne et al., 
2008).  Briefly, passive targeting takes advantage of the EPR effect. Here the nanosized 
particles tend to accumulate in the tumours due to leaky angiogenic vasculature and poor 
lymphatic drainage. The EPR effect has been shown to be effective in particles of only a 
particular size range, the cut-off for which is between 400-600 nm. However, the EPR 
effect is not seen in sizes below 100 nm (Society, 2013, Matsumura and Maeda, 1986). 
This is because the smaller particles can diffuse freely in and out of the tumour 
vasculature. Therefore their concentration in the tumour site falls once their concentration 
in the plasma decreases. Nanoparticles behave as macromolecules which are big enough 
to escape renal clearance (Longmire et al., 2008). Even though they cannot pass through 
normal vasculature, extravasation through tumour vasculature can take place with ease 
due to the EPR effect. Thus their concentration inside the tumour increases steadily and 
goes many folds above that of the plasma as the lymphatic drainage in the tumour is poor 
(Greish, 2007, Iyer et al., 2006). This effect can be exemplified by the study of a 
polymer-protein conjugate SMANCS (Styrene maleic acid neocarzinostatin). SMANCS 
is neocarzinostatin modified with a synthetic polymer [(styrene)l -3(maleic acid4-
7/anhydride1)]. Maeda and co-workers have shown that these particles accumulate in the 
tumours at a higher concentration than the protein alone (Maeda et al., 1979, Maeda, 
2001). This phenomenon was attributed to the presence of a high concentration of 
vascular permeability factors such as bradykinin, nitric oxide, peroxynitrate and VPF 
(vascular permeability factor, which is identical to VEGF) in the tumour tissue all of 
which are shown to be retained inside the solid tumours in excess of 100 hours. Excessive 
accumulation in the lymph nodes is also noticed for these macromolecules in contrast to 
the small molecule drugs. The efficacy of targeting via the EPR effect has been shown in 
many types of solid tumours (Maeda et al., 2000). Figure 1.9 displays how EPR occurs 
in cancerous tissues.  
 
 However, once in the tumour microenvironment, these particles may not be taken 
up by the cells or release the drug. It is due to this uncertainty; that most bio-recognition 
molecules are conjugated onto the surface of the nanoparticle to enhance specificity. This 
is an active targeting approach which not only distinguishes between normal cells and 
cancer cells but also between different types of cancer (Wang and Thanou, 2010). These 
moieties decide the final destination of the particles, which are cell surface proteins 
overexpressed on cancer cells. Figure 1.10 shows that once the ligand is bound to its 
receptor on the cancer cell, the particle is either engulfed by the process of receptor 
mediated endocytosis (Davis et al., 2008) or its interaction with the cell surface induces 
drug leakage. This leaking drug ultimately enters the cell via diffusion (Düzgüneş and 
Nir, 1999).  
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Figure 1.9. Mechanism of the EPR effect 
 
Notes. (A) Normal Tissue: Nanoparticles (NPs) generally do not exocytose through 
normal tissue which has normal development of endothelial and smooth muscle cells. (B) 
Malignant Tissue: NPs in the effective size range extravasate the abnormal vasculature 
having wide fenestrations. 
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Figure 1.10. Nanoparticles can enter cells via endocytosis 
 
Notes. This figure shows a transmission electron micrograph of nanoparticles at the 
surface of a cancer cell, entering the cell and within endocytic vesicles (Davis et al., 
2008).  
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1.3.  Barriers for Delivery of Chemotherapeutics to B Cell Malignancies Using 
Immunoliposomes as Carriers 
 
 The key contrast between targeting solid tumors and targeting cancers that have a 
largely floating population of malignant cells, such as B cell malignancies, is that solid 
tumors can be targeted via both the targeting procedures; i.e. passive and active targeting.  
Thus, when chemotherapeutic agents are targeted to a solid tumor, for example breast 
cancer, using an immunoliposomal delivery system, the malignant cells will experience a 
drug concentration which is a result of the EPR effect in addition to the binding of the 
immunoliposome to its specific receptor on the malignant cells. However, passive 
targeting would not be an option for the floating malignant cells as the EPR would be 
ineffective due to lack of the anatomy required for EPR. The only method available to 
target circulating malignant cells would be by active targeting, which is by targeting 
specific overexpressed receptors on the surface of the B cells primarily. Hence, targeting 
immunoliposomal chemotherapy to B cell cancers is not the same as targeting the same 
delivery system to solid tumors. A number of additional barriers to targeting 
immunoliposomes to cancers have been discussed by Peer et al (Peer et al., 2007). A brief 
discussion on the most significant factors is given here.  
 
 The efficacy of antibody targeted drug delivery systems relies immensely on the 
specific binding of the targeting monoclonal antibody (mAb)-drug delivery system 
conjugate with the receptor to which it is targeted (DiJoseph et al., 2006). To actively 
target immunoliposomes to a particular type of cancer, the choice of surface receptor 
targeted is critical. To maximize targeting efficiency, the surface receptor must be 
overexpressed on the malignant cells relative to the normal cells. In the case of B cells, 
CD19 is one such receptor that is overexpressed on malignant B cells. An optimum 
receptor density would be 104-105 copies per cell (Peer et al., 2007). However, as one 
particular receptor is constantly targeted, the immune system potentially down-regulates 
or even eliminates the antigen being targeted. This is known as ‘immunoediting’ (Dunn et 
al., 2002).  
 
 Also, CD19 is an internalizing receptor, which means that upon ligand binding, it 
undergoes receptor mediated endocytosis, thus delivering the entire drug load inside the 
CD19+ malignant B cell. This results in higher drug concentrations inside the cell 
compared to the immunoliposomes targeted to non-internalizing receptors such as CD20 
(Sapra and Allen, 2002). The binding affinity between the ligand and receptor must also 
be optimum as shown by Allen (Allen, 2002). A higher affinity between the receptor and 
ligand promotes binding but eventually prevents internalization.  
 
 Another debate exists regarding the use of whole mAbs or their fragments. As 
discussed by Allen (Allen, 2002), use of whole antibodies for targeting purposes is 
always advantageous due to the presence of two binding sites on a single antibody. 
However, the crystallizable fragment (Fc) of a whole mAb can also bind to the Fc 
receptor of normal cells thus increasing immunogenicity. Another advantage of using 
whole mAb is the stability it has during long term storage. Although advantages of 
employing whole antibodies rather than their fragments for targeting purposes exists, 
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research is slowly shifting towards the use of fragmented antibodies since they are safer 
and display reduced non-specific binding (Cheng and Allen, 2008, Loomis et al., 2010, 
Sapra et al., 2004).  
 
 Rapid clearance by the reticulo-endothelial system (RES) and MPS (mononuclear 
phagocytic system) is another challenge faced by lipid based drug delivery systems. This 
can be overcome by using PEGylated liposomes. However, this is not always the case as 
there are also non-pegylated liposomes such as Daunosome® and Myocet® in the market 
today, although their circulation times are not as long as the pegylated liposomes such as 
Doxil®.  
 
 Pegylated liposomes are themselves susceptible to a phenomenon called 
accelerated blood clearance (ABC) (Ishida et al., 2006). This process causes the rapid 
clearance of pegylated liposomes from circulation upon repeated injection. PEG specific 
IgM antibodies are secreted by the B cells (Ichihara et al., 2011), which increase in 
concentration after the first dose is injected. Thus, the first dose is unaffected by this 
phenomenon. However the second dose is exposed to the anti-PEG IgM’s secreted and is 
thus rapidly cleared. Ishida et al. reported that this phenomenon is inversely dependent on 
the concentration of the phospholipids injected. A concentration of 5 μM total 
phospholipids failed to induce ABC; however, a concentration of 1 μM did induce the 
immune response. Another criterion for the immune reaction as reported by the group, is 
that DOX loaded pegylated liposomes will mount a much weaker response as compared 
to placebo liposomes. Therefore it is essential to identify the appropriate concentration of 
drug and lipid to facilitate maximum circulation time in the blood.  
 
 
1.4. Targeted Liposomal Systems for B Cell Malignancies 
 
 It has been suggested that targeting of B cell lymphomas can occur by leveraging 
the EPR effect (Xiao et al., 2011). However, this is yet to be demonstrated and lacks 
literature evidence. The answer may be inherent in the problem itself where it is known 
that the leukemias generally do not manifest as solid tumour and hence do not exist as a 
malignant tissue with leaky vasculature. This physiological fact precludes the use of the 
passive targeting approach via the EPR effect. This being said, different types of 
lymphomas have different manifestations and in some instances the lymph nodes are 
affected. In such manifestations of the disease the EPR effect may be used effectively 
(Xiao et al., 2011), but for malignant cells in circulation, active targeting becomes vital.  
 
 In one approach for targeted delivery the drug molecule is conjugated to the 
antibody directly. These molecules are known as ADC’s. This has limitations in terms of 
loss of antibody specificity, drug activity, long purification times, and stability and also in 
terms of the economic viability, as coupling each drug molecule with a molecule of 
antibody, proves to be an expensive therapeutic option. These shortcomings have 
encouraged the development of other systems that are capable of carrying a higher drug 
load with the usage of comparatively fewer antibodies, carbohydrate molecules or any 
other targeting ligands, compared to the number of drug molecules that they carry. There 
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are a number of ADC products used in the clinic today such as Gemtuzumab ozogamicin 
and Inotuzumab ozogamicin. Gemtuzumab is specific for CD33 and Inotuzumab is 
specific for CD22. Both these receptors are overexpressed in the respective B cell 
malignancies (Alley et al., 2010). A major advantage of a liposomal drug delivery system 
is the potential for surface modification lending it as a versatile system. A number of 
targeting molecules or ligands conjugated to nanoparticulate drug delivery systems have 
been explored for the treatment of haematological malignancies (Lopes de Menezes et al., 
1998, de Menezes et al., 1999, Ishida et al., 2001, Sapra and Allen, 2004, Sapra et al., 
2004, Allen et al., 2005, Cheng and Allen, 2008). Additionally, the use of specific lipids 
such as, lipid-PEG conjugates when inserted into the liposomal structure, afford superior 
targeting and pharmacokinetic behaviours (Newman et al., 1999).  
 
 
1.5. Epitopes Targeted by Liposomal Systems for B Cell Malignancies 
 
 One of the advantages of using liposomes for drug delivery is their ability to 
afford a higher therapeutic index from drugs with a low therapeutic index (Bhattacharjee 
et al., 2010). Another advantage is their biodegradable nature that has made them an 
attractive option to deliver the cytotoxic drugs for the treatment of cancer. Currently there 
is at least one liposomal product that is approved by the FDA for use in patients with 
acute lymphoblastic leukemia (ALL) (Rodriguez et al., 2009). Table 1.2 gives 
comprehensive information about liposomal drugs that are currently approved for 
marketing or in different stages of clinical and pre-clinical trials.  The formulation 
characteristics of this liposomal product, called Marqibo®, are discussed later in this 
section (Sarris et al., 2000). A liposomal annamycin product which shows promise for 
treatment of paediatric relapsed ALL is currently in phase 1 clinical trials (Booser et al., 
2002).  Another liposomal product called LEM-ETU, encapsulating Mitoxantrone, is in 
Phase 1 clinical trials (Chang and Yeh, 2012). A review of liposomal drug products 
currently approved by the FDA and those in various stages of clinical trials can be found 
in Allen and Cullis (Allen and Cullis, 2013) and Chang and Yeh (Chang and Yeh, 2012). 
Maqibo® is a passively targeted liposome and so are the ones in clinical trials mentioned 
above. This review of literature attempts to summarize the efforts of various groups with 
a focus on actively targeted liposomal systems for the therapy of lymphoproliferative 
disorders.  
 
 Targeting may be achieved actively or in a passive way. In case of active 
targeting, for B cells, the targets can be either internalizing such as CD19, CD22 and 
CD74 or non-internalizing such as CD20 (Sapra and Allen, 2002). The mechanism by 
which the drug reaches its site of action (the nucleus for most drugs) is different for both 
types of targets. For non-internalizing epitopes, the drug gets released slowly at the cell 
surface and subsequently enters the cell by passive diffusion or other transport 
mechanisms. It is speculated that the rate at which the drug diffuses away from the site 
exceeds the rate at which the drug enters the cell and thus the complete drug load is not 
utilized even though it is delivered near the site of action.  
 
 However, in case of internalizing epitopes, the drug load in the liposome is 
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Table 1.2. Liposomal drugs currently approved for marketing or in pre-
clinical/clinical trials 
 
Drug Receptor 
targeted 
Model Results Reference 
Marketed 
Vincristine 
(Marqibo®) 
Untargeted Approved by 
FDA for use in 
humans 
-- (Sarris et al., 
2004) 
Clinical Trials 
Annamycin (L-
annamycin, 
Phase II) 
Untargeted Human 
refractory ALL 
patients 
62% of patients 
had an efficacy 
signal with 
complete 
clearing of 
circulating 
peripheral blasts.  
(Wetzler et al., 
2013) 
Pre-clinical Studies 
Dexamethasone CD74 CB-17 SCID 
Mice 
CD74-IL-DEX 
vs. CD74-ILs 
Difference in 
days of survival: 
13.56 
(Mao et al., 
2013) 
Doxorubicin CD19 CB-17 SCID 
Mice 
Mean survival 
time: 
Free DOX: 29 
days 
Anti-CD19-
HSPC [DOX]: 
47 days 
(Allen et al., 
2005) 
Doxorubicin CD22 Human Burkitt 
lymphoma cell 
line, Raji 
Compared to 
PLD, IL-PLD 
are 3.1 to 5.4 
times more 
cytotoxic in 
CD22+ Raji 
cells 
(O’Donnell et 
al., 2010) 
Doxorubicin CD22 CB-17 SCID 
Mice 
Both PLD and 
IL-PLD were 
more efficacious 
and showed 
reduced 
cytotoxicity 
compared to free 
DOX.  
(Tuscano et al., 
2010) 
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delivered inside the cells so the possibility of the drug diffusing away from the site of 
action is eliminated or reduced. After the liposome binds to its internalizing target, such 
as CD22, the complete immunoliposomal complex is endocytosed by a process described 
as receptor mediated endocytosis (Sapra and Allen, 2002). Receptor mediated 
endocytosis is the process by which cells internalize molecules or particles upon receptor 
interaction. Once the complex is inside the cell, the drug is released due to action of 
lysosomal and endosomal enzymes. This should result in higher concentrations of the 
drug inside the cell compared to non-internalizing epitope targeted systems.  
 
 Four targets for treatment of B cell malignancies that have been studied 
extensively are CD19, CD20, CD22 and CD74. Of these CD19, CD22 and CD74 are 
internalizing whereas CD20 is non-internalizing. In this literature review an attempt has 
been made to summarize the findings of several research groups that have studied these 
targets. Table 1.3 provides a concise format of the most important information in the 
literature. Also given are the ratios of the formulation excipients used in the studies.  
 
 
1.5.1. CD19  
 
 CD19, an internalizing epitope, is a differentiation antigen from the B cell lineage 
and is expressed early in its cycle (Rickert et al., 1995). Initially, it was shown that DOX 
loaded CD19 targeted liposomes were superior to the free drug, untargeted liposomes, 
free anti-CD19 antibody and combinations thereof (Lopes de Menezes et al., 1998). The 
liposomes were prepared using the same method as described by Cheng et al (Cheng and 
Allen, 2008). Briefly, the dried lipid films were hydrated using 25 mM HEPES (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) and 140 mM NaCl buffer (pH 7.4). The 
hydrated liposomes (multilamellar vesicles, MLV’s) were sequentially extruded at 65°C 
through a series of polycarbonate filters of pore sizes from 0.4 μm - 0.08 μm to give 
SUV’s (small unilamellar vesicles). For preparing hydrazide derivatized liposomes the 
mPEG2000-DSPE (1, 2-distearoyl-sn-glycero-3-phosphoethanolamine-N-
[methoxy(polyethylene glycol)-2000]) was substituted with hydrazide-PEG2000-DSPE 
(HZ-PEG2000-DSPE). Doxorubicin was loaded using the ammonium sulfate gradient 
method as described by Haran et al. The hydrazide coupling method was utilized to 
couple the anti-CD19 mAb to the long circulating liposomes (Benita, 2006). These 
liposomes were tested in malignant B cells expressing CD19 surface antigens (Namalwa 
Cells). Compared to untargeted liposomes, these gave three times higher binding to B 
cells. Studies in SCID (severely combined immune deficiency) mice showed that CD19 
targeted SIL-DOX (DOX loaded stealth® immunoliposomes) compared to untargeted or 
free DOX gave a much higher therapeutic effectiveness and also long term survivors (2/9 
in one study and 4/9 in another). 
 
 Although CD19 targeted DOX loaded liposomes accumulate less rapidly 
compared to free DOX, the cellular levels of DOX were several folds higher in cells 
treated with the targeted liposomes compared to cells treated with non-targeted liposomal 
DOX (de Menezes et al., 1999). It was also seen that the targeted liposomes appeared 
mainly at the cell surface after 1 hour, with some DOX sequestered in vesicular structures 
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Table 1.3. Summary of literature on liposomal systems for B cell malignancies 
 
Drug Receptor 
targeted 
Lipid ratio  Ligand Ligand 
binding 
procedure 
Ligand 
amount 
Size 
(nm)  
Drug loading Reference 
Doxorubicin CD19 HSPC:CHOL:mPEG2000-
DSPE, 2:1:0.1 
HD37 
mAb/ 
Fab’/ScFv 
Post 
Insertion 
Ligand: Mal-
PEG2000-
DSPE, 1:10 
100 ± 
10 
0.26 μmol 
DOX/μmol 
phospholipid 
(Cheng and 
Allen, 
2008) 
Doxorubicin CD19 HSPC:CHOL:mPEG2000-
DSPE/ Hz-PEG2000-DSPE, 
2:1:0.10 
Anti-CD19 
mAb 
Hydrazone Ligand: PL, 
1:1000 
110 ± 
10 
140-160 μg 
DOX/μmol 
phospholipid 
(Lopes de 
Menezes et 
al., 1998) 
Doxorubicin CD19 HSPC:CHOL:Hz-PEG2000-
DSPE, 2:1:0.10 
HSPC:CHOL:mPEG2000-
DSPE:Mal- PEG2000-
DSPE, 2:1:0.08:0.02 
Anti-CD19 
mAb 
Hydrazone 
 
Thioether 
Ligand: PL, 
1:2000 
95-110 0.26 mmol 
DOX/mmol 
phospholipid 
(de 
Menezes et 
al., 1999) 
Doxorubicin CD19 Major 
Lipid:CHOL:mPEG2000-
DSPE, 2:1:0.10 
Major lipid = DMPC, 
DOPC, DSPC, PMPC, 
HSPC, POPC, SMPC)  
Anti-CD19 
mAb 
Thioether - 100 ± 
20 
NA (Charrois 
and Allen, 
2004) 
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Table 1.3. Continued 
 
Drug Receptor 
targeted 
Lipid ratio  Ligand Ligand 
binding 
procedure 
Ligand 
amount 
Size 
(nm)  
Drug loading Reference 
Doxorubicin CD19 HSPC:CHOL:mPEG2000-
DSPE/Hz-PEG2000-DSPE, 
2:1:0.1 
Anti-
CD19 
mAb 
Hydrazone 50 μg 
ligand/μmol 
PL 
95-110 150 μg 
DOX/μmol 
(Lopes de 
Menezes et 
al., 2000) 
Doxorubicin CD19 DOPE/CHEMS Anti-
CD19 
mAb 
Thioether Ligand: PL, 
1:2000 
120 ± 
10 
NA (Ishida et al., 
2001) 
Doxorubicin CD19 Non-pH Sensitive: 
HSPC:CHOL:mPEG2000-
DSPE, 2:1: 0.01 
HSPC:CHOL:mPEG2000-
DSPE:Mal- PEG2000-DSPE, 
2:1:0.08:0.02.  
pH-sensitive: 
DOPE:mPEG2000 –
DSPE:Mal- PEG2000-DSPE, 
10:0.4: 0.1 
DOPE:CHEMS:mPEG2000-
DSPE:Mal-PEG2000-DSPE, 
6:4:0.24: 0.6 
Anti-
CD19 
mAb 
 
Thioether Ligand: PL, 
1:2000 
95-110 150μg 
DOX/μmol 
phospholipid 
(Kirchmeier 
et al., 2001) 
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Table 1.3. Continued 
 
Drug Receptor 
targeted 
Lipid ratio  Ligand Ligand 
binding 
procedure 
Ligand 
amount 
Size 
(nm)  
Drug 
loading 
Reference 
Doxorubicin CD19 HSPC:CHOL:Hz-PEG2000-
DSPE, 2:1:0.10 
HSPC:CHOL:mPEG2000-
DSPE:Mal- PEG2000-
DSPE, 2:1:0.08:0.02 
HSPC:CHOL:mPEG2000-
DSPE/ Hz-PEG2000-DSPE, 
2:1:0.10 
Anti-CD19 
mAb 
Thioether 
Or 
Hydrazone 
Or 
Post 
Insertion 
Ligand: PL, 
1:2000 
NA NA (Allen et 
al., 2002d) 
Doxorubicin CD22 DSPC:CHOL:PEG2000-
DSPE/ BPCNeuAc-PEG-
DSPE, 60:35:5 
BPCNeuAc Ethyl amine  Ligand:PL, 
1:19 
100 ± 10 Loading 
efficiency 
90% 
(Chen et 
al., 2010) 
Doxorubicin CD22 HSPC:CHOL: PEG2000-
DSPE:dl-α-tocopherol, 
56.1:38.2:5.5:0.2 
HB22.7 Post 
Insertion 
NA PLD: 118 
± 10 
IL-PLD: 
165 ± 10 
NA (O’Donnel
l et al., 
2010) 
Doxorubicin CD22 NA Anti-
CD22-
ScFv 
NA 200μg 
ligand for 
10-20 mg 
PL 
80-100 NA (Loomis et 
al., 2010) 
Doxorubicin CD19 or 
CD20 
HSPC:CHOL:mPEG2000-
DSPE, 2:1:0.1 
HSPC:CHOL:mPEG2000-
DSPE- Mal-PEG2000-
DSPE, 2:1:0.08:0.02 
αCD19 
αCD20 
Thioether Ligand: PL, 
1:2000 
100 ± 10 NA (Sapra and 
Allen, 
2002) 
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Table 1.3. Continued 
 
Drug Receptor targeted Lipid ratio  Ligand Ligand 
binding 
procedure 
Ligand 
amount 
Size 
(nm)  
Drug 
loading 
Reference 
Vincristine 
or 
Doxorubicin 
CD19 SGML:CHOL:mPEG2000-
DSPE, 55:40:5 
SGML: CHOL: mPEG2000-
DSPE: Mal-PEG2000-DSPE, 
55:40:4:1 
HSPC:CHOL:mPEG2000-
DSPE, 2:1:0.1.  
HSPC:CHOL:mPEG2000-
DSPE:Mal-PEG2000-DSPE, 
2:1:0.08:0.02 
Anti-
CD19 
mAb or 
anti-
CD19 
mAb 
Fab’ 
fragment 
Thioether Ligand: 
PL, 
1:2000 
Or 
Ligand: 
PL, 
1:1000 
120-
130 
or 
100 
± 10 
NA (Sapra et 
al., 2004) 
 CD19 or CD20 SGML:CHOL:mPEG2000-
DSPE, 55:40:5. 
SGML: CHOL: mPEG2000-
DSPE: Mal-PEG2000-DSPE, 
55:40:4:1 
HSPC:CHOL:mPEG2000-
DSPE, 2:1:0.1.  
HSPC:CHOL:mPEG2000-
DSPE:Mal-PEG2000-DSPE, 
2:1:0.08:0.02 
αCD19 
IgG2a) 
or 
αCD20 
(IgG1) 
Thioether Ligand: 
PL, 
1:2000 
120 
± 10 
or 
100 
± 10 
NA (Sapra and 
Allen, 
2004) 
Vincristine Untargeted EPC: CHOL or DSPC: 
CHOL, 55:45 
-- -- -- 120-
1000 
Loading 
efficiency 
95% 
(Mayer et 
al., 1994) 
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Table 1.3. Continued 
 
Drug Receptor 
targeted 
Lipid ratio  Ligand Ligand binding 
procedure 
Ligand 
amount 
Size (nm)  Drug 
loading 
Reference 
Norcanthridin CD19 SPC:CHOL:mPEG
2000-PE, 2:1:0.1 
SPC:CHOL:mPEG
2000-PE: Mal-
PEG2000-DSPE, 
2:1:0.08:0.02 
Anti-CD19 
mAb 
 
Post Insertion Ligand: 
Mal-
PEG2000-
DSPE, 
1:250/50/
25 
Untargeted 
104.12 
 
Targeted 
118.32 
Loading 
efficiency 
46.51% 
(Zhang et 
al., 2010) 
FUdR-dO CD74 EPC:DPPE-
PEG2000-Mal: 
FUdR-dO, 
1:0.2:0.1 
Anti-CD74 
(LL1) 
Thioether NA ~110 NA (Lundberg 
et al., 
2004) 
Milatuzumab CD74 HSPC:CHOL:mPE
G2000-DSPE, 
2:1:0.1 
HSPC:CHOL:mPE
G2000-DSPE, 
2:1:0.08:0.02 
Anti-CD74 
(Milatuzumab
) 
Thioether Ligand: 
PL, 
1:2000 
NA NA (Hertlein 
et al., 
2010) 
Dexamethasone CD74 EPC:CHOL:mPEG
2000-DSPE, 
65:33.5:1.5 
HSPC:CHOL:mPE
G2000-DSPE:Mal-
PEG2000-DSPE 
Anti-CD74 Thioether Ligand: 
PL, 
1:1000 
~103 NA (Mao et 
al., 2013) 
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in the cells, compared to the untargeted formulation, which appeared only at the surface 
of the cells. After two hours almost all of the targeted formulation was sequestered into 
the vesicular structures inside the cells with the untargeted formulation still only present 
at the surface. After 48 hours incubation it was shown that the targeted formulation 
started accumulating DOX inside the nucleus, which is its site of action. Menezes et al 
have experimentally acquired a 5 fold higher cytotoxicity compared to the untargeted 
formulation, and this too, selectively in CD19+ cells only (de Menezes et al., 1999). In 
this study two different types of conjugations were analysed, hydrazide and thioether. 
The HSPC (hydrogenated soy phosphatidylcholine):CHOL (cholesterol):HZ-PEG2000-
DSPE  liposomes were prepared using the same ratio of lipids and the method as 
described above in Cheng et al (Cheng and Allen, 2008). The HSPC:CHOL:mPEG2000-
DSPE:mal -PEG2000-DSPE liposomes were prepared in the molar ratio 2:1:0.08:0.02 and 
using the same method as the other set of targeted liposomes. It was seen that the 
hydrazide coupling method had a coupling efficiency of 32% and the thioether method 
had a coupling efficiency of 80%.  
  
 Other than the rate of uptake, another important parameter that must be studied 
for targeted formulations is the effect of variable release rates of the drug from the 
liposome on cytotoxicity. This study has been performed by Charrois et al (Charrois and 
Allen, 2004). They have shown that the drug release rates of DOX from untargeted 
liposomes are responsible for toxicities in an orthotropic 4T1 murine mammary 
carcinoma model. Liposomes with three release rates were studied – fast, intermediate 
and slow. Liposomes with varying release rates were prepared by altering the liposome 
fluidity by changing the fatty acyl chain length and/or degree of saturation of the 
phosphatidylcholine in the liposomes. The lipids used in the formulations were, primary 
lipid lipid:CHOL:mPEG2000-DSPE and the molar ratios in which they were used were 
2:1:0.1. The primary lipids that they tested were DMPC 
(dimyristoylphosphatidylcholine), DOPC (dioleoylphosphatidylcholine), DSPC 
(distearoylphosphatidylcholine), HSPC, PMPC (palmitoyl-
myristoylphosphatidylcholine), POPC (palmitoyl-oleoylphosphatidylcholine) and SMPC 
(stearoyl-myristoylphosphatidylcholine). The method of liposome preparation and drug 
loading was the similar to the one described in Cheng et al (Cheng and Allen, 2008). Of 
the seven lipid formulations tested, the liposomes prepared using DOPC, POPC, and 
DSPC were selected for studies in tumor bearing mice. Liposomes prepared from DOPC 
gave fastest release rates, POPC gave intermediate and DSPC gave the slowest drug 
release rates. The researchers tested the concentration of DOX in the tumour and in 
cutaneous tissues. It was seen that the formulation with the slowest release rates gave the 
highest DOX concentrations in both the tumour and the cutaneous tissues and also best 
therapeutic activity, whereas the fastest releasing formulations gave the lowest 
concentrations in both. However, unexpected toxicities were noticed in case of the 
intermediate formulations and these toxicities had no particular pattern with respect to the 
composition of the liposomes. It was speculated then that this toxicity may be controlled 
by targeting the formulations with anti-CD19 antibody.  
 
 In a related study (Allen et al., 2005) conducted in Namalwa cells by conjugating 
CD19 specific antibodies to the liposomes via the thioether bond by using mal-PEG-
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DSPE (Benita, 2006) . Five different formulations comprising of HSPC, DPPC, PMPC, 
DOPC and POPC were tested. Their drug release rates varied from 11.2 -85.5 hours in 
the order POPC<DOPC<PMPC<DPPC<HSPC. The molar ratio of the lipids, major 
lipid:CHOL:mPEG2000-DSPE was 2:1:0.1. For preparing targeted liposomes, 0.02 mole% 
of the mPEG2000-DSPE was substituted with mal- PEG2000-DSPE. Liposomes were 
prepared in the same method as described by Cheng et al. (Cheng and Allen, 2008).  
The results revealed that there was a significant increase in the life span of all test groups. 
The test group for CD19 targeted slow release formulation gave an increase in life span 
(ILS) of 88% with one long term survivor compared to the non-targeted one that gave 
only 12%. The CD19 targeted fast release formulation gave an ILS of 46% compared to 
only 12% of the non-targeted. The intermediate release results for ILS were all below the 
fast and slow release formulations but the CD19 targeted formulations gave 
comparatively better results compared to the non-targeted formulations. This pair of 
studies showed that the toxicity and the therapeutic effect of a formulation is the result of 
liposome composition, mechanism of liposome uptake and the drug release rates from the 
liposome.   
 
 A similar formulation targeted to CD19+ B cells has shown to be efficacious in 
patients with multiple myeloma (MM) (Lopes de Menezes et al., 2000). They coupled 
anti-CD19 antibody to the long circulating liposomes using the hydrazide method 
(Benita, 2006). To promote visualization, a fluorescent lipid, 12-[N-(nitrobenz-2-oxa-1,3-
diazol-4-yl) amino] dodecanoyl phosphatidylethanolamine (NBD-PE), 0.1%, was 
incorporated into the liposomes when preparing them. Liposomes were composed of 
HSPC:CHOL:mPEG2000-DSPE/HZ-PEG2000-DSPE in the ratio 2:1:0.1. The method of 
preparation was the same as described in Cheng et al. (Cheng and Allen, 2008). Targeted 
liposomes carrying DOX showed higher binding to and cytotoxicity against the CD19+ 
ARH77 MM cell line, than did the non-targeted liposomal DOX or liposomal DOX that 
was targeted using isotype matched antibodies. The internalizing nature of CD19 was 
noted by the observation of fluorescence in the early endosomes that were formed. Ex 
vivo studies were also done using the peripheral blood mononuclear cells (PBMC) from 
patients of MM. These cells were treated in three separate groups with free DOX, 
untargeted liposomal DOX (DOX-SL) and targeted DOX immunoliposomes (DOX-SIL-
anti-CD19). It was seen that the free DOX was equally cytotoxic to both B and T cells, 
the DOX-SL were minimally toxic to both B and T cells whereas the SIL-DOX-anti-
CD19 were selectively cytotoxic for B cells in PBMC. This study showed that targeted 
liposomes had an IC50 at a 0.98 μM concentration of DOX whereas untargeted liposomes 
had an IC50 of 10.4 μM DOX, which suggests that antibody targeted liposomes are more 
effective than untargeted therapies. 
 
 DOX appears to be the molecule of choice so far for researchers working on B 
cell malignancies. Few studies have been undertaken to compare the efficacy of 
liposomal encapsulation of DOX with other cytotoxic drugs.  Liposomal encapsulation of 
vincristine (VCR) is also known to reduce the neurotoxic effects that are elicited by its 
free drug form (Sarris et al., 2000). VCR gets concentrated more specifically in lymph 
nodes and in tumours than in nerves. The method of preparation of VCR liposomes is 
briefly described. Liposomes comprising of sphingomyelin (SGML) and CHOL were 
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prepared at a lipid concentration of 100 mg/ml. 1 ml of VCR sulfate at a concentration of 
100 mg/ml was added to the preformed liposomes followed by addition of 5 ml sodium 
phosphate for injection (14.2 mg/ml). This mixture was heated for 10 minutes at 60-
65°C. These liposomes are currently approved for use in patients with relapsed non-
Hodgkin’s lymphomas (NHLs) and ALL. The study concluded that liposomal VCR can 
be used in patients with relapsed NHL with only a fraction of patients showing 
neurotoxicity. Thus, it is suggested that liposomal VCR can also be used in previously 
untreated patients.  
 
 Sapra et al have compared targeting liposomal VCR and liposomal DOX to CD19 
via the whole antibody or just it’s the Fab’ fragment (Sapra et al., 2004).  The untargeted 
VCR liposomes were prepared using SGML: CHOL: mPEG2000-DSPE at a molar ratio of 
55:40:5. The CD19 targeted VCR liposomes were composed of SGML: CHOL: 
mPEG2000-DSPE: Mal-PEG2000-DSPE at a molar ratio of 55:40:4:1. Briefly, the dried 
lipid film was hydrated in a 300 mM citrate buffer to give MLV’s. The liposomes were 
then extruded through a series of polycarbonate membranes. VCR was loaded using a 
transmembrane pH dependant procedure. Untargeted DOX liposomes were composed of 
HSPC:CHOL:mPEG2000-DSPE at a molar ratio of 2:1:0.1. CD19 targeted DOX loaded 
liposomes were composed of HSPC:CHOL:mPEG2000-DSPE:Mal-PEG2000-DSPE at a 
molar ratio of 2:1:0.08:0.02. The antibody or its Fab’ fragment was attached to the 
liposomes via the Mal-PEG-DSPE using the thiol reaction (Benita, 2006) and all the 
above described  formulations were tested in Namalwa cells. It was seen that the targeted 
liposomes using the whole antibody (SIL [αCD19]) or the Fab’ fragment (SIL [Fab’]) had 
a higher binding compared to the non-targeted liposomes. The (SIL [Fab’]) had a longer 
circulation time than (SIL [αCD19]). VCR gave faster release rate from the liposomes 
than DOX and also VCR formulations gave a better therapeutic effect compared to DOX 
formulations. For DOX formulations the (SIL [Fab’]) was more efficacious than the (SIL 
[αCD19]). However, for VCR, both the formulations were equally effective.  
 
 Liposomal VCR emerges more efficacious compared to liposomal DOX.  The 
reason for this is that the efficacy of liposomal VCR is largely dependent upon two 
parameters. First, it is dependent on the composition of the vesicles. Using egg 
phosphatidylcholine (EPC)/cholesterol for preparing vesicles, the ILS does is not 
significant compared to free VCR. However, when distearoylphosphatidylcholine 
(DSPC)/cholesterol vesicles are prepared, ILS increased to values as high as 133%. 
Secondly, it was seen that liposomal VCR activity is also largely dependent on particle 
size. If the size of the vesicles is increased from 100 nm to 1 μm, the ILS falls from 
133.3% to 55.6% (Mayer et al., 1994). In this study, the vesicles were prepared in a 
method similar to the one described by Sarris et al. (Sarris et al., 2000). The only 
difference here is that five freeze thaw cycles were used followed by ten cycles of 
extrusion via polycarbonate membranes. EPC: CHOL vesicles were prepared in a molar 
ratio 55:45, and the DSPC: CHOL vesicles were also prepared using the same molar 
ratios.  
 
 Norcanthridin (NCTD) is another molecule for which similar studies have been 
performed.  For the study testing the efficacy of CD19 targeted liposomal NCTD, 
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untargeted liposomes were prepared using SPC (soy phosphatidylcholine):CHOL: 
mPEG2000-PE at a molar ratio of 2:1:0.1. The CD19 targeted liposomes were prepared 
using SPC:CHOL:mPEG2000-PE (mPEG2000-phosphatidylethanolamine):Mal-PEG2000-
DSPE at a molar ratio of 2:1:0.08:0.02. The antibody used was the human anti-CD19 
monoclonal antibody 2E8. The liposomes were prepared using the film dispersion 
method followed by extrusion via stacked polycarbonate membranes, and the antibody 
incorporated using the post insertion method (Allen et al., 2002a) to give 2E8-NCTD-
liposomes. The formulation was tested in the human leukemic B cell line NALM-6 and 
an MTT assay showed specific cytotoxicity toward NALM-6 cells in a dose and time 
dependent manner and the viability of these treated cells was much lower than the same 
cells treated with the untargeted formulation or free NCTD (Zhang et al., 2010). 
However, the efficacy of this formulation was not tested in vivo, thus it is difficult to 
arrive at a conclusion as to how effective targeting or liposomal encapsulation of this 
molecule may be to ILS or number of long term survivors.  
 
 One of the novel ways for targeting CD19 was recently studied by Ishida and co-
workers.  They have explored the possibility of making stimuli sensitive targeted 
liposomes sensitive to change in pH (Ishida et al., 2001). This study tested CD19 targeted 
and untargeted variants of two types of liposomes, one being pH sensitive and the other 
not sensitive to pH. The pH sensitive liposomes were prepared by means of a disulphide 
bond introduced in mPEG2000-DSPE to give mPEG-S-S-DSPE. This link was known to 
break down at pH 5.5. The major lipid used for preparing the pH sensitive liposomes was 
DOPE (dioleoylphosphatidylethanolamine) or DOPE and CHEMS (cholesteryl 
hemisuccinate).  CHEMS is a stabilizing molecule which assists DOPE in forming a 
bilayer structure at neutral pH. For the non-pH sensitive liposomes the major lipid used 
was HSPC. Detailed molar ratios of the ten formulations tested and their procedure for 
preparation can be referred to in Ishida et al. (Ishida et al., 2001). Briefly, the dried lipid 
films were hydrated using an appropriate buffer and extrude via a series of polycarbonate 
membranes. These CD19 targeted liposomes were prepared using the anti-CD19 
antibody, which was coupled to the liposomes using the maleimide derivatized PEG 
(mal-PEG) to give a thioether bond (Benita, 2006). In vitro leakage, nuclear 
accumulation, cytotoxicity and in vivo elimination in BALB/c inbred mice was studied. It 
was observed that the pH sensitive liposomes showed enhanced delivery of DOX to the 
nuclei of cells and thus higher cytotoxicity compared to non-pH sensitive liposomes. This 
result was seen in human plasma but not in culture media. The in vitro study concluded 
that pH sensitive formulations delivered drug more efficiently and had a higher 
cytotoxicity than the other formulations. The in vivo studies also suggested that CD19 
targeted pH sensitive formulations were the most effective in ILS compared to other 
formulations. The non-pH sensitive CD19 targeted liposomes gave a mean survival time 
of 42 days and a percent ILS of 101%, whereas the pH sensitive CD19 targeted 
liposomes gave a mean survival time of 54 days and an ILS of 156%. These results were 
statistically significant and exhibited that using pH sensitive delivery can increase the 
therapeutic efficacy of targeted liposomes.  
 
 Another method employed to form pH sensitive liposomes is by using PE’s like 
DOPE (Kirchmeier et al., 2001). As already mentioned, these lipids are known to form a 
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bilayer entrapping the drugs at physiological pH or at pH 8.0. However, when the pH is 
dropped to below physiological the lipid assumes a non-bilayer state and instantaneously 
releases its contents. The pH at which it assumes this non-bilayer structure can be 
dropped even lower by including some stabilizing molecules such as CHEMS. Thus, 
when liposomes that include DOPE/CHEMS in their formulation are internalized via one 
of the internalizing molecules (CD19/CD22), they would be in the cytoplasm in vesicular 
forms until lysosomes fuse with these endosomes lowering the pH and thus releasing the 
liposomal contents into the cytoplasm in a pH dependent manner. It was possible for 
Kirchmeier and co-workers to study this mechanism by monitoring the rate of drug 
accumulation in the nuclei. The five types of formulations of DOX tested were free DOX, 
pH sensitive targeted, pH sensitive untargeted, non-pH sensitive targeted and non-pH 
sensitive untargeted liposomes. Non-pH sensitive liposomes were composed of 
HSPC:CHOL:mPEG2000-DSPE at a molar ratio of 2:1: 0.01 or, for mAb coupling 
experiments, of HSPC:CHOL:mPEG2000-DSPE:Mal- PEG2000-DSPE at a molar ratio of 
2:1:0.08:0.02. pH-sensitive liposomes were composed of either DOPE:mPEG2000-
DSPE/Mal-PEG2000-DSPE at a molar ratio of 10:0.4:0.1 or DOPE:CHEMS:mPEG2000-
DSPE/Mal-PEG2000-DSPE at a molar ratio of 6:4:0.24: 0.6. These studies suggest the 
pH sensitive targeted liposomal formulation gave the most rapid release from lysosomes 
and the highest cytotoxicity. For an in depth review on stimuli sensitive nanocarriers, the 
reader is advised to read (Torchilin, 2009).  
 
 
1.5.2. CD22  
 
 Another internalizing epitope is CD22. It is a B cell specific member and belongs 
to an immunoglobulin like lectin family which in addition to recognizing the ligands also 
internalizes them thus delivering the entire drug load inside the cell (Powell and Varki, 
1994). Since it belongs to the lectin family, it retains the potential of binding to 
polysaccharides or oligosaccharides. It has been shown that CD22 positive B cells can be 
targeted using glycan ligands which are attached onto the liposomal surface by using N-
hydroxysuccinimide (NHS) activated pegylated lipids (Chen et al., 2010). They have 
used DSPC:CHOL:PEG2000-DSPE in a 60:35:5 molar ratio to prepare the untargeted 
naked liposomes. To prepare the CD22 targeted liposomes, they first conjugated the high 
affinity glycan ligand 9-N-biphenylcarboxyl-NeuAcα2-6Galß1-4GlcNAc (BPCNeuAc) 
with an N-hydroxy succinimide (NHS) activated pegylated lipid, via an ethyl amine 
linkage. This lipid-ligand conjugate, BPCNeuAc-PEG-DSPE, is then substituted for 
PEG2000-DSPE and CD22 targeted liposomes are prepared. Liposomes were prepared by 
dissolving the lipids in a mixture of chloroform and DMSO (dimethyl sulfoxide). This 
solution was lyophilized for 16 hours following which the lipids flakes were hydrated 
with water to give a final phospholipid concentration of 10 mM. This lipid dispersion is 
then extruded through stacked polycarbonate filters. DOX was loaded remotely using 
gradients of ammonium sulfate. This liposomal formulation was tested for efficacy in a 
standard Daudi lymphoma model in SCID mice and the results showed that the 
BPCNeuAc liposomes were far more efficacious compared to the naked, non-targeted 
ones. The control group that was injected with just PBS (phosphate buffered saline) 
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showed a mean time of survival (MTS) of 50 days compared to 73 days and 100 days for 
2% and 5% BPCNeuAc coupled liposomes.  
 
 Another research group has targeted CD22 using the antibody HB22.7 which is 
specific for CD22 only (O’Donnell et al., 2010). The method they used to prepare 
pegylated liposomal doxorubicin (PLD) has been described by Sakakibara et al. 
(Sakakibara et al., 1996). Briefly, an ethanol solution of HSPC:CHOL:PEG2000-DSPE:dl-
α-tocopherol in a molar ratio of 56.1:38.2:5.5:0.2 was injected into ammonium sulfate 
desferal and shaken at 60°C for 1 hour. This liposomal suspension was then extruded 
though polycarbonate filters of predetermined sizes. DOX was loaded by the process of 
remote loading as previously described (Haran et al., 1993). The CD22 specific HB22.7 
mAb was successfully coupled to the surface of pegylated liposomal DOX  to give 
immunoliposomal PLD (IL-PLD) using the post insertion method (Allen et al., 2002a). 
Immunofluorescence staining exhibited binding of these IL-PLD’s to CD22 expressing 
cells and the cytotoxicity observed specifically in CD22+ cells. For IL-PLD, the group 
have reported an IC50 which is 3.1 to 5.4 times lower than that of PLD in CD22+ cell 
lines. Tuscano et al later studied the efficacy, biodistribution and the pharmacokinetics of 
these CD22 targeted IL-PLD’s in xenograft mouse models and the results further 
strengthened their previous findings (Tuscano et al., 2010). Both targeted and untargeted 
liposomal formulations increased efficacy and reduced toxicity compared to non-
liposomal DOX (NL-DOX). PLD also had a higher half-life compared to NL-DOX. PLD 
and IL-PLD were less myelotoxic compared to the NL-DOX. 
 
 Internalization of ligands by CD22 is a temperature dependant process. This was 
shown by Loomis et al. (Loomis et al., 2010) in a DOX loaded liposomal system, 
targeted via an anti-CD22 immunotoxin, HA22. Liposomes were prepared using the 
probe sonication method as described by Puri et al. (Puri et al., 2008). Briefly, a lipid film 
was formed which was reconstituted in HBSE buffer (10 mM HEPES, 150 mM NaCl, 9.1 
mM EDTA, pH 7.5). These MLV’s were sonicated for 10 minutes using a probe 
sonicator, which gave liposomes in the size range 100-150 nm diameter. Temperature 
dependant internalization was shown by comparing internalization at two temperatures 
and results show successful internalization at 37°C and not at 4°C. Two to three fold 
higher accumulation and 2 to 4 fold higher killing rates were noted for targeted liposomes 
in CD22+ Raji cells compared to CD22- SUP-T1 cells. However, it must be noted that at 
4°C, which is an unfavourable temperature for the growth of the above cells, other 
processes may also cease which may in turn affect the internalization. Therefore, further 
studies are necessary to show that for an in vitro study it is only the internalization that is 
affected at 4°C and no other cell processes.  
 
 All internalizing epitopes do not have equivalent efficacy of internalization. A 
study has compared the potential of internalization of CD22 to CD19. The study used two 
immunotoxins, FMC63 (Fv)-PE38 targeting CD19 and RFB4 (Fv)-PE38 (BL22) 
targeting CD22. The lymphoma cell lines that they have used had 4-9 times more surface 
expressed CD19 compared to CD22. Still the amount of RFB4 (Fv)-PE38 (BL22) 
internalized by CD22 (2-3 times more immunotoxin internalized than the number of 
CD22 molecules) over one hour was far more than the amount of FMC63 (Fv)-PE38 
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internalized by CD19 (5.2% to 16.6% of the surface bound immunotoxin). It was also 
seen that the intracellular reservoir of CD22 greatly decreased after internalization which 
proved that CD22 was actually involved in the internalization process  (Du et al., 2008). 
Therefore, CD22 appears to be a better target for use in targeted therapy for B cell related 
cancers.  
 
 
1.5.3. CD74  
 
 CD74 is a part of the HLA class II major histocompatibility complex. It is 
overexpressed on malignant B cells and displays the property of receptor mediated 
internalization. A few research groups have utilized this feature of the CD74 antigen to 
target drug loaded liposomes to malignant B cells. Lundberg et al. (Lundberg et al., 2004) 
have compared the efficacy of targeting CD74+ malignant B cells with targeted and 
untargeted emulsions and liposomes. The emulsion was composed of Triolein (TO), EPC, 
Polysorbate 80, DPPE-PEG2000- MAL, and the anti-neoplastic agent 3’, 5’-O-dioleoyl-5-
fluorouridine deoxyribose (FUdR-dO) in the ratio 2:2:0.8:0.6:0.3. The liposomes were 
composed of EPC, DPPE-PEG2000-MAL, and FUdR-dO in the ratio 1:0.2:0.1. The 
liposomes were prepared by hydrating the dried lipid films in HEPES buffer followed by 
five freeze thaw cycles and subsequent sonication for two minutes. The anti-CD74 
antibody (LL1) was covalently attached to the liposome using the thioether bond (Benita, 
2006). These formulations along with solution FUdR were tested for cytotoxicity in 
CD74+ Raji cells and the IC50 values were 2.5 ± 0.2, 5.3 ± 0.3 and 7.0 ± 0.3 μM for the 
LL1-emulsion, LL1-liposomes and the solution FUdR. The researchers have concluded 
that the study demonstrated the potential of utilizing LL1 conjugated drug-carriers for site 
specific drug delivery of anti-neoplastic agents.   
 
 CD74 signalling is associated with inhibition of apoptosis and cell proliferation 
(Binsky et al., 2007, Gore et al., 2008). Disruption of this signalling pathway presents a 
potential therapeutic option for the treatment of CLL and other CD74+ malignancies. 
This function of the pathway has been utilized by Hertlein et al. (Hertlein et al., 2010) to 
target liposomes coupled to Milatuzumab, an anti-CD74 mAb, to malignant B cells. They 
have demonstrated that Milatuzumab by itself mediates direct cytotoxicity by a 
mechanism involving the aggregation of CD74 on the cell surface. Furthermore, the 
targeting of milatuzumab incorporated into liposomes potentiates the cytotoxic activity of 
the mAb. The immunoliposomes for this study were prepared using the components and 
ratio as described by Sapra and Allen (Sapra and Allen, 2002).  
 
 Dexamethasone was used as a model drug to develop liposomes specific for 
CD74+ B cell malignancies by Mao et al. (Mao et al., 2013). They have prepared 
liposomes as described by Sapra and Allen (Sapra and Allen, 2002) and compared the in 
vitro and in vivo effects of solution dexamethasone with CD74 targeted dexamethasone 
loaded immunoliposomes. The results show that CD74 targeted liposomes were 
preferentially taken up by the CD74-positive B cells compared to the CD74-negative T 
cells. The immunoliposomal dexamethasone was also more cytotoxic in the CD74-
positive B cells and primary CLL cells. Furthermore, the  immunoliposomal 
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dexamethasone displayed an enhanced therapeutic efficacy against a CD74 positive B 
cell model in SCID mice engrafted with Raji cells (Mao et al., 2013).  
 
 
1.5.4. CD20  
 
 CD20 is a non-internalizing type of antigen that has been targeted for B cell 
malignancies. It is a phosphoprotein specifically expressed on the surface of all B cells 
progressively increasing in concentration until maturity (Golay et al., 1985, Bofill et al., 
1985). Sapra and co-workers (Sapra and Allen, 2002) have compared the efficacy of 
targeting DOX loaded liposomes to internalizing (CD19) and non-internalizing (CD20) 
epitopes. Untargeted liposomes were prepared using HSPC:CHOL:mPEG2000-DSPE at a 
molar ratio of 2:1:0.1 and for targeted liposomes 0.02 mole percent of mPEG2000-DSPE 
was substituted with Mal-PEG2000-DSPE. Liposomes were prepared by hydration of thin 
lipid films as described previously followed by extrusion through stacked polycarbonate 
membranes (de Menezes et al., 1999). The thiol reaction (Kirpotin et al., 1997) was used 
to attach the anti-CD19 and the anti-CD20 antibodies to the liposomes and studied their 
efficacy in SCID mice that were injected with Namalwa cells at the tail vein. Using a 
confocal fluorescence microscopy, they showed that both anti-CD19 tagged and anti-
CD20 tagged liposomes bound the B cells with equal affinity. However, fluorescence in 
the cytoplasm was not seen in the anti-CD20 tagged liposomes, compared to the anti-
CD19 tagged liposomes, which showed bright red fluorescence in the cytoplasm. This 
result can be attributed to the non- internalizing nature of the CD20 epitope. In vivo 
studies in SCID mice injected with Namalwa cells suggested that targeting internalizing 
epitopes like CD19 increased the life spans relative to treatment with liposomes targeted 
to non-internalizing epitopes such as CD20. DOX loaded immunoliposomes targeted to 
CD20 showed an ILS of 24.3% where those targeted to CD19 had an ILS of 65.2%.  
 
 However, it is not that targeting only the internalizing epitopes would give a 
higher cytotoxicity when compared to non-internalizing ones. A study (Sapra and Allen, 
2004) compared the effects of using DOX loaded liposomes targeted to CD19, CD20 or 
combination of both, to VCR loaded liposomes targeted similarly, in SCID mice injected 
with Namalwa  cells . For the doxorubicin loaded liposomes, the ratio of lipids used, the 
formulation process and the process for mAb attachment was the same as described 
previously (de Menezes et al., 1999), whereas for the VCR loaded liposomes, the 
parameters and process were the same as described previously by Sapra et al. (Sapra et 
al., 2004). Results showed that the VCR-loaded liposomes targeted to CD20 gave far 
better increase in life spans and long term survivors (93% and 2/7) compared to similarly 
targeted liposomes loaded with DOX (24% and 0/7). Even better results were reported 
using a combination of CD19 and CD20 targeted liposomes. With VCR an increase of 
258% in life span was reported with 5/7 long-term survivors and 76% and 0/7 in case of 
DOX.  
 
 Menezes et al have compared cytotoxicity profile, half-lives, cellular 
internalization and in vivo stability of targeted liposomes prepared by various coupling 
methods. The liposome formulation process and the molar ratios of the lipids used were 
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the same as described previously (de Menezes et al., 1999). Their results show that 
liposomes prepared by the Mal-PEG-DSPE method have a short plasma half-life whereas 
the methods which eliminate or mask the Fc region of the ligand have half-lives similar 
to untargeted liposomes. Liposomes prepared by the post insertion method showed half-
lives comparable to ones prepared by conventional coupling procedures. These systems 
were tested in different animal models of either haematological malignancies, pseudo 
metastatic disease of solid tumours, and their results have shown that successful in vivo 
targeting was achieved when the target was either small or at a position easily accessible 
by the vasculature and/or had an internalizing epitope (like CD19) that was being 
targeted (Allen et al., 2002d).  
 
 
1.6. Hypothesis and Specific Aims 
 
 130,000 Americans are diagnosed with a blood malignancy every year and 
approximately 44,000 lose their battle against this deadly disease. Leukemias are the 
most common cause of cancer in children and young adults less than 20 years of age and 
almost 3/4th of these are ALL.  Chemotherapy, the primary therapy for blood 
malignancies has debilitating adverse effects such as loss of function of healthy tissue, 
thrombocytopenia, neutropenia, nausea, vomiting and tiredness (Zhang et al., 2007, 
Sahoo et al., 2007). These adverse effects can be attributed largely to the non-specific 
interactions of the drug with healthy tissues of the body and drug specific toxicities such 
as cardiomyopathy with DOX therapy and neuropathy with VCR therapy. The non-
specific interactions can be moderated by using drug delivery systems that can deliver 
drugs specifically to the malignant cells/tissues and the drug specific toxicities can be 
decreased or even eliminated by using superior molecules such as AD 198.  
 
 Entrapment of AD 198 in liposomes should alter bio-distribution of the molecule, 
thereby minimizing dose related toxicities and improving therapeutic efficacy. However, 
conventional liposomes are prone to rapid clearance by the RES and premature drug 
leakage. Therefore the physicochemical parameters of the liposomal formulation such as 
size, charge, drug encapsulation and drug release will be optimized to maximize safety 
and efficacy of the drug delivery system. Also, to ensure targeted delivery to malignant 
cells primarily, an active targeting approach will increase drug concentration in the target 
malignant cells particularly. For this purpose, the AD 198 loaded liposomal system will 
be targeted to CD22 using Fab´ fragments of an anti-CD22 monoclonal antibody. CD22 
is a B cell specific receptor of the lectin binding family and is overexpressed on 
malignant B cells which undergoes receptor mediated endocytosis. This should improve 
uptake of AD 198 in the malignant B cells preferentially.  
 
 The efficacy and specificity of the formulation can be verified using in vitro 
models of the malignant B cells. Cellular uptake and cytotoxicity studies along with 
tracing levels of key cell cycle regulatory molecules should give a well-defined 
understanding of the potential of the system compared to solution formulations of AD 
198.  
 
 36 
 Long term stability of the liposomal formulation would be a challenge given that 
the liposomal components are prone to oxidation in aqueous media. Removal of the water 
from the final formulation by lyophilization should increase stability of the liposomal 
formulations. However, water being an integral component of liposomal formulations, 
removal of water would prove detrimental to the final product. Therefore, the lyophilized 
formulations and the lyophilization process needs to be optimized to warrant an active 
and stable final drug product. This lyophilized product should be more stable than the 
liquid liposomal dispersions but equally effective.  
 
 The main objective of this project is the design and development of a stable and 
effective liposomal formulation for AD 198 that would be specific for CD22 
overexpressing malignant B cells. In keeping with this objective, the following 
hypotheses were proposed.  
 
1. AD 198 encapsulated CD22 targeted liposomal formulations can be developed 
to deliver drug preferentially to CD22 overexpressing malignant B cells.  
 
2. The liposomal formulation will have approximately the same cytotoxicity as 
solution AD 198 over prolonged periods.  
 
3. The formulation will be endocytosed via the clathrin- and caveolin-
independent endocytotic pathway and localized in lysosomes within the 
malignant cells where it will eventually release AD 198. The targeted 
liposomal drug will activate classical apoptotic pathways and supress 
oncoproteins.  
 
4. The dispersed liquid formulation will not be adequately stable for long term 
storage and thus a lyophilized formulation will be required to enhance 
stability.  
 
 To test these hypotheses, my specific aims were to:  
 
1. Develop and characterize prototype formulations of long circulating 
liposomal AD 198. Here I tested the various excipients in different rations for 
developing the basic liposomal formulations of AD 198. Formulation and 
process parameters were identified and optimized to achieve an acceptable 
prototype formulation.  
 
2. Conjugate a targeting ligand to the liposomes. Basic liposomes prepared 
were conjugated with a fragment of the anti-CD22 antibody RFB4 to give 
CD22 targeted liposomes. Conjugation efficacy was tested and the average 
number of antibody molecules per liposome were calculated.  
 
3. Evaluate in vitro cellular uptake and cytotoxicity of long circulating CD22 
targeted liposomal AD 198. In vitro studies were performed in target and 
non-target cells to substantiate preferential uptake and cytotoxicity in the 
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target population of CD22 overexpressing malignant B cells.  
 
4. Evaluate in vitro intracellular trafficking and effect on induction of 
apoptosis. To ascertain the route of uptake and intracellular localization of the 
CD22 targeted liposomal AD 198 in the target cells studies were performed 
over short period and various analytical techniques such as flow cytometry 
and confocal and electron microscopy were employed.  
 
5. Enhancement and evaluation of stability of long circulating CD22 
targeted liposomal AD 198. Since the stability of liposomes in dispersed 
conditions during storage was a major concern, the optimized liposomal 
dispersion was lyophilized. The lyophilization cycle parameters and 
formulation was optimized. The formulation that displayed optimum 
physicochemical characteristics was tested for stability for 30 days and 
compared to the dispersed formulation.  
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CHAPTER 2.    DEVELOPMENT AND CHARACTERIZATION OF 
PROTOTYPE FORMULATIONS OF LONG CIRCULATING LIPOSOMAL 
AD 198 (LCLA) 
 
 
 Alec Bangham and R.W. Horne first saw liposomes under the electron 
microscope in 1964 when they dispersed dry lecithin in water. They noted that these tiny, 
closed, bilayered structures formed spontaneously and resembled the bilayers of living 
cells (Bangham and Horne, 1964). They were initially referred to as ‘Bangasomes’ and it 
was only later that a Greek word was coined for them. ‘Lipos’ meaning fat and ‘somas’ 
meaning body gave rise to liposomes. It was not until 1971, that Gregoriadis et al 
successfully encapsulated enzymes into liposomes to be used as a vehicle for drug 
delivery (Gregoriadis et al., 1971, Gregoriadis and Ryman, 1971). However, they were 
quick to notice some of the limitations to the system, such as accumulation of the 
particles in the liver and were able to conclude that these systems could be used 
successfully only for drug delivery to the spleen and the liver (Gregoriadis and Ryman, 
1972a, Gregoriadis and Ryman, 1972b). Therefore they started development work on 
more complex systems for delivery to other diseases or affected organs (Gregoriadis, 
1973). Soon after Gregoriadis discovered that the liposomal concentration was slightly 
higher in the tumor than other tissues in the body and also concluded that this was due to 
higher vascularization of the tumor tissue (Gregoriadis et al., 1974).  
 
 Ever since the liposomes were discovered as a vehicle for drug delivery, various 
aspects have surfaced that govern the effectiveness of the final delivery system. 
Composition of liposomes is one such aspect which determines physico-chemical 
parameters such as liposome size, surface charge or bilayer fluidity (Kersten and 
Crommelin, 1995, Lian and Ho, 2001, Kaasgaard and Andresen, 2010, Torchilin, 2005, 
Drummond et al., 1999, Maurer et al., 2001, De Gier et al., 1968). These factors primarily 
affect the behavior of the liposomal dispersion in vivo. For example, the rate of uptake by 
the RES increases with the increase in size of the liposome (Lian and Ho, 2001). With the 
inclusion of PEG to make long circulating liposomes, the effective upper size for 
liposomes is between 150-200 nm (Lian and Ho, 2001). As for surface charge the RES 
works differently. Neutral liposomes have a lower tendency to be taken up by the RES, 
but then they are unstable due to their tendency to aggregate. Thus, liposomes are 
formulated as anionic. This negative charge increases stability but also increases the rate 
of uptake by the RES. This limitation is overcome by making the surface more 
hydrophilic which avoids recognition by the RES. Surface hydrophilicity is increased by 
modifying the surface with hydrophilic polymers such as PEG (Lian and Ho, 2001).  
 
 Bilayer fluidity is another parameter that governs stability of the final 
formulation. Fluidity of the bilayer depends on the lipids it is composed of. Every lipid 
has a glass transition temperature (Tg), which is the temperature at which 50% of the lipid 
changes from gel to liquid phase. Below the Tg the lipids are in a well-ordered gel phase, 
whereas above the Tg the lipids become more fluid and lack order. It is the Tg at which 
maximum drug leakage is observed (Lian and Ho, 2001). Lipids with high melting points 
such as cholesterol can also be incorporated into the membrane to ensure low fluidity 
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(Drummond et al., 1999). It is essential that when developing liposomes, these 
parameters be optimized to ensure the safety, stability and effectiveness of the final drug 
product. In the following sections the studies that were performed for optimization of the 
formulation of LCLA have been described and the results discussed.  
 
 
2.1. Materials and Methods 
 
 
2.1.1 Materials 
 
 HSPC, EPC and mPEG2000-DSPE were purchased from Avanti Polar Lipids, 
Alabaster, AL, USA, cholesterol was purchased from Sigma-Aldrich Co. LLC, St. Louis, 
MI, USA, chloroform, methanol, Whatman® Nucleopore track etched polycarbonate 
membranes, 200 proof ethanol, 10x PBS (phosphate buffered saline) and HPLC (high 
pressure liquid chromatography) grade water, Slide-A-Lyzer® MINI Dialysis Devices, 
3.5K MWCO (molecular weight cut off), 0.5 mL capacity, ammonium hydroxide and 
80% formic acid and immobilized pepsin were purchased from Thermo Fisher Scientific, 
Waltham, MA, USA, ultrapure nitrogen was purchased from Nexair, Memphis, TN, 
USA, Sephadex G50 pre-filled macro SpinColumns® were purchased from Harvard 
Apparatus, Holliston, MA, USA, Total Recovery HPLC vials were purchased from 
Waters, Milford, MA, USA.  
 
 
2.1.2. Thermal characterization (Tg) of LCLA ingredients and formulation 
 
 The glass transition (Tg) temperature is critical for liposomal formulations since it 
determines the temperature at which the formulation is supposed to be extruded. For this, 
the ingredients and the LCLA ingredient mixtures were thermally analyzed using a DSC 
(TA Instruments Q2000 differential scanning calorimeter equipped with refrigerated 
cooling system). Five to ten mg of the excipient, drug or the excipient-drug mixture were 
loaded onto T-Zero aluminum pans and hermetically sealed. An empty pan prepared in a 
similar manner was used as reference. The samples were equilibrated at 25°C and then 
cooled at 5°C/min to -50°C. After equilibration, the samples were heated at the rate of 
10°C/min to 200°C.  
 
 
2.1.3. Preparation and formulation optimization of long circulating liposomal AD 
198 (LCLA)  
 
 The liposomes were prepared by the Bangham method followed by extrusion via 
polycarbonate membranes. Briefly, the lipids and drug were weighed accurately and 
dissolved in 3 mL’s 9:1 solvent mixture of chloroform:methanol in a round bottom flask. 
A thin lipid film was formed at the bottom of the flask by evaporating the solvent using a 
BUCHI Rotavapor®. Rotations were maintained at rotation speed no 3 and temperature 
was maintained at 40°C using a BUCHI heating bath. This step was carried out for 1 hour 
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following which the vacuum was released and the water bath heated to 65°C. 
Simultaneously, 1X PBS (phosphate buffered saline) was prepared from the 10X PBS 
and added to the thin lipid film for hydration. Rotations were maintained at the number 3 
setting. Hydration was carried out for 1 hour which gave MLV’s. The MLV’s were 
extruded through polycarbonate filters in two steps to give SUV’s. Extrusion was carried 
out using LIPEX® Extruders purchased from Northern Lipids, Burnaby, BC, Canada, 
connected to a high pressure ultrapure nitrogen tank. In the first step of extrusion, 
polycarbonate membranes of two sizes, 100 nm (nanometers) and 200 nm, were stacked 
and the drug loaded liposomes extruded only once using 450 psi pressure. In the second 
step, the resulting liposomes were extruded three times via 80 nm and 100 nm stacked 
membranes again using 450 psi pressure.  Since there was some loss of volume during 
the rehydration and extrusion process, the final volume is made up to 3 mL’s with 1x 
PBS.  
 
 
2.1.4. Removal of un-encapsulated AD 198  
 
 The un-encapsulated drug was removed using Sephadex - G50 prefilled macro-
column. Briefly, the dried G50 gel was rehydrated using 1X PBS for 15 minutes and 
centrifuged using a Thermo Scientific IEC CL31R centrifuge at 4°C for 4 minutes at 
1500 rpm. The resulting gel was washed three times using 150 μL’s of blank liposomes 
containing no AD 198, under the same centrifugation conditions as mentioned above. 
This was to block any non-specific retention of drug loaded liposomes in the column. 
Then 150 μL’s of the AD 198 loaded liposomes were passed through the treated column. 
The final eluate was reconstituted to 150 μL’s.  
 
 
2.1.5. Analysis of liposomal encapsulated drug content  
 
 Encapsulated AD 198 content in the liposomes was calculated using a Waters 
Alliance e2695 HPLC (High Pressure Liquid Chromatography) coupled to a Waters 2998 
UV Photodiode Array Detector. Samples were prepared at a dilution factor of 20. Briefly, 
50 μL of the purified liposomes were dissolved in 950 μL of 1:1 methanol: ethanol. 
Samples were briefly vortexed to give a clear solution and 300 μL’s transferred to Waters 
total recovery HPLC vials. These vials were loaded into the auto sampler of the HPLC 
separations module. The column used for separation was Waters Nova-Pak® C18 4μm, 
3.9x150 mm and was maintained at 30°C throughout the separation process. The mobile 
phase was a 70:30 Acetonitrile: pH 4.0 Ammonium Formate buffer. The ammonium 
formate buffer was prepared by adding 3.85 mL’s of ammonium hydroxide to 950 mL’s 
of HPLC grade water. The pH was adjusted to 4.0 using 80% formic acid and the volume 
was made up to 1 L. The flow rate for the mobile phase was maintained at 1.2 mL/ 
minute, the injection volume was 20 μL’s and the run time for each injection was 7 
minutes. AD 198 eluted between 3 and 4 minutes and was detected at a wavelength (λ) of 
254 nm.  
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2.1.6. Analysis of liposome size and zeta (ζ) potential  
 
 The final liposomal drug was diluted 40 times using HPLC water and the 
liposome size and ζ-potential was measured using a Malvern Zetasizer Nano ZS.  
 
 
2.1.7. Determination of phospholipid concentration  
 
 To calculate the amount of HSPC retained in the final formulation of LCLA, total 
phospholipids were estimated using the following procedure. 2.703 G (grams) ferric 
chloride hexahydrate and 3.04 G ammonium thiocyanate was dissolved in 100 mL 
distilled water and mixed to give ferrithiocyanate reagent. To determine the concentration 
of HSPC in the LCLA dispersion, an HSPC standard curve was made ranging from 10 to 
60 μg/mL. Analysis of these standards was done as follows. A mixture of 2 mL 
chloroform, 2 mL ferrithiocyanate reagent and 100 μL of the standard solution was made 
for each standard and vortexed vigorously for exactly one minute each. The mixture was 
allowed to settle and the lower layer containing chloroform was aspirated carefully and 
transferred to a 1 mL quartz cuvette. The absorbance for each standard was measured at λ 
488 against a chloroform blank. Samples of LCLA were prepared in the same method 
and the absorbance measured. Absorbance of the standard vs. HSPC concentration was 
plotted for each standard concentration and the unknown amount of HSPC in the LCLA 
sample was determined.  
 
 
2.1.8. LCLA dissolution  
 
 Drug release in 1x PBS at pH 7.4 and 37°C was tested for the LCCTLA’s as 
described by Zhang et al (Zhang et al., 2008). Briefly, 100 μL’s of the LCLA’s were 
placed in Slide-A-Lyzer® MINI Dialysis Devices, 3.5K MWCO, 0.5 mL capacity. 5 time 
points were tested; 6, 12, 24, 48 and 72 hours. Each sample was tested in triplicates. The 
sample loaded dialysis devices were loaded into floats introduced into a 3000 mL beaker 
containing 3000 mL of 1x PBS preheated to 37°C and dissolution started. Samples were 
taken out at the pre-determined time points and the drug content measured by HPLC as 
stated earlier.  
 
 
2.1.9. LCLA characterization by TEM (transmission electron microscopy) 
 
 Liposome size and shape were studied by TEM. LCLA was prepared as stated 
above. Samples for TEM were prepared by loading approximately 10-15 μL of the LCLA 
dispersion onto a copper grid. The sample was air dried for a short period (5-10 minutes) 
and stained with Uranyl Acetate to increase contrast and electron density since Uranyl 
Acetate stains lipids. The sample loaded copper grids were then loaded into the TEM and 
images taken at various magnifications.  
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2.1.10. LCLA numerical characterization 
 
 LCLA was characterized for its drug encapsulation per liposome. This was done 
by using the following assumptions, the average size of the liposomes was 120 nm 
(diameter), the lipid bilayer thickness was 5 nm (Gramse et al., 2013) and the cross 
sectional area of a phosphatidylcholine head-group was 0.71 nm2 (Torre et al., 2007).  
 
 
2.2. Results and Discussion 
 
 EPC and HSPC are two lipids that were studied for their effect on the 
encapsulation of AD 198. Both lipids are derived from natural sources and both are 
biodegradable. However, HSPC and EPC differ in their composition such that EPC is a 
more crude mixture between saturated and unsaturated lipids of varying chain lengths, 
whereas HSPC is primarily composed of saturated lipids of a fixed chain length. The 
effect that this has on the lipid bilayer is that the longer chain length lipids in EPC 
increase the thickness of the bilayer (not the size of the liposome) (Lian and Ho, 2001). 
The more saturated a lipid is the higher is its transition temperature, thus imparting lesser 
fluidity and possibly increased stability (Lian and Ho, 2001). A variable length between 
the two tail group chains also reduces the order of packing in the liposomal bilayer. 
Saturated lipids such as HSPC also have higher circulation half-lives compared to lipids 
with un-saturations such as EPC (Gregoriadis and Senior, 1980, Senior, 1987).  
 
 
2.2.1. Thermal characterization of the excipients, drug and excipient-drug mixture  
 
 Figure 2.1 shows results for the thermal characterization. The thermograms for 
AD 198, CHOL, mPEG2000-DSPE, mal-PEG2000-DSPEm HSPC and the optimized ratio 
of drug and excipients for the LCLA formulation have been shown. The highest Tg that is 
observed is that for the drug, AD 198 at 64.81°C. The Tg form the drug-excipient 
mixture is at approximately 51°C. The values for the other excipients are melting points 
(PEG and CHOL). Cholesterol melts at approximately 148°C but the peak at 42°C is 
possible from a different isomer. Since the highest Tg was 64.81°C, the rehydration of 
the lipid bilayer and the extrusion was carried out at 65°C.  
 
 
2.2.2. Effect of lipid composition in the bilayer  
 
 Studies were performed using different lipids at various ratios to optimize the 
physico-chemical properties of the liposomal bilayer. Figure 2.2 shows EPC and HSPC 
formulations studies in various ratios for their effect on AD 198 encapsulation and 
liposomal size. It explained that EPC and HSPC did not necessarily control the degree of 
AD 198 encapsulated in the liposome or the liposomal size. However, the dependence of 
ζ-potential on the HSPC:EPC ratio was evident as portrayed in Figure 2.3. As the ratio of 
HSPC:EPC was increased the ζ-potential on the liposome became more negative.  
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Figure 2.1. DSC thermograms of excipients, drug and excipient-drug mixture 
 
Notes. The thermograms for AD 198, CHOL, mPEG2000-DSPE, mal-PEG2000-DSPEm 
HSPC and the optimized ratio of drug and excipients for the LCLA formulation have 
been shown. The highest Tg that is observed is that for the drug, AD 198 at 64.81°C. The 
Tg form the drug-excipient mixture is at approximately 51°C. The values for the other 
excipients are melting points (PEG and CHOL). Cholesterol melts at approximately 
148°C but the peak at 42°C is possible from a different isomer. Since the highest Tg was 
64.81°C, the rehydration of the lipid bilayer and the extrusion was carried out at 65°C. 
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Figure 2.2. Effect of lipid composition on AD 198 encapsulation and liposomal 
size (n=3) 
 
Notes. At the end of the extrusion cycles the product volume was made up to batch size 
before AD 198 encapsulation and size were measured. Theoretical concentration of AD 
198 used was 500 μg/mL. The liposome size and AD 198 encapsulation was determined 
after the free AD 198 was removed using G50 Sephadex prefilled macro columns. EPC 
and HSPC did not necessarily control the degree of AD 198 encapsulated in the liposome 
or the liposomal size. Error bars represent standard deviation around the mean. 
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Figure 2.3. Effect of lipid composition on ζ-potential (n=3) 
 
Notes. ζ-potential is dependent on the HSPC:EPC ratio. As the ratio of HSPC:EPC was 
increased the ζ-potential on the liposome became more negative. Error bars represent 
standard deviation around the mean.  
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 This may possibly be attributed to the chloride ion on the EPC molecules 
interacting with the cationic nature of AD 198. The cationic AD 198 molecules may 
adsorb onto the anionic EPC and form a positive coat thus giving near zero or positive ζ-
potential. However, when HSPC concentration was higher than the EPC concentration, 
the electronegativity from the O- ion on the HSPC was not as high compared to the 
chloride ion on the EPC, which gave lesser AD 198 adsorption onto the liposomal surface 
resulting in more negative ζ-potential. 
 
 
2.2.3. Effect of total phospholipids on AD 198 encapsulation, liposomal size and ζ-
potential 
 
 Liposomes were prepared using the Bangham method in increasing 
concentrations of total HSPC. Four concentration of HSPC tested were 25, 50, 75 100 
and 125 mM. The drug concentration was maintained at 2000 μg/mL. The batch with 
25mM HSPC failed to extrude. The possible reason for that may be attributed to the 
excess amount of drug in the system that the little amount of carrier (HSPC) would need 
to encapsulate. Thus, the system could not be extruded. The results for 50 – 125 mM 
HSPC are shown in Figures 2.3, 2.4 and 2.5. It would be logical to believe that with 
increase in the amount of HSPC in the system, which is the major encapsulating material, 
the amount of encapsulated drug would tend to increase. However, Figure 2.4 suggests 
that the amount of drug encapsulated may not be related to the amount of lipid in the 
system. This result can be explained with Figure 2.5 which explains that during 
processing, a considerable amount of phospholipid was being lost as the total lipid 
content was increased beyond 75 mM. In Figure 2.5 we can see that the amount of HSPC 
loss during processing at 75 mM HSPC is approximately 25% (almost the same as 50 
mM). However at 100 and 125 mM the amount of phospholipid loss was more than 40 %, 
whereas the benefits in terms of AD 198 encapsulation and liposomal size were 
negligible (Figure 2.4). Although there was a pronounced increase in the net negative 
charge on the liposomal surface, as depicted in Figure 2.6, the size of the liposome 
increased considerably which warranted the conclusion of total phospholipid 
concentration at 75 mM to be optimum. An additional justification for the conclusion was 
that the extrusion time (result not shown here) with total phospholipid concentration 
above 75 mM increased considerably (more than 10 times).  
 
 The increase in the negative charge of the liposomes when the phospholipid 
concentration is increased from 50 mM to 75 mM and then not such a defined increase 
from 75 mM to 100 mM and 125 mM can possibly be explained with the excess amount 
of AD 198 that remains un-encapsulated. Since AD 198 has a cationic nature and HSPC 
an anionic nature, the excess AD 198 in the dispersion could be adsorbed onto the 
liposomal surface thus shielding the anionic nature of HSPC. 
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Figure 2.4. Effect of total phospholipid concentration on liposome size and AD 
198 encapsulation (n=3) 
 
Notes. Theoretical concentration of AD 198 used was increased to 2000 μg/mL. 
Liposomes were prepared using only HSPC as the major lipid. EPC was not used from 
this point forward. The amount of AD 198 encapsulated is not related to the amount of 
lipid in the system. This result can be explained with Figure 2.5. Error bars represent 
standard deviation around the mean.  
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Figure 2.5. Optimization of HSPC concentration (n=3) 
 
Notes. A considerable amount of phospholipid was lost in processing as the total lipid 
content was increased beyond 75 mM. The amount of HSPC loss during processing at 75 
mM HSPC is approximately 25% (almost the same as 50 mM). However at 100 and 125 
mM the amount of phospholipid loss was more than 40 %, whereas the benefits in terms 
of AD 198 encapsulation and liposomal size were negligible (Figure 2.4). Error bars 
represent standard deviation around the mean.  
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Figure 2.6. Effect of total phospholipid concentration on ζ-potential (n=3) 
 
Notes. Although there was a pronounced increase in the net negative charge on the 
liposomal surface, the size of the liposome increased considerably which warranted the 
total phospholipid concentration at 75 mM to be optimum. Error bars represent standard 
deviation around the mean.  
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2.2.4. Effect of AD 198 concentration on AD 198 encapsulation and ζ-potential 
 
 Five concentrations of AD 198 ranging from 500 μg/mL to 2500 μg/mL were 
tested to see their effect on AD 198 encapsulation and ζ-potential. Figure 2.7 shows that 
as the AD 198 concentration was increased from 500 -1500 μg/mL the AD 198 
encapsulation increased steadily. However when the AD 198 concentration was increased 
from 1500 to 2000 μg/mL, the AD 198 encapsulation almost doubles. However, if the 
AD 198 concentration was increased further, there was not a considerable increase in AD 
198 encapsulation. The ζ-potential was relatively constant up to 2000 μg/mL. However, 
once the AD 198 concentration reached 2500 μg/mL, the ζ-potential became lesser 
negative. Again, this can be attributed to the excess un-encapsulated cationic AD 198 
adsorbing onto the predominantly anionic HSPC liposomes, which will shield the 
negative charge due to HSPC. Hence, 2000 μg/mL was selected as the optimum AD 198 
concentration.  
 
 
2.2.5. Effect of cholesterol concentration on AD 198 encapsulation and liposomal 
size 
 
 Cholesterol is incorporated into the membrane to obtain an optimum bilayer 
fluidity (Drummond et al., 1999, Lian and Ho, 2001). However, with encapsulation of 
hydrophobic drugs in the bilayer it is important to consider effects of cholesterol 
concentrations on the encapsulation of the drug even before bilayer fluidity is considered. 
This is shown in Figure 2.8 which depicts the results from a study on the effects of 
increasing cholesterol concentrations. Four concentrations of cholesterol ranging from 5 
mM to 30 mM were studied. Liposomal size was relatively similar for 5 and 10 mM 
cholesterol concentrations. However, the size increased considerably at 15 and 30 mM 
cholesterol. This may be attributable to the liposomal bilayer trying to accommodate both 
the AD 198 and the increasing cholesterol molecules which could possibly increase the 
liposomal size. AD 198 concentration falls suddenly when cholesterol concentration was 
increased from 15 mM to 30 mM. Since part of the cholesterol molecular structure is 
similar to that of AD 198, the excess cholesterol molecules trying to occupy volume 
within the bilayer may be pushing out the AD 198. This was also in agreement with the 
liposomal size results. Once excess AD 198 was pushed out, the liposomal size reduced 
by approximately 50 nm. These results suggest that in view of AD 198 encapsulation and 
liposomal size approximately 10 mM cholesterol was optimum for LCLA.  
 
 
2.2.6. Optimization of mPEG2000-DSPE concentration  
 
 To determine the optimum amount of mPEG2000-DSPE, four concentrations of 
mPEG2000-DSPE ranging from 1 to 5 mole% were studied. Figure 2.9 represents the 
effect of mPEG2000-DSPE concentration on liposomal size and ζ-potential. Liposomal 
size was observed to increase with increasing concentrations of mPEG2000-DSPE.  
 
 Conversely, ζ-potential was observed to become more negative with increase in 
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Figure 2.7. Effect of AD 198 concentration on AD 198 encapsulation and ζ-
potential (n=3) 
 
Notes. As the AD 198 concentration was increased from 500 -1500 μg/mL the AD 198 
encapsulation increased steadily. However when the AD 198 concentration was increased 
from 1500 to 2000 μg/mL, the AD 198 encapsulation almost doubles. However, if the 
AD 198 concentration was increased further, there was not a considerable increase in AD 
198 encapsulation. The ζ-potential was relatively constant up to 2000 μg/mL. However, 
once the AD 198 concentration reached 2500 μg/mL, the ζ-potential became lesser 
negative (p<0.05). Again, this can be attributed to the excess un-encapsulated cationic 
AD 198 adsorbing onto the predominantly anionic HSPC liposomes, which will shield 
the negative charge due to HSPC. Hence, 2000 μg/mL was selected as the optimum AD 
198 concentration. Error bars represent standard deviation around the mean. 
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Figure 2.8. Effect of cholesterol concentration on AD 198 encapsulation and 
liposome size (n=3) 
 
Notes. Liposomal size was relatively similar for 5 and 10 mM cholesterol concentrations 
(p>0.05). However, the size increased considerably at 15 and 30 mM cholesterol 
(p<0.05). This may be attributable to the liposomal bilayer trying to accommodate both 
the AD 198 and the increasing cholesterol molecules which could possibly increase the 
liposomal size. AD 198 concentration falls suddenly when cholesterol concentration was 
increased from 15 mM to 30 mM. This may be due to the excess cholesterol molecules 
trying to occupy volume within the bilayer. This was also in agreement with the 
liposomal size results. Once excess AD 198 was pushed out, the liposomal size reduced 
by approximately 50 nm. These results suggest that in view of AD 198 encapsulation and 
liposomal size approximately 10 mM cholesterol was optimum for LCLA. Error bars 
represent standard deviation around the mean.  
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Figure 2.9. Effect of mPEG2000-DSPE concentration on ζ-potential and liposome 
size (n=3) 
 
Notes. Liposomal size was observed to increase with increasing concentrations of 
mPEG2000-DSPE.  Error bars represent standard deviation around the mean. Conversely, 
ζ-potential was observed to become more negative with increase in mPEG2000-DSPE 
concentration which may be attributable to the anionic nature of mPEG2000-DSPE. 
mPEG2000-DSPE is a large molecule (MW = 2805.497). The increase in the number of 
mPEG2000-DSPE molecules may cause the net size of the liposome to increase as justified 
by Woodle and co-workers (Woodle et al., 1992). However, a balance needs to be 
maintained between optimum size and optimum ζ-potential. Hence, 2 mole% mPEG2000-
DSPE was selected as the optimum concentration.  
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mPEG2000-DSPE concentration which may be attributable to the anionic nature of 
mPEG2000-DSPE. mPEG2000-DSPE is a large molecule (MW = 2805.497). The increase 
in the number of mPEG2000-DSPE molecules may cause the net size of the liposome to 
increase as justified by Woodle and co-workers (Woodle et al., 1992). However, a 
balance needs to be maintained between optimum size and optimum ζ-potential. Hence, 2 
mole% mPEG2000-DSPE was selected as the optimum concentration. 
 
 
2.2.7. LCLA dissolution 
 
 Long circulating liposomal AD 198 was tested for its release characteristics in 1x 
PBS at 37°C. Figure 2.10 shows that approximately 30% AD 198 release was observed 
over the first 12 hours following which only about 10% more AD 198 was released over 
the next 48 hours. This may be due a biphasic release in which the drug is released in two 
separate phases. Possibly there may be micelles which are less stable compared to 
liposomes which may be releasing the drug faster than liposomes. Once micelle drug 
release is over the liposomal AD 198 release predominantly manifests the kinetics.  
 
 The release is also in conjunction with the proposed theory of active targeting in 
which the liposome requires a certain period of time before it encounters a CD22+ 
malignant B cell, binds to it and gets internalized. The drug must largely be released once 
the liposome is inside the malignant cell. Therefore the delayed release of AD 198 over 
>72 hours is beneficial for the LCLA drug delivery system altogether.  
 
 
2.2.8. TEM analysis of LCLA 
 
 LCLA was analyzed by TEM. Figure 2.11 was taken at 30,000x and Figure 2.12 
was taken at 150,000x magnification respectively. In Figure 2.11 we can see the vast 
population of LCLA’s all over the copper grid. Some parts of the image are in focus and 
other are out of focus due to the multiple layers of the sample. If we look at Figure 2.12 
which is at a higher magnification, we are able to better identify the liposome size and the 
shape. The size as shown by the two scale bars are at 88.7 and 85.3 nm. This size is in 
agreement with the process used to produce them. The smallest diameter of the 
membrane used for extrusion was 80 nm. Since liposomes are waxy spherical structures a 
little larger vesicle may be able to squeeze out of an 80 nm pore. However, compared to 
the size range from the DLS (dynamic light scattering) instrument from Malvern, which 
is in the range of 120 – 140 nm, the size given by the TEM is more accurate. This is 
because the dynamic light scattering instrument gives the hydro-dynamic size of a 
nanoparticle. The Malvern Zetasizer® Nano ZS calculates particle size by converting the 
velocity of a particle in a certain media into its size by using the Stokes-Einstein 
equation. There are many variables in this equation which may not be accurately 
estimated at each measurement.  
 
 Also, when the nanoparticles move through the suspending medium, a thin layer 
of charged ions move along with it, which alter its velocity in the medium, which in turn 
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Figure 2.10. LCLA dissolution at 37°C (n=3) 
 
Notes. Approximately 30% AD 198 release was observed over the first 12 hours 
following which only about 10% more AD 198 was released over the next 48 hours. This 
may be due a biphasic release in which the drug is released in two separate phases. 
Possibly there may be micelles which are less stable compared to liposomes which may 
be releasing the drug faster than liposomes. Once micelle drug release is over the 
liposomal AD 198 release predominantly manifests the kinetics. The release is also in 
conjunction with the proposed theory of active targeting in which the liposome requires a 
certain period of time before it encounters a CD22+ malignant B cell, binds to it and gets 
internalized. The drug must largely be released once the liposome is inside the malignant 
cell. Therefore the delayed release of AD 198 over >72 hours is beneficial for the LCLA 
drug delivery system altogether. Error bars represent standard deviation around the mean.  
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Figure 2.11. TEM of LCLA at magnification 30,000x (magnified on next page) 
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Figure 2.12. TEM of LCLA at magnification 150,000x 
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would have an impact on the size. Therefore, size displayed on an electron microscopic 
image of the nanoparticles would be relatively more accurate.  
 
 The shape of the particles in the image looks roughly spherical but not uniformly 
spherical for all particles. This may be attributable to the hollow nature of liposomes 
which would collapse when water was removed. However, the polydispersity of the 
particles in the image can be noted to be relatively low. Calculated by DLS, the 
polydispersity of this sample was 0.071.  
 
 
2.2.9. Number of AD 198 molecules/liposome 
 
 The number of HSPC molecules per mL of the LCLA were calculated by using 
the Avogadro’s number, 6.023 x 1023 molecules/mole. This gave 3.25 x 1022 HSPC 
molecules/mL of LCLA as per the analyzed concentration of HSPC, 54 mM from the 
HSPC assay results. The number of AD 198 molecules/mL of LCLA were calculated 
similarly from the analyzed concentration of AD 198 to be 1250 μg/mL. This gave 1.05 x 
1021 AD 198 molecules/mL of LCLA. The outer surface area of the liposomal bilayer 
was calculated from Equation 2.1.  
 
 ?????????????????? ? ???? (Eq. 2.1) 
 
Here ‘r’ was the outer radius of the liposome. The thickness of the bilayer was denoted 
‘h’. Then the inner surface area was calculated from Equation 2.2.  
 
 ?????????????????? ? ???? ? ??? (Eq. 2.2) 
 
The cross sectional area of a phosphatidylcholine head-group was denoted as ‘a’ and the 
number of HSPC molecules per liposome calculated from Equation 2.3.  
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(Eq. 2.3) 
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This gave us the number of liposomes/mL from Equation 2.4.  
 
 
??????????????????? ?
?????????? ???? ???????????
?????????? ???? ?????????????????
 
(Eq. 2.4) 
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???? ? ????
???????
?? ???? ? ???? 
 
Number of AD 198 molecules per liposome were calculated from Equation 2.5.  
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 (Eq. 2.5) 
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2.3. Summary and Conclusions 
 
 The formulation and process parameters were identified and optimized in the 
preparation of LCLA. Lipid film formation parameters were optimum at 40°C and 
rotation speed at number 3. With the same rotations, rehydration was performed 
optimally at 65°C. For extrusions of the LCLA, extrusion was performed in two steps. In 
the first step the stacked membranes used had a cut off pore diameter of 100 nm and 200 
nm, a pressure of 450 psi at 65°C. This cycle was performed only once. In the second 
step extrusion was performed using the same parameters only using stacked 80 nm and 
100 nm membranes. The second step was performed thrice. Using these parameters the 
following composition of LCLA formulation ingredients were found to be optimum; 
HSPC was the lipid of choice and was used at 75 mole %, mPEG2000-DSPE 2 mole %, 
Cholesterol 10 mole % and AD 198 2 mg/mL. The physicochemical parameters of the 
optimized formulation were as follows; size 115-145 nm, ζ-potential -8 to -15 mV, AD 
198 encapsulation 1000-1500 μg/mL and dissolution of not more than 30% AD 198 
occurred for 72 hours. The size of the LCLA as per TEM was found be in the range of 
80-90 nm. This variability in size measurement could be attributed to the way the 
Zetasizer calculated nanoparticle size using DLS which calculated hydrodynamic size. 
We inferred that LCLA size as shown by the TEM was more accurate since it did not 
take into consideration the ionic cloud that was present on the surface of the LCLA as 
done by DLS. TEM micrographs indicated spherical morphology of the liposomes. Given 
the assumptions of size and lipid bilayer thickness, the number of HSPC molecules per 
liposome were calculated to be approximately 117,196 and the number of AD 198 
molecules were calculated to be 3790 per liposome. These liposomes serve as a platform 
for the delivery of AD 198.  
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CHAPTER 3.    DEVELOPMENT OF PROTOTYPE FORMULATION OF LONG 
CIRCULATING CD22 TARGETED LIPOSOMAL AD 198 (LCCTLA) 
 
 
 To make actively targeted liposomes, there are two principal methods for 
coupling ligands onto the liposomal surface, covalent and non-covalent methods (Benita, 
2006). Generally, covalent linkage affords a more stable bonding between the ligand and 
liposomes whereas non-covalent linkage is dependent on weaker electrostatic and 
hydrophobic interactions (Benita, 2006, Nobs et al., 2004). Weaker interactions can be 
susceptible to breakdown due to minor changes in environmental conditions such as 
temperature or pH, leading to loss of targeting efficiency. An exception to this is the 
biotin-avidin conjugation method. This is a non-covalent conjugation method which has 
bonding energies comparable to covalent bonds (Miyamoto and Kollman, 1993).  
 
 
3.1. Covalent Coupling 
 
 For the covalent attachment of a targeting ligand, a hydrophobic anchor with the 
desired functional groups for conjugation is necessary. Generally the anchor is a 
phospholipid, such as phosphatidylethanolamine or phosphatidylinositol, which is 
embedded in the liposomal bilayer. There are different ways in which the anchor can be 
included onto the liposomal bilayer. The most frequently used method embeds the anchor 
into the bilayer during liposome formation followed by the reaction for attachment of the 
ligand. A variation to this approach is to first carry out the reaction for attachment of the 
ligand to the anchor followed by inclusion of this complex while preparing liposomes (Li 
et al., 2010). Another alternative is to prepare the liposome and the anchor attached to the 
ligand discretely, followed by incubation of the anchor-ligand with the preformed long 
circulating liposomes (Cheng and Allen, 2008).  
 
 Although a number of anchor ligands have been explored, palmitic acid was the 
first reported long chain fatty acid employed for covalent coupling of targeting ligands. 
Huang and co-workers have reported the use of a succinimidyl ester of the fatty acid as a 
viable substrate for covalent conjugation, wherein the ester can react with primary amines 
lending a stable amide bond (Huang et al., 1980). It was only later that phospholipids 
were employed for conjugation purposes. Phosphatidylethanolamine is the most widely 
used because it is relatively simpler to modify for the required functional groups. Chen et 
al have successfully conjugated glycan ligands of certain receptors to the liposome using 
phosphatidylethanolamine as the anchor (Chen et al., 2010).  
 
 Ligands on the other hand usually carry the necessary functional groups required 
for conjugation, but if they are absent, methods have been devised to introduce them by 
attachmemt of ligands. Figure 3.1 depicts the covalent reactions that are mostly used for 
coupling ligands to the anchors. These reactions utilize the thioether, disulfide, and 
hydrazone linkages, because the functional groups required for these linkages are most 
often already present on the ligand. Cross-linking reactions between the primary amines 
or the carboxylic acid functions on the surface of the liposomes with the primary amine  
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Figure 3.1. Schematic diagram of the different coupling methods 
 
Notes. Reaction between maleimide and thiol functions (A), formation of a disulfide bond 
(B), reaction between carboxylic acid and primary amine group (C), reaction between 
hydrazide and aldehyde function (D), and cross-linking between two primary amine (E). 
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of the ligands have also been explored (Benita, 2006).  
 
 The thioether bond is a stable bond.  Covalent linkages based on this linkage 
generally require a multistep reaction for coupling ligands. However, since the ligand or 
the protein may be devoid, inaccessible or may have insufficient number of native thiol 
groups, chemical modifications are required.  
 
 Such modifications can be accomplished by using cross-linking agents or by 
reducing the existing disulphide linkages within the ligand (Sapra and Allen, 2002, 
Kirpotin et al., 1997, Sapra and Allen, 2004, Cheng and Allen, 2008, Ishida et al., 2001, 
Sapra et al., 2004, Loomis et al., 2010, Kirchmeier et al., 2001). Commonly used cross 
linkers are N-hydroxysuccinimidyl-3-(2-pyridyldithio) propionate (SPDP) and N-
succinimidyl-S-acetylthioacetate (SATA). The most frequently used anchors are N-(4-(p-
maleimidophenyl) butyryl) phosphatidylethanolamine (MPB-PE) and maleimide-
derivatized PEG2000 (Mal-PEG) (Benita, 2006).  
 
 Another reliable method involves coupling two thiol functions to give a disulfide 
bond (Benita, 2006). This too is a multi-step reaction as thiolated ligands need to be made 
available by reduction of the disulfide bonds or by using cross linking agents like SATA 
or SPDP. Using these agents conjugated protein bound dithiopyridine is obtained, which 
protects the disulfide bond but can easily be reduced using dithiothreitol (DTT).  These 
thiolated ligands can then be attached to the anchor using maleimide groups as shown 
previously or to pyridyldithio groups on the anchor to form disulfide bonds (Martin et al., 
1981).  
 
 Although the SATA coupling reactions can be utilized for small molecules as 
targeting ligands, such reactions may be detrimental to targeting ligands of biological 
origin. The reaction conditions can always pose a potential risk of the protein fragment 
losing its conformation while the modification is being made. In such scenarios, the 
carboxylic acid functional groups on the surface of liposomes can also be utilized to cross 
link with the primary amines of the ligands. For carrying out this bonding, distearoyl-N-
(3-carboxypropionoylpoly(ethyleneglycol)succinyl)phosphatidylethanolamine (carboxyl-
PEG2000-DSPE) has often been used (Magalhaes et al., 1995). The C-terminal end of the 
polyethylene glycol (PEG) provides the carboxylic acid function. A stable amide bond is 
yielded when a cross linking agent 1-ethyl-3-(3- dimethylaminopropyl) carbodiimide 
(EDAC) is added which forms an acyl amino ester which reacts with the primary amine 
of the ligand. This method of coupling is advantageous over the other two above 
mentioned methods because no prior modification of the ligand is required which reduces 
the risk of denaturation and activity loss. Therefore careful and extensive studies must be 
conducted to verify the conjugation of the ligand with the anchor and also to validate the 
activity of the ligand. Similar to the carboxylic acid functional group, the primary amine 
on anchor have also been used to cross link with the primary amine of the ligands and 
reaches a coupling efficiency of 60% (Torchilin et al., 1978).  
 
 Hydrazide groups can be introduced onto the liposomal surface that can 
covalently bind antibodies using their carbohydrate moieties. The aldehyde groups are 
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obtained by mild oxidation reactions of the carbohydrates on the constant region of the 
heavy chain of the antibody. These aldehyde groups in turn react with the hydrazide 
groups on the surface of the liposomes to yield a hydrazone linkage (Lopes de Menezes 
et al., 1998, Lopes de Menezes et al., 2000, Benita, 2006, de Menezes et al., 1999).  
 
 The expanding concept of "click chemistry" has also been exploited by Hassane 
and co-workers wherein ligands on the surface of preformed SUV’s have been 
conjugated in an efficient method. In such conjugation reactions mild conditions are 
employed in aqueous buffer systems and in the presence of metal ion chelators such as 
copper. This approach is exemplified by the conjugation of liposomes comprising of a 
synthetic lipid carrying a terminal alkyne function to an unprotected α-D-mannosyl 
derivative carrying a spacer arm functionalized with an azide group (Hassane et al., 
2006). Although this method is mild and efficient, it suffers from the limitation of use of 
copper catalysts. These reagents have been associated with degradative side-reactions 
that are oxidative in nature and render the bilayer leaky (Agard et al., 2004). The reaction 
scheme for conjugation utilizing click chemistry has been depicted in Figure 3.2.  
 
 
3.2. Non-covalent Coupling 
 
 Non-covalent interactions are an alternative way to couple ligands to liposomes. 
These methods have the advantage of incorporating the ligand more easily compared to 
the covalent methods and doing this without using aggressive reagents. However, the 
unreliability of the conjugation and the loss of activity of the targeting ligand have led to 
the wider acceptance of covalent attachment procedures when compared to non-covalent 
linkages. The methods that have been investigated previously include innovative ways of 
synthesizing lipid conjugated antibodies, which are essentially lipids conjugated to single 
chains of antibodies. These lipo-proteins are then incorporated into the liposomal 
membranes or adsorbed onto preformed liposomes (Laukkanen et al., 1995, Laukkanen et 
al., 1993).  However, it may be debated that this method does not involve chemical 
reactions thus the ligand may detach and diffuse away from the surface of the liposome.  
 
 Another technique includes the use of haptens that are displayed on the surface of 
the vesicles (Benita, 2006). These liposomes tend to bind to their targets in the presence 
of their specific antibodies. In a related study, hapten derivatized 
phosphatidylethanolamine (PE) were prepared and incorporated into the surface of the 
liposomes. However, a major drawback of using this method is that these liposomes 
deliver very little drug to the tumour cells. The reason is that the soluble hapten inhibits 
the liposomes from binding to the target cells.  
 
 One of the initial approaches to tag liposomes with antibodies was to heat 
aggregate the antibodies onto the surface of the liposomes (Benita, 2006). Here the 
interaction between the liposome and the aggregated immunoglobulin’s is based on 
electrostatic and hydrophobic interactions. These interactions are preferentially with the 
Fc (constant fragment) region of the immunoglobulins. Bonding via these sites is usually 
not very stable and displays poor efficiency of coupling of the antibody on the liposomal  
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Figure 3.2. Reaction scheme for click chemistry 
 
Notes.  1 = 2-Carboxyethyl 2,3,4,6-tetra-0-acetyl-1-thio-β-D-galactopyranoside, 2 = O-
(2-Aminoethyl)-O′-(2-azidoethyl)undecaethylene glycol, 3 = N-[(2-(2-
Azidoethoxy)ethoxy10)ethyl-(1-deoxy-2,3,4,6-tetra-O-acetyl-thio-α-D-
mannopyranosyl)]propionamide, 4 = N-[2-(2-Azidoethoxy)ethoxy10)-ethyl(1-deoxy-1-
thio-α-D-mannopyranosyl)]propionamide, 5 = N-[2-(2-(2-(2-(2,3- 
Bis(hexadecyloxy)propoxy)ethoxy) ethoxy)-ethoxy)ethyl]hex-5-ynamide.  
To a solution of 1 (ligand) in dichloromethane (CH2Cl2), N,N'-Dicyclohexylcarbodiimide 
(DCC) and N-Hydroxysuccinimide (NHS) are added and stirred for 45 minutes at room 
temperature (RT) under argon. A solution of 2 in CH2Cl2 containing N,N-
Diisopropylethylamine (DIEA) is added and stirred for 18 hours. Then, DIEA and 0.2 
equivalents of 2 are added and stirred for 48 hours. This gives a precipitate of 3 which is 
removed and purified. 3 is dissolved in methanol (MeOH) and potassium carbonate 
(K2CO3) is added with a few drops of water. This deprotection reaction is performed 
under argon at RT for 4 hours. The reaction product gives 4 which is a yellow coloured 
oil and is separated and purified. DCC and NHS are added to a solution of 5-hexynoic 
acid in CH2Cl2. Functionalized vesicles are prepared by adding the anchor 5, which 
carries the alkyne moiety, to the lipid solution of the lipids in chloroform/methanol (9/1, 
v/v).  The functionalized liposome and the azidomannose (4) are then incubated together 
with bathophenanthrolinedisulphonate (L), CuSO4, Na-Ascorbate and NaCl in HEPES 
buffer at a pH of 6.5 and stirred for 6 hours at RT. This gives liposomes conjugated to 
mannose residues on the surface.  
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surface, thus the amount of antibody getting coupled onto the surface cannot be 
controlled. Another major drawback of this method is that the heat aggregated antibody 
acts as an antigen and eventually the host can develop inhibitory antibodies against it 
(Purohit et al., 2006).  
 
 A non-covalent bond that has a binding constant comparable to covalent bonds is 
the avidin – biotin interaction. This is also a multi-step approach in which one can use a 
biotinylated lipid molecule such as DSPE-PEG-Biotin, which is embedded in the 
liposomal surface while the liposome is processed followed by avidin attachment to the 
biotin on the surface of the liposome. The biotinylated antibody is then attached to the 
avidin thus giving antibody coupled liposomes (Loughrey et al., 1987). Figure 3.3 shows 
the conjugation of ligands to nanoparticles using the avidin-biotin reaction.  
 
 
3.3. Post Insertion Method 
 
 The post insertion method is different from all the other methods previously 
described. It can be used to conjugate whole antibodies, antibody fragments, peptides or 
other ligands. In this method, the ligand of choice is coupled to micelles composed of 
Mal- PEG- DSPE using the thiol reaction (Benita, 2006), which are then incubated with 
the preformed drug loaded liposomes under the conditions that allow the transfer of the 
ligand-PEG-DSPE onto the liposomes (Allen et al., 2002a, Zhang et al., 2010). For 
example, the authors have described the transfer of ligand coupled mPEG-DSPE to DOX 
or vincristine (VCR) loaded vesicles at the transition temperature of the lipid mix, 60 – 
65 °C for 0.5 to 1 hour. Time and temperature are the only two variables on which the 
conjugation is dependent. The advantage of this method is that the condition for 
conjugation is decoupled from the conditions for the preparation of liposomes. The 
features of targeted liposomes prepared by this method are not different from those 
prepared by covalent or non-covalent methods.  
 
 Other than the type of conjugation utilized, the choice of ligand for targeting is 
also important. If the ligands are antibodies they can be used as the whole antibody 
molecule, the Fab’ or as a fragment of the antibody chain for conjugation. All three 
ligands have been successfully utilized in targeting cancer cell specific epitopes. 
However, their efficacies differ to some extent due to their altered half lives in the blood. 
Cheng et al (Cheng and Allen, 2008) have compared SIL-DOX targeted to CD19 using 
either whole monoclonal antibody (HD37mAb), the Fab’ fragment (HD37 Fab’) or 
HD37–c-myc–Cys–His5 single chain Fv (variable fragment), HD37-CCH, which is only 
a part of the Fv fragment of the antibody HD37. The HD37-CCH was produced by 
recombinant DNA technology in E. coli. For antibody conjugation, a modification of the 
post-insertion method was utilized (Iden and Allen, 2001). Briefly, the HD37-CCH and 
the HD37 F(ab´)2 were reduced with DTT in HBS. After removal of unreacted DTT, the 
HD37-CCH or HD37 Fab´ were immediately coupled to the Mal-PEG2000-DSPE micelles 
at a molar ratio of 1:4 [short chain variable fragment (scFv) or Fab´:Mal-PEG2000-DSPE]. 
The whole mAb HD37 was thiolated using Traut's reagent. The thiolated mAb was 
coupled to Mal-PEG2000-DSPE/mPEG2000-DSPE (1:4 molar ratio) micelles at a molar  
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Figure 3.3. Ligand attachment to nanoparticles using the biotin-avidin reaction 
 
Notes. A biotinylated lipid molecule such as DSPE-PEG-Biotin, is embedded in the 
liposomal surface while the liposome is processed followed by avidin attachment to the 
biotin on the surface of the liposome. The biotinylated antibody is then attached to the 
avidin giving antibody coupled liposomes.  
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ratio of 1:10 (mAb:Mal-PEG2000-DSPE). The micelles conjugated with the three distinct 
forms of the HD37mAb were then incubated with preformed liposomes. Once studied in 
mice, it was observed that the immunoliposomes tagged with HD37 Fab’ had the longest 
circulation half-lives and also were most effective in prolonging survival times compared 
to SIL-DOX targeted via either HD37-CCH or HD37mAb. This can be attributed to the 
rapid clearing of the HD37mAb by the liver and spleen by Fc mediated uptake and the 
clearance of HD37-CCH by the liver due to the poly-His and the c-myc tags in the scFv 
construct.  
 
 Since the Fab´ has a longer circulation half-life compared to the whole antibody 
as shown by a number of groups (Cheng and Allen, 2008, Sapra et al., 2004), in the 
present study, anti-CD22 Fab´ was used for targeting LCLA to CD22+ B cell 
malignancies. Since the thioether bond displayed to be most stable of the conjugation 
techniques, it was used for the conjugating the anti-CD22 Fab´ to the mal-DSPE-PEG2000 
derivatized liposomes. The method used for the conjugation and the studies performed to 
validate it are briefly outlined below.  
 
 
3.4. Materials and Methods 
 
 
3.4.1. Materials 
 
 Mal-DSPE-PEG2000 was purchased from Avanti Polar Lipids, Alabaster, AL, 
USA, Thermo Scientific™ CL-XPosure™ Film (X-Ray Film), Sepharose CL4B gel 
filtration gel, anhydrous citric acid and empty PD-10 columns were purchased from 
Thermo Fisher Scientific, Waltham, MA, USA, anti-CD22 monoclonal antibody (RFB4) 
was a generous gift from the lab of Dr. Ellen Vitetta, University of Texas, Southwestern 
Medical Center, Dallas, TX, USA, empty macro SpinColumns® were purchased from 
Harvard Apparatus, Holliston, MA, USA, Amicon® Ultra – 0.5 mL centrifugal filters, 
Ultracel® - 100K and Ultracel® - 30K were purchased from Millipore, Bellericka, MA, 
Laemmli buffer, polyacrylamide gels were purchased from Bio-Rad, Hercules, CA, USA, 
and materials for SEM (scanning electron microscopy) were generously provided by 
Bioscience Research Center, College of Dentistry, UTHSC.  
 
 
3.4.2. Fab’ generation from whole anti-CD22 antibody 
 
 The antibody was first purified by passing through a G50 prefilled macro column. 
The Fc (constant fragment) region was first digested using immobilized pepsin. Briefly, 
the immobilized pepsin was first separated from the vehicle by loading the immobilized 
pepsin suspension into an empty macro column and centrifuging it for 2 minutes at 5000g 
and 4°C. The purified anti-CD22 monoclonal antibody was then incubated with the 
immobilized pepsin at pH 3.0, 37°C for 6 hours. pH 3.0 was adjusted using 1M citric acid 
solution. After the given time, the antibody was collected by centrifuging the 
immobilized pepsin and antibody digest in an empty macro spin column at 5000g for 2 
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minutes at 4°C. The collected antibody digest was then incubated with 10μl of 5 mM 
TCEP (tris(2-carboxyethyl)phosphine) at room temperature for 1 hour. This gave 2Fab’ 
fragments from each molecule of antibody. The resulting digest mix was purified by 
filtration using two filters 100K and 30K MWCO and the appropriate fraction containing 
the 50 kD Fab’ was collected and used for conjugation. A schematic or this reaction is 
given in Figure 3.4.  
 
 
3.4.3. Conjugation of Fab’ to liposomes to give long circulating CD22 targeted 
liposomal AD 198 (LCCTLA) 
 
 For conjugation with antibody, liposomes were prepared in the same method as 
mentioned above, only 50% of m-DSPE-PEG2000 was replaced with mal-DSPE-PEG2000 
to serve as an anchor for the antibody. 100 μL of the Fab’ was incubated with an equal 
volume of the maleimide derivatized liposomes at 4°C for 12-15 hours. Following 
incubation, unconjugated antibody fragments were removed by gel filtration 
chromatography using Sepharose CL4B gel. Briefly, the 70% gel slurry in ethanol was 
filled in an empty PD-10 column and centrifuged at 1000g for 150 seconds at 4°C to 
remove the ethanol. Three 1x PBS washes followed the removal of ethanol. The column 
was the saturated with placebo liposomes in three separate runs and then the 200 μL of 
targeted liposomes were passed through the column. The final reaction for the 
conjugation between the maleimide derivatized liposomes is depicted in Figure 3.5. The 
resulting solution is analyzed for proof of conjugation by western blotting.  
 
 
3.4.4. Verification of conjugation  
 
 Conjugation of the 50 kD Fab’ fragment to the liposomes was verified by western 
blotting as done by Oliveira et al (Oliveira et al., 2010). Briefly, 4 samples were studied: 
the targeted liposomes, the fraction higher than 100 kD, the fraction below 50 kD and the 
whole antibody were quantified for total protein by the BCA assay and 20 μL (10 μL 
sample and 10 μL Laemmli buffer) of an equal concentration sample of protein (250 ng) 
were loaded into a 4-15% polyacrylamide gel. Samples were run at 100V for 
approximately one hour (until the Laemmli dye reached the end of the gel). The protein 
bands were then transferred from the gel onto a PVDF (polyvinylidene fluoride) 
membrane. The membrane was probed with a mouse secondary antibody and the blot was 
developed on an x-ray film.  
 
 
3.4.5. Calculation of number of antibody molecules per liposome 
 
 The number of anchors (maleimide groups) and the number of antibody 
molecules per liposome were calculated by first calculating the number of liposomes as 
in the previous chapter. Then number of antibody molecules and maleimide were 
calculated in one mL of the LCCTLA by using Avogadro’s number and substituting the 
values in Equation 3.1.  
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Figure 3.4. Generation of anti-CD22 Fab´ fragments 
 
Notes. Purified anti-CD22 monoclonal antibody was incubated with immobilized pepsin 
at pH 3.0, 37°C for 6 hours. The partially digested antibody was collected by centrifuging 
the immobilized pepsin and antibody digest in an empty macro spin column at 5000g for 
2 minutes at 4°C. The collected antibody digest was then incubated with TCEP  for 1 
hour. This gave 2Fab’ fragments from each molecule of antibody. 
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Figure 3.5. Conjugation of anti-CD22 Fab´ to maleimide derivatized LCLA 
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(Eq 3.1) 
 
Where ‘x’ may be the maleimide or anti-CD22 Fab´.  
 
 
3.4.6. SEM evaluation of morphology of LCCTLA nanoparticles 
 
 Morphology of LCCTLA particles where analyzed by SEM. Briefly, 100 μL of 
the LCCTLA particles were loaded onto standard SEM pin stub mounts. They were dried 
overnight and coated with gold dust for 20 seconds. The samples were then viewed under 
the Carl Zeiss EVO LS15 scanning electron microscope.  
 
 
3.5. Results and Discussion 
 
 
3.5.1. Verification of conjugation 
 
 A western blot of the conjugated liposomes was run with the other fractions and 
the whole antibody. The results are shown in Figure 3.6B. Results for whole antibody 
and the fraction below 50 kD are not shown here. The whole antibody gave a very intense 
band at the 150 kD region whereas the concentration of protein for the fraction below 50 
kD was very low and bands were too faint to be seen. However, the fraction larger than 
100 kD has been shown here. Figure 3.6A shows the possible combinations of the 
antibody digests that may be produced and may show up on the blot. Fab´ would be 50 
kD each, F(ab´)2 would be 100 kD, the Fc region has been digested by pepsin thus would 
be broken into very small peptides possible smaller than 10 kD, and undigested antibody 
would be 150 kD.  
 
 In Figure 3.6B in the targeted liposomes lane, we see a clear band at 50 kD. Since 
we have removed other fragments such as the Fc pepsin digests and whole antibody from 
the 50-100 kD fraction, this is the possibly band for the anti-CD22 Fab´. In the lane with 
the fraction >100 kD, we see two bands, one at 150 kD and one at 100 kD. The 150 kD 
band most possibly is the whole anti-CD22 whole antibody whereas the 100 kD band 
could be the F(ab´)2. The appearance of a strong band at 50 kD in the LCCTLA sample 
proves that conjugation between the liposomes and the Fab´ was successful. 
 
 
3.5.2. Number of anti-CD22 Fab´ and maleimide per liposome 
 
 2.2 mg/mL of mal-DSPE-PEG2000 was added to make LCCTLA particles. This 
equals 748 μM of mal-DSPE-PEG2000. Using Avogadro’s number we get 4.5 x 1020 mal-
DSPE-PEG2000 molecules/mL. As specified in the method, the number of maleimide’s 
per liposome can be calculated by the Equation 3.2.   
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Figure 3.6. Verification of anti-CD22 Fab´ conjugation 
 
Notes. (A) Anti-CD22 possible digest variants. Fab´ would be 50 kD each, F(ab´)2 
would be 100 kD, the Fc region has been digested by pepsin thus would be broken into 
very small peptides possible smaller than 10 kD, and undigested antibody would be 150 
kD. (B) Verification of conjugation of anti-CD22 Fab´ by western blotting. A clear 
band at 50 kD was oberved. Since I removed other fragments such as the Fc pepsin 
digests and whole antibody from the 50-100 kD fraction, this is the possibly band for the 
anti-CD22 Fab´. In the lane with the fraction >100 kD, two bands were observed, one at 
150 kD and one at 100 kD. The 150 kD band most possibly is the whole anti-CD22 
whole antibody whereas the 100 kD band could be the F(ab´)2.  
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 The number of anti-CD22 Fab´ molecules were calculated in a similar method. 
The analyzed concentration of Fab´ fragments in LCCTLA was 313 μg/mL which equals 
6.26 μM. Using the Avogadro’s number the number of anti-CD22 Fab´ molecules/mL 
were calculated to be 3.77 x 1018 molecules/mL. Substituting these numbers in Equation 
3.3: 
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(Eq. 3.3) 
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3.5.3. Morphology of LCCTLA particles by SEM 
 
 Figure 3.7 is a scanning electron micrograph of LCCTLA particles. It was 
observed that the particles were spherical in shape and were approximately 130 – 150 nm 
in size. Some of the nanoparticles appear to be aggregated which may be due to drying of 
the sample in an uncontrolled environment. Also, only a single layer of the LCCTLA 
particles is visible in the image, and therefore 20 seconds of gold dust coating can be 
reduced to 15 seconds or less if deeper layers of the dried LCCTLA are to be viewed.  
 
 
3.6. Summary and Conclusions 
 
 The 50 kD anti-CD22 Fab´ was successfully produced by the digestion and 
reduction of the whole RFB4 andti-CD22 antibody. It was effectively isolated using two 
filters of 100 kD and 30 kD MWCO filters. The results from the western blot analysis 
suggest that the thioether bonding was effectively utilized to conjugate the anti-CD22 
Fab´ to the maleimide derivatized liposomes to give LCCTLA. 1% mal-DSPE-PEG2000 
was optimum for the conjugation as suggested by approximately 1626 maleimide 
molecules per liposome as compared to only 13 anti-CD22 Fab´ molecules per liposome. 
There was an excess of maleimide for every antibody molecule and that is how it is 
suggested it should be so that maximum number of antibody molecules can be conjugated 
to the liposomes.  
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Figure 3.7. SEM image of LCCTLA (Magnification - 8000x) 
 
Notes. It was observed that the particles were spherical in shape and were approximately 
130 – 150 nm in size. Some of the nanoparticles appear to be aggregated which may be 
due to drying of the sample in an uncontrolled environment. Also, only a single layer of 
the LCCTLA particles is visible in the image, and therefore 20 seconds of gold dust 
coating can be reduced to 15 seconds or less if deeper layers of the dried LCCTLA are to 
be viewed.  
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CHAPTER 4.    IN VITRO EVALUATION OF CELLULAR UPTAKE AND 
CYTOTOXICITY OF LCCTLA 
 
 
 Confocal and fluorescence microscopy is routinely utilized to study the uptake of 
molecules or particles into cells (Ducat et al., 2011). Laser scanning confocal microscopy 
(CSLM) is an established technique to obtain high resolution images of a variety of 
biological specimens (Suh et al., 1998). Daudi cells are used by researchers for their high 
expression of CD22 and CD19 which can be exploited as potential targets for malignant 
B cell nano-therapies (Chen et al., 2010, Carnahan et al., 2007, DiJoseph et al., 2006, Du 
et al., 2008, Loomis et al., 2010, Tuscano et al., 2010). These cells were derived from a 
16 year old Black male with Burkitt’s lymphoma. Daudi cells are tumorigenic in nude 
mice and can be used to implant tumors or disease in animals for study. These cells are 
also very sensitive to interferon-α and their growth is inhibited by very low concentration 
of this interferon.  Jurkat cells are malignant T cells that can be used to compare results 
with Daudi cells since they are devoid of the CD22 and CD19 receptors. These cells were 
originally derived from the peripheral blood of a 14 year old boy  with a cancer of th T-
cells. Jurkat cells are characteristically used in the studies of cytokines since they produce 
interleukin-2. Treatment of these cells with fluorescent nanoparticles or with 
nanoparticles loaded with fluorescent molecules enables intracellular nanoparticle 
tracking.  
 
 Flow cytometry is another technique that is extensively used for a variety of study 
applications including cellular uptake of drug loaded nanoparticles such as liposomes 
(Huth et al., 2006, Wender et al., 2000, Koller-Lucae et al., 1999, Ducat et al., 2011). 
Using a fluorescent drug molecule or incorporating a fluorescent lipid such as NBD-PC 
into the liposome bilayer, enables quantitative analysis of cellular nanoparticle uptake by 
flow cytometry. The number of nanoparticles internalized will be proportional to the 
fluorescence intensity (read by flow cytometry). Higher fluorescence intensity 
corresponds with a higher nanoparticle uptake. Flow cytometry is also used to measure 
cellular association of the nanoparticles to the cells. Receptor mediated endocytosis is an 
ATP dependent process (Schmid and Carter, 1990) and its activity is greatly reduced at 
4°C (Dautry-Varsat et al., 1983). To confirm the mechanism of uptake of LCCTLA into 
CD22 expressing Daudi cells the cells can be incubated at 4°C and their uptake compared 
to cells incubated at 37°C.  
 
 One way of determining the therapeutic efficacy of drug loaded liposomes is by 
determining the viability of the cancer cells under equivalent doses over the same period 
of treatment as free drug formulations. The MTT assay (Mosmann, 1983) is an assay that 
has been used for decades now to measure the number of viable cells in culture. In the 
MTT assay, live cells are detected by conversion of the MTT dye (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) into insoluble formazan in the 
presence of NAD(P)H dependent enzymes. The purple colored insoluble formazan dye 
can be solubilized by using solubilizing agents such as DMSO or an acidic solution of a 
strong detergent such as SDS (sodium dodecyl sulfate). The absorbance of this reactant 
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mixture is measured at λ 570 nm. The absorbance of the mixture increases with cell 
viability. Therefore the more potent a drug, the lesser the absorbance will be.  
 
 In the following segment, studies were conducted to ascertain AD 198 uptake and 
cytotoxicity in CD22 overexpressing Daudi cells and CD22 deficient Jurkat cells. To 
determine uptake, fluorescent LCCTLA and LCLA were prepared by substituting 0.125 
mole% of HSPC with NBD-PC (a fluorescent lipid). For cellular cytotoxicity, the non-
fluorescent liposomes were used.  
 
 
4.1. Materials and Methods 
 
 
4.1.1. Materials 
 
 Daudi and Jurkat cells were purchased from ATCC, Manassas, VA, MTT (3-(4, 
5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide) was purchased from Sigma-
Aldrich Co. LLC, St. Louis, MI, USA, NBD-PC was purchased from Avanti Polar 
Lipids, Alabaster, AL, USA, SDS, DMF (dimethylformamide), DMSO, 80% acetic acid 
and 1N HCl (hydrochloric acid) were purchased from Thermo Fisher Scientific, 
Waltham, MA, USA, and Vectashield® cell mounting medium with DAPI (4', 6-
diamidino-2-phenylindole) was purchased from Vector Labs, Burlingame, CA, USA.  
 
 
4.1.2. Cellular uptake of LCLA and LCCTLA by flow cytometry 
 
 To determine and compare cellular uptake in CD22+ Daudi and CD22- Jurkat 
cells CD22 targeted liposomes were prepared in the same method as specified previously 
only 0.125 mole % of the HSPC was substituted with an equal mole % of NBD-PC for 
fluorescence imaging. Six time points were tested ranging from 5 minutes to 4 hours 
(Huth et al., 2006). 10 ml each of Daudi and Jurkat cells at a cell density of 7x105/ml 
were grown in T25 flasks for each time point. At each time point, both cell types were 
treated with two types of 1 μM AD 198 formulations, LCLA and LCCTLA separately. At 
the end of the each time point the cells were centrifuged at 4°C and 100g for 4 minutes. 
The pellet obtained was washed with 1x PBS thrice and the final cell pellet was re-
suspended in 1 mL of 1x PBS and tested for fluorescence intensity for NBD-PC per 
10,000 cells using the BD Accuri™ C6 Flow cytometer. 
 
 
4.1.3. Cellular uptake of LCLA and LCCTLA by confocal scanning laser 
microscopy 
 
 Jurkat and Daudi cells were prepared and treatments were given in the same 
method as in the method for the determination of cellular uptake by flow cytometry (Huth 
et al., 2006). In the present study one time point was tested at 30 minutes. The cell pellet 
obtained after three PBS washes was re-suspended in a single drop of Vectashield® cell 
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mounting medium with DAPI. These cells were mounted onto a microscope slide and 
covered by a Fisherbrand number 1 coverslip. The slide was allowed to dry in a fume 
hood for approximately 30 minutes and the edges are sealed using a transparent nail 
polish. The nail polish was also allowed to dry in a fume hood for another 30 minutes 
after which the slide was viewed under a Nikon Eclipse E800 confocal scanning laser 
microscope. The lasers were set at the wavelength for NBD-PC, AD 198 and DAPI and 
images were taken.  
 
 
4.1.4. Evaluation of LCCTLA cytotoxicity 
 
 To determine cellular cytotoxicity, the MTT assay was used (Mosmann, 1983). 
Briefly, Daudi and Jurkat cells were grown to the required cell density. The assay was set 
up in 96 well plates. Three different formulations of AD 198 were tested; LCCTLA, 
LCLA and free AD 198. Free AD 198 was prepared in DMSO such that the final 
concentration of DMSO was less than 3% in any treatment well.  Two time points were 
prepared for each treatment, 24 hours and 48 hours. For the 24 hour treatment 17,500 
cells per well were plated and for the 48 hour treatment 8750 cells per well were plated. 
Treatment was done for 10 concentrations of each of the three AD 198 formulations 
ranging from 0.01 μM to 3 μM and the control was cells with no drug treatment. These 
plates were incubated at 37°C and 5% CO2 for the study time period. At the end of the 
study time (24 or 48 hours) 15 μL of 5 mg/mL concentration of MTT dye was added to 
each well of study and incubated under the same conditions mentioned above for 4 more 
hours. Following the 4 hour incubation the insoluble formazan dye formed as a result of 
the reaction was dissolved in 100 μL of solubilization buffer (20% SDS in 50% DMF, 
0.5% of 80% acetic acid and 0.4% 1N HCl) and incubated for 3 hours. After incubation 
absorbance is read at λ 570 nm using the Molecular Devices, SpectraMax M2e® 
microplate reader.  
 
 
4.2. Results and Discussion 
 
 
4.2.1. Cellular uptake of LCLA and LCCTLA 
 
 Flow cytometry and confocal laser scanning microscopy were utilized to 
determine the uptake of LCLA and LCCTLA in Daudi and Jurkat cells. Figure 4.1 
summarizes the results for cellular uptake of both formulations in both Daudi and Jurkat 
cells. It was observed that the maximum uptake at each time point was for LCCTLA in 
Daudi cells. The least uptake was seen with LCLA treated Jurkat cells at every time 
point. Daudi cells treated with LCLA and Jurkat cells treated with LCCTLA had 
intermediate uptake. Maximum uptake in Daudi cells treated with LCCTLA was 
understandable due to the CD22 receptor being overexpressed on the Daudi cells and the 
LCCTLA having the antibody for this overexpressed receptor. However, the Jurkat cells 
having higher uptake with LCCTLA than LCLA is more complicated to explain. One 
theory we suggest is that the Jurkat cells may have some receptor on their surface with  
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Figure 4.1. Time dependent cell uptake of LCLA and LCCTLA in Daudi and 
Jurkat cells (n=3) 
 
Notes. It was observed that the maximum uptake at each time point was for LCCTLA in 
Daudi cells compared to other cell types and formulations (p<0.05 for all groups). The 
least uptake was seen with LCLA treated Jurkat cells at every time point. Daudi cells 
treated with LCLA and Jurkat cells treated with LCCTLA had intermediate uptake. 
Maximum uptake in Daudi cells treated with LCCTLA was understandable due to the 
CD22 receptor being overexpressed on the Daudi cells and the LCCTLA having the 
antibody for this overexpressed receptor. However, the Jurkat cells having higher uptake 
with LCCTLA than LCLA is more complicated to explain. One theory we suggest is that 
the Jurkat cells may have some receptor on their surface with which the anti-CD22 Fab´ 
non-specifically interacts, thus causing higher uptake. Also, it was seen for Daudi cells 
treated with LCCTLA, the uptake plateaued at approximately one hour. Therefore, 
maximum uptake had already taken place by one hour. Error bars represent standard 
deviation around the mean.  
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which the anti-CD22 Fab´ non-specifically interacts, thus causing higher uptake. Also, it 
was seen for Daudi cells treated with LCCTLA, the uptake plateaued at approximately 
one hour. Therefore, maximum uptake had already taken place by one hour. These results  
were consistent with CSLM results (Figure 4.2) which indicated a fluorescence pattern in 
the cells consistent with the flow cytometry data.  
 
 
4.2.2. Analysis of cytotoxicity of LCCTLA 
 
 Once that the cellular uptake studies and the mechanism of liposome uptake was 
known, cellular cytotoxicity studies were performed. As mentioned above three different 
formulations were tested in two cell types, CD22 expressing Daudi and non-CD22 
expressing Jurkat cells. The study was performed to see the cytotoxic effect of the 
formulations at two lengths of exposure, 24 and 48 hours. Figures 4.3 to 4.6 depict the 
results from this study. Figure 4.3 exhibits the cytotoxic effects of the three formulations, 
free drug, LCLA and LCCTLA over 24 hours in Daudi cells. The difference in 
cytotoxicity between different formulations is clearly pronounced. All through from 0.01 
μM to 3 μM AD 198 concentration, free AD 198 turns out to be the most cytotoxic, with 
an IC50 of approximately 0.25 μM. LCLA has an IC50 at about 0.5 μM, but LCCTLA 
have an IC50 of 1.5 μM. Up to 1 μM LCLA was more cytotoxic than LCCTLA and 
almost equally cytotoxic at 1.5 μM. At 2 μM and 3 μM, LCCTLA displayed higher 
cytotoxicity. This may be attributable to the process of receptor mediated endocytosis 
which may possibly take some additional time to endocytose the targeted liposomes. The 
Jurkat cells are devoid of theses receptors and thus we see the results as displayed in 
Figure 4.4, which are the results for the 24 hour study in Jurkat cells. Since the CD22 
receptor is absent in Jurkat cells, LCCTLA is not as cytotoxic as LCLA or free AD 198.  
 
 Moving on to the 48 hour cytotoxicity study, a steadily increasing cell death 
pattern was noticed in both Jurkat (Figure 4.5) and Daudi cells (Figure 4.6) from 0.01 
μM to 0.5 μM for all formulations. Then from 0.75μM up to 3 μM, there is not much of a 
pronounced difference between concentrations and also between the formulations. This 
result may be attributed to the overburdening of the cells with drug in all types of 
formulations. Since the drug is not being cleared as in in vivo systems, all the drug from 
the formulation eventually enters the cells and kills them. This may be controlled by 
developing a system that would mimic blood circulation as in whole animals. One such 
model was developed by Budha et al at the University of Tennessee Health Science 
Center (Budha et al., 2009). Nevertheless, in vivo models would always give more 
accurate representations of how the drug would behave in clinical settings.  
 
 
4.3. Summary and Conclusions 
 
 In vitro studies for determination of cellular uptake and the MTT assay for cell 
cytotoxicity were successfully conducted. The cellular uptake of AD 198 formulations 
result suggested that uptake of LCCTLA was highest in Daudi cells and reached a plateau 
between 30 minutes and 1 hour. Next highest uptake was seen for LCCTLA in Jurkat  
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Figure 4.2. CSLM images of cellular uptake studies in Daudi and Jurkat cells 
(n=3) 
 
Notes. Maximum uptake of the CD22 targeted liposomes in Daudi cells was confirmed 
by confocal microscopy. These results corroborated the results from the flow cytometry 
studies.  
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Figure 4.3. 24 hours Daudi AD 198 cytotoxicity (n=3) 
 
Notes. Refer to section 4.2.2 for a detailed discussion. Error bars represent standard 
deviation around the mean.  
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Figure 4.4. 24 hours Jurkat AD 198 cytotoxicity (n=3) 
 
Notes. Refer to section 4.2.2 for a detailed discussion. Error bars represent standard 
deviation around the mean.  
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Figure 4.5. 48 hours Jurkat cytotoxicity (n=3) 
 
Notes. Refer to section 4.2.2 for a detailed discussion. Error bars represent standard 
deviation around the mean.  
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Figure 4.6. 48 hours Daudi cytotoxicity (n=3) 
 
Notes. Refer to section 4.2.2 for a detailed discussion. Error bars represent standard 
deviation around the mean. 
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cells, which could be due to non-specific binding of the anti-CD22 antibody on other 
receptors on the Jurkat cell surface. These results were confirmed with CSLM images of 
liposome uptake, where again LCCTLA fluorescence in Daudi cells was highest 
compared to other cells and formulations. 24 hour cell cytotoxicity results suggested a 
delay in the LCCTLA cytotoxicity in Daudi cells, but ultimately, this cytotoxicity was the 
highest as portrayed in Figure 4.3. The delay could be attributed to the process of 
receptor mediated endocytosis which could be the rate limiting step for drug action. The 
48 hour results possibly were lacking drug clearance which was not built into the model, 
due to which the cytotoxicity of free drug, LCLA and LCCTLA was relatively similar. 
Thus, it was concluded that further studies were required in whole animal models which 
would better mimic clinical settings.  
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CHAPTER 5.    IN VITRO ANALYSIS OF INTRACELLULAR TRAFFICKING 
AND EFFECT ON INDUCTION OF APOPTOSIS  
 
 
 The process of endocytosis has evolved as a method to bring nutrients and other 
molecules into the cell (Sigismund et al., 2012).  However, endocytosis happens to be 
more than just for transport purposes. It is a method of communication with the 
extracellular environment and is deeply engrained and intertwined with cell signaling and 
intracellular communications (Sigismund et al., 2012). Receptor mediated endocytosis is 
one of the many types of endocytotic mechanisms. It can be either constitutive or ligand 
induced. Both processes are very similar apart from the fact that ligand induced requires 
to be triggered by receptor-ligand interaction. The internalized receptors may or may not 
be returned to the cell surface, but if they do, they do in a location that maximizes their 
utility. The invagination and the membrane ripping to form endosomes requires a great 
deal of energy and thus these processes require energy in one form or the other (Doherty 
and McMahon, 2009).  
 
 Specific pathways for endocytosis utilize adaptor proteins to employ additional 
molecules such as clathrins or caveolins. Depending on the molecule required for the 
endocytosis to be successfully completed the pathways are better known as clathrin-
mediated endocytosis or caveolae-mediated endocytosis (CME). Other endocytotic 
pathways such as macropinocytosis also exist which function independent of receptors. 
LCCTLA could employ either one of these pathways. Sanders et al first observed 
nanoparticle endocytosis in rat intestinal epithelia cells when they administered 220 nm 
polystyrene particles intra-gastrically (Sanders and Ashworth, 1961). To determine if the 
pathway is energy dependent, uptake studies can be performed at 4°C at which ATP 
dependent processes cease or slow down to a rate at which they become negligible. 
Comparing uptake results from this with uptake results at 37°C will conclusively suggest 
the uptake mechanism.  
 
 Once confirmed that active endocytotic mechanisms are involved, the next step 
would be to determine the specific endocytotic pathway. Two types of endocytotic 
pathways exist, phagocytosis and pinocytosis. Phagocytosis is the primary mechanism for 
engulfment of opsonized particles by macrophages whereas pinocytosis is the mechanism 
for cells to take in fluid, solutes or suspensions containing small particles such as 
nanoparticles. Pinocytosis can be classified into macropinocytosis, clathrin mediated 
endocytosis, caveolae mediated endocytosis and caveolae and clathrin independent 
endocytosis (Wang et al., 2011). Clathrin mediated endocytosis takes place in all 
mammalian cells. It is dependent on the GTPase activity of dynamin, which helps form 
the clathrin coated vesicles (Pucadyil and Schmid, 2009). This is the main mechanism by 
which CD22 internalizes its ligands (O'Reilly et al., 2011). The caveolae dependent 
endocytotic pathway is one that can bypass fusion with lysosomes and is a preferred 
pathway of entry for pathogens to avoid acid labile degradation. This is mainly a caveolin 
dependent process. Caveolins are proteins which exist in most cells. There are three 
isoforms, Caveolin-1, 2 and 3. However, lymphocytes such as B cells are devoid of 
caveolins (Benmerah and Lamaze, 2007). Macropinocytosis is a caveolae and clathrin 
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independent process. It is induced by growth factor, is driven by energy supplied by actin 
and is largely responsible for internalizing surrounding fluid into vacuoles (Benmerah 
and Lamaze, 2007, Mercer and Helenius, 2009). However, another pathway exists that is 
still not very well understood. This is known as the clathrin and caveolin independent 
pathway. It is so named because of its inherent nature to function even after being devoid 
of both the classical endocytotic proteins. Information that is known about this pathway is 
that it functions using either Arf6, Cdc42 or Rhoa (Mayor and Pagano, 2007). Dynamin 
is also known to play a significant role in this pathway although its function is not yet 
deeply understood. The endocytotic apparatus may contain clathrin independent carrier 
(CLIC) or a GPI-anchored protein-enriched early endosomal compartment (GEEC) 
(Benmerah and Lamaze, 2007).  
 
 Of the methods used to study the mechanisms of the endocytotic pathways, two 
main methods can be utilized, markers and inhibitors. Markers such as low density 
lipoprotein (LDL) (Duit et al., 2010) or transferrin (Liu et al., 2010), which are known to 
enter cells via specific pathways can be used. Another method is to use inhibitors specific 
to a particular pathway is to block the pathway. Inhibitors such as genistein, methyl-β-
cyclodextrin (M-β-CD) or filipin can be used to block caveolae dependent endocytosis, 
chlorpromazine can be used to block clathrin mediated pathway and amiloride can be 
used to block macropinocytosis. Also, mutant cell lines that lack a particular protein 
required by a particular pathway can also be used (Kou et al., 2013).  
 
 Apart from the receptor-ligand interaction or the type of cell, the physicochemical 
characteristics of the nanoparticle also plays a role in which pathway is used for 
endocytosis. The size of nanoparticles has always been believed to play a considerable 
role in the endocytosis of nanoparticles (Zhang et al., 2009). For endocytosis to take 
place, the size range has been 10 nm – 500 nm (Benmerah and Lamaze, 2007). Larger 
particles are engulfed via macropinicytosis. Clathrin mediated pathways are efficient with 
approximately 100 nm sized particles whereas caveolae mediated pathway is more 
efficient with 60-80 nm particles (Benmerah and Lamaze, 2007). Other investigators 
suggest that the size may not be important for the endocytotic process (Huang et al., 
2002). Surface charge plays an important role. Given that the cell membrane is negatively 
charged interaction of cationic particles with the cell surface is higher whereas anionic 
particles may be endocytosed via interaction with the positive charge on the proteins in 
the membrane (Yeung et al., 2008). Hydrophopic particles have a higher interaction with 
the cell but then are picked up by the RES relatively quickly, and require a balance 
between hydrophobic and hydrophilic groups on the surface (Kou et al., 2013).  
 
 Another parameter of particle trafficking was the final fate of the nanoparticle in 
the cell post endocytosis. The theory of endocytosis states that endosomes are usually 
formed post-endocytosis (Kou et al., 2013). However, since the liposomes need a slightly 
acidic environment to aid in immediate drug release, the endosomes containing the 
LCCTLA need to fuse with the lysosomes to bring the pH down and aid in drug release 
(Belchetz et al., 1977, Chu et al., 2005). The localization of liposomes post endocytosis 
can be viewed in a couple of different ways. The best way is to tag lysosomes with 
LysoTracker®, a dye that is available from Life Technologies, which binds to lysosomes 
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or endolysosomes. Another method is to view the cells under a TEM. If the nanoparticles 
can be made electron dense, they can be visualized inside the endosomes using a TEM.  
 
 The effect of AD 198 to induce apoptosis was studied by monitoring the protein 
expressions of specific proteins that are the hallmarks of apoptosis or cancer such as 
caspase-3 or phosphorylated protein kinase B (pAKT) (Edwards et al., 2013). The 
expressions of these proteins can be quantitatively measured by running a western blot 
and probing for the specific proteins of interest.  
 
 In the following section, studies that were conducted to determine the route and 
mechanism of uptake of LCCTA, the intracellular localization of LCCTLA and the effect 
of LCCTLA on expression of hallmark apoptotic and oncogenic proteins are reported.  
 
 
5.1. Materials and Methods 
 
 
5.1.1. Materials 
 
 Amiloride, genistein, M-β-CD and chlorpromazine were purchased from Sigma-
Aldrich Co. LLC, St. Louis, MI, USA, LysoTracker® Deep Red was purchased from 
Thermo Fisher Scientific, Waltham, MA, USA, Iron oxide nanoparticles were purchased 
from Ocean NanoTech, San Diego CA, USA, antibodies for c-myc #5605, pAKT #4058, 
caspase-3 #9662 and anti-mouse secondary #7076 were purchased from Cell Signaling 
Technologies, Danvers, MA, USA and antibodies for pJNK (sc-571), β-actin (sc-130065) 
and anti-rabbit secondary (sc-2357) were purchased from Santa Cruz Biotechnology, 
Dallas, TX, USA. TEM sample preparation materials were generously provided by the 
Imaging Center at the Neuroscience Institute at UTHSC, Memphis, TN, USA.  
 
 
5.1.2. Energy dependent or independent pathway for LCCTLA internalization 
 
 To confirm that the mechanism of uptake of LCCTLA particles into Daudi cells 
was by receptor mediated endocytosis cellular association studies were performed 
(Oliveira et al., 2010). Briefly, 10 ml of Daudi cells at a cell density of 7x105/ml were 
grown in two separate T25 flasks. One was pre-cooled to 4°C and treated with 1 μM 
fluorescent LCCTLA for one hour and the other was treated with 1 μM fluorescent 
LCCTLA at 37°C for one hour. . At the end of the time point the cells were centrifuged at 
4°C and 100g for 4 minutes. The pellet obtained was washed with 1x PBS thrice and the 
final cell pellet was re-suspended in 1 mL of 1x PBS and tested for fluorescence intensity 
for NBD-PC per 10,000 cells using the BD Accuri™ C6 Flow cytometer.  
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5.1.3. Route of uptake of LCCTLA into Daudi cells 
 
 To determine the mechanism of entry of LCCTLA into the Daudi cells, various 
inhibitors were used to block specific pathways and then the uptake analyzed as done in 
the determination of CD22 targeted liposomal drug uptake in cells by flow cytometry. As 
per Douglas et al (Douglas et al., 2008) three specific inhibitors were used; amiloride for 
micropinocytosis, genistein for caveolae mediated endocytosis and chlorpromazine for 
clathrin mediated endocytosis. 10 mL Daudi cells at a concentration of 7 x 105 cells/mL 
were incubated with the inhibitors for one hour at the following specific concentrations; 
amiloride 10 μM, genistein 0.2 μM and chlorpromazine 10 μg/mL. Following this the 
inhibitor treated cells were treated with 1 μM fluorescent CD22 targeted liposomal AD 
198 (as prepared in section 4.1.2) for 1 hour. At the end of treatment the cells were 
processed in the same method as for the determination of LCCTLA uptake in Daudi cells 
by flow cytometry.  
 
 
5.1.4. Intracellular trafficking of LCCTLA by TEM  
 
 
 5.1.4.1.    MLV preparation and treatment of Daudi cells. To view the 
intracellular localization of LCCTLA in the Daudi cells (Gao et al., 2013, Suresh et al., 
2014), 15 nm sized magnetic iron oxide nanoparticles in water (with carboxylic acid 
functional group) were processed into the liposomes (Päuser et al., 1997). Briefly, 1% 
w/w iron oxide nanoparticles were added to the 1x PBS that was used to rehydrate the 
dried lipid film. The MLV’s thus obtained were sonicated for 5 seconds with 5 minute 
intervals. During the sonication and the interval the liposomal suspension was kept in ice. 
The sonication is repeated three times to give magnetic LCLA (MLCLA). The anti-CD22 
Fab´ was conjugated as specified in section 3.2.3 to give magnetic LCCTLA 
(MLCCTLA). 10 mL Daudi cells at a density of 7 x 105 cells/mL were treated with 1 μM 
of the MLCCTLA for 4 hours. After treatment, the cells were centrifuged at 100g for 5 
minutes at 4°C. The pellet was washed with ice cold 1x PBS thrice and suspended in 
1mL 2.5% gluteraldehyde in 1x PBS. 
 
 
 5.1.4.2.    TEM sample preparation. Once the cells were fixed in 2.5% 
gluteraldehyde overnight they were spun down at 100g for 5 minutes and washed with 
10x PBS thrice for 20 minutes each. Then the cells were stained with a 4% osmium 
tetroxide in PBS solution for 1 hour at room temperature and excess stain washed off 
using 10x PBS thrice for 20 minutes each. The cell sample was then dehydrated in an 
ethanol (EtOH) series gradually increasing from 50% EtOH to 100% EtOH in four steps. 
Each dehydration cycle was done once for 10 minutes and the 100% EtOH thrice. The 
cells were then infiltrated with 50% Spurr’s resin in EtOH under rotation overnight. 
Infiltration was continued with 100% Spurr’s resin the next day thrice for 2 hour periods. 
With the 100% Spurr’s resin, the centrifugation was done at 800g for 20 minutes. The 
cells were then embedded in fresh Spurr’s resin in a mold and cured at 65°C for 48 hours. 
Once the resin hardened the sample block was placed in an ultramicrotome and 
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approximately 80 nm sections cut using a diamond knife. Chloroform was used to 
smoothen the sections. The sections were loaded onto copper grids and stained with 
Uranyl Acetate and Lead Citrate to increase contrast and electron density. The grids were 
then inserted into the TEM for viewing. 
 
 
5.1.5. Intracellular trafficking of LCCTLA by CLSM  
 
 To confirm that the intracellular vesicles the magnetic liposomes were observed 
in were endolysosomes, cells were stained with endolysosome specific dye (Wu et al., 
2014, Jiang et al., 2012). Briefly, 10 mL Daudi cells were cultured to a cell density of 7 x 
105 cells/mL and treated with 10 μL of placebo fluorescent CD22 targeted liposomes (as 
prepared in section 4.1.2. without any AD 198) for 1 hour. During the final 5 minutes of 
treatment, 50 nM LysoTracker® Deep Red was added to the treated cell culture. The 
media was then removed by centrifugation and the cell pellet thus obtained was washed 3 
times using 1x PBS. The final cell pellet was suspended in a single drop of Vectashield® 
cell mounting medium with DAPI. This final cell suspension was mounted onto a 
microscope slide and covered by a Fisherbrand number 1 coverslip. The slide was 
allowed to dry in a fume hood for approximately 30 minutes and the edges were sealed 
using a transparent nail polish. The nail polish was also allowed to dry in a fume hood for 
another 30 minutes after which the slide was viewed under a Nikon Eclipse E800 
confocal scanning laser microscope. The lasers were set at the wavelength for NBD-PC, 
LysoTracker® Deep Red and DAPI and images were obtained. 
 
 
5.1.6. Effect of LCCTLA on cell cycle regulatory molecules by western blot 
 
 To study the efficacy of the drug delivery system on induction of apoptosis in the 
cancer cells, the cells were treated with the LCCTLA and the expression of 4 proteins 
was monitored, Caspase 3, c-myc, p-JNK, pAKT. β-actin was used as a control to signify 
equal loading. The process has been briefly outlined below.  
 
 
 5.1.6.1.    Sample preparation. 10 mL of Daudi cells at a density of 7 x 105 cells 
/ml were treated with 1 μM of LCCTLA at three separate time points, 2, 4 and 6 hours. 
The control was the same density and volume of cells but without any drug treatment. At 
the end of the treatment, cells were centrifuged in a Thermo Scientific Sorvall Legend X1 
centrifuge at 100g for 4 minutes at 4°C. The pellet obtained was washed with 1x PBS 
thrice and then suspended in 70 μL whole cell lysis buffer [Tris HCl 50mM, NaCl 
(sodium chloride) 150 mM, Triton X-100 1%, SDS 0.1%, EDTA (ethylene diamine tetra 
acetic acid) 5mM, Na2HPO4 (disodium phosphate) 30 mM, NaF (sodium fluoride) 50 
mM, NaVO4 (sodium orthovandate) 0.5 mM, PMSF (phenylmethylsulfonylfluoride) 
2mM and protease inhibitor at 1 μL/106 cells]. This cell suspension was sonicated using 
a Virtis Virsonic® Ultrasonic Cell Disrupter. The samples were sonicated thrice for 5 
seconds each with 5 minute intervals. During the intervals, the cell debris suspension was 
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placed on ice. The cell debris suspension was then centrifuged at 1000 rpm at 4°C for 10 
minutes and the supernatant collected. The pellet obtained was discarded.  
 
 
 5.1.6.2.    Polyacrylamide gel electrophoresis (PAGE). The protein content in 
the supernatant collected was quantified using the microplate BCA (bicinchoninic acid) 
protein assay. A volume of protein was calculated such that all samples had an equal 
concentration of protein. These whole cell protein samples were then mixed with an equal 
volume of 2x Laemmli sample buffer and boiled for 5 minutes. Samples were then cooled 
to room temperature (RT) for 3 minutes and loaded onto a 4-15% polyacrylamide gel of 
50 μL well capacity. The buffer reservoir was filled up with electrode running buffer 
(composition in Appendix) to the given mark. The electrodes were connected to a Bio-
Rad power pack and samples were electrophoresed at 100V for approximately one hour 
(until the Laemmli sample dye reached near the bottom of the gel).  
 
 
 5.1.6.3.    Blotting. The gel was then loaded onto a transfer cassette to transfer the 
protein bands onto a PVDF membrane. The sized membrane was first soaked in 100% 
methanol followed by transfer buffer (composition in Appendix). It was then placed over 
the gel in the cassette and the transfer apparatus set up. A stir bar was placed at the 
bottom of the buffer reservoir along with a freezer pack. Transfer buffer was then poured 
into the reservoir to a level such that the freezer pack was fully submerged and also 
covered the cassette completely. The electrodes were connected to a Bio-Rad power pack 
and transfer was done at 100V for one hour.  
 
 
 5.1.6.4.    Primary and secondary antibody probing. Once the bands were 
transferred to the membrane, the membrane is blocked using either 5% powdered milk or 
5% BSA (bovine serum albumin) in TBST (Tris buffered saline and Tween® 20) 
(composition in Appendix). The blocking was done at RT for 1 hour on a shaker. After 
the blocking was complete, excess milk or BSA was washed off the membrane with 
TBST (a quick wash) and the primary antibody for a specific protein was added at a 
dilution of 1:1000 (only β-actin 1:40,000) in TBST. The blot was incubated with the 
primary antibody for 12-15 hours at 4°C on a rocker. At the end of the incubation period, 
the excess primary antibody was washed off the membrane using TBST. The wash was 
done thrice for 5 minutes each. Then, the membrane was incubated with secondary 
antibody specific for the particular antibody used (anti-rabbit for c-myc, pJNK, pAKT 
and caspase-3 and anti-mouse for β-actin) at a dilution of 1:25000 for 1 hour at RT. The 
excess secondary antibody was then washed off the membrane using TBST thrice for 15 
minutes each.  
 
 
 5.1.6.5.    Analysis. Once the secondary antibody was probed onto the membrane, 
the substrate (hydrogen peroxide+ luminol) was added and briefly incubated for 1-2 
minutes. The membrane was then loaded onto an x-ray film cassette and covered with a 
fresh x-ray film. This film was then developed and the results recorded.   
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 5.1.6.6.    Membrane stripping. The membrane was reused for probing another 
protein with another antibody. For this, the previous antibody was removed by a process 
called stripping and was done by a stripping buffer (composition in Appendix). The 
membrane already bound with the primary and secondary antibody was incubated with 
the stripping buffer for 5 minutes at 45°C following which it was washed with TBST and 
was reused for probing the next protein starting at step number 5.1.6.4.  
 
 
5.2. Results and Discussion 
 
 
5.2.1. Cellular association 
 
 Figure 5.1 shows the results for the cellular association studies. It was observed 
that the LCCTLA uptake in Daudi cells was significantly reduced when the uptake study 
was being performed at 4°C compared to when it was done at 37°C. As we already know 
receptor mediated endocytosis is a specific process that requires ATP for appropriate 
functioning and is also temperature dependent (with optimum temperature being 37°C). It 
may be possible that the reduced uptake in the 4°C study group was due to the uptake 
mechanism for the LCCTLA being receptor mediated endocytosis. Since the mechanism 
is greatly reduced and even possible halted, the uptake seen may be a result of the 
receptor associated LCCTLA being internalized before the washes were done. This result 
suggests that the mechanism of uptake of LCCTLA into CD22 expressing Daudi cells is 
receptor mediated endocytosis.  
 
 
5.2.2. LCCTLA particles are endocytosed into cells by a clathrin- and caveolae-
independent pathway 
 
 Figure 5.2 shows the results for LCCTLA uptake under the effect of inhibitors for 
certain specific pathways. The control data is for uptake results under no inhibitor use. 
Compared to the control, the other pathways that were inhibited, macropinocytosis, 
caveolae mediated internalization or clathrin mediated internalization, LCCTLA uptake 
seems to have somewhat increased if not significantly. These results suggest that none of 
these pathways is the mechanism for uptake of LCCTLA in CD22 expressing Daudi 
cells, which in turn suggests that LCCTLA uptake could be via the fourth pathway which 
is independent of clathrin or caveolin proteins and that the uptake of LCCTLA was not 
affected in the presence of these inhibitors because its uptake was not dependent on those 
pathways (Kou et al., 2013). This complete mechanism for this pathway is not yet 
currently understood especially the late stage of vesicle formation.  
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Figure 5.1. Cell association of LCCTLA in Daudi cells (n=3) 
 
Notes. It was observed that the LCCTLA uptake in Daudi cells was significantly reduced 
when the uptake study was being performed at 4°C compared to when it was done at 
37°C (p<0.05). As we already know receptor mediated endocytosis is a specific process 
that requires ATP for appropriate functioning and is also temperature dependent (with 
optimum temperature being 37°C). It may be possible that the reduced uptake in the 4°C 
study group was due to the uptake mechanism for the LCCTLA being receptor mediated 
endocytosis. Since the mechanism is greatly reduced and even possible halted, the uptake 
seen may be a result of the receptor associated LCCTLA being internalized before the 
washes were done. This result suggests that the mechanism of uptake of LCCTLA into 
CD22 expressing Daudi cells is receptor mediated endocytosis. Error bars represent 
standard deviation around the mean.  
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Figure 5.2. LCCTLA uptake in Daudi cells under different inhibitors (n=3) 
 
Notes. The control data is for uptake results under no inhibitor use. Compared to the 
control, the other pathways that were inhibited, macropinocytosis, caveolae mediated 
internalization or clathrin mediated internalization, LCCTLA uptake seems to have 
somewhat increased if not significantly. These results suggest that none of these 
pathways is the mechanism for uptake of LCCTLA in CD22 expressing Daudi cells, 
which in turn suggests that LCCTLA uptake could be via the fourth pathway which is 
independent of clathrin or caveolin proteins and that the uptake of LCCTLA was not 
affected in the presence of these inhibitors because its uptake was not dependent on those 
pathways (Kou et al., 2013). This complete mechanism for this pathway is not yet 
currently understood especially the late stage of vesicle formation. Error bars represent 
standard deviation around the mean.  
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5.2.3. LCCTLA nanoparticles were localized intracellularly in endosomes 
 
 Figures 5.3 shows a whole Daudi cell image acquired by TEM post-MLCCTLA 
treatment. Two parts of the image have been enlarged in Figures 5.4 and 5.5. As in 
Figure 5.4 an MLV inside an endocytotic vesicle can be observed. The size of each of 
the three dark structures inside the vesicle are approximately 70 nm in diameter, 
indicating that these are the SUV’s inside the outer, larger MLV. In Figure 5.5 another 
endocytotic vesicle carrying SUV’s was observed. These SUV’s are approximately 50 
nm in diameter. The size of these vesicles correspond with the size of the MLCCTLA 
(data not shown here). This data confirms that the intracellular localization of the 
MLCCTLA is in endosomes. Later, these endosomes must fuse with lysosomes to form 
endolysosomes to release AD 198. 
 
 
5.2.4. The endosomes fuse with lysosomes to give endolysosomes 
 
 Figure 5.6 shows the images for the study to determine if the endosome in which 
the LCCTLA were localized were endolysosomes. The cells shown here are Daudi cells 
treated with 10 μL of placebo LCCTLA and LysoTracker® Deep Red (a dye that binds to 
late endolysosomes). After washing off the excess LCCTLA, the images showed red 
circular structures inside the Daudi cells (white arrows). Since the dye for tagging the 
endolysosomes was red, it was deduced that these circular red structures were the 
endolysosomes. The liposomes were processed with NBD-PC, a fluorescent green lipid, 
which also show up in the images as bright green (green arrows). When these two images 
were overlaid, it was observed that the endolysosomes and the LCCTLA were co-
localized inside the cells (yellow arrows). This establishes that the LCCTLA were 
intracellularly localized in endosomes (as from Figures 5.4 and 5.5) and these endosomes 
were later fusing with the lysosomes to give endolysosomes (Figures 5.6) 
 
 
5.2.5. LCCTLA activates classical apoptotic pathways 
 
 With LCCTLA treatment in Daudi cells, it was observed that expression of 
oncogenic markers decreased and apoptotic markers increased. Figure 5.7A shows the 
proteins that were affected along with their functions and Figure 5.7B gives a 
comparison of their expressions with the control. C-myc is a marker for Burkitt’s 
lymphoma and is a regulator gene that codes for a transcription factor (Finver et al., 
1988). The protein is multi-functional playing roles in apoptotic inhibition and cell cycle 
progression. Treatment with LCCTLA reduced the expression of c-myc in a time 
dependent manner as shown in Figure 5.7B.  
 
 LCCTLA, once internalized is believed to release drug due to pH reduction in the 
endolysosomes. The intracellularly released AD 198 binds to PKC holoenzyme. Later the 
catalytic segment (CS) dissociates. The CS activates PLS3 which depolarizes the 
mitochondria releasing Cyt C. The Cyt C activates caspase 3. Caspase 3 being an 
apoptotic protein eventually results in apoptosis (He et al., 2005). Thus, we see a time  
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Figure 5.3. TEM image of LCCTLA intracellular localization in Daudi cells 
 
Notes. Refer to section 5.2.4 for a detailed description.  
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Figure 5.4. Enlarged from Figure 5.3 showing an MLV of MLCCTLA inside an 
endosomal structure 
 
Notes. Refer to section 5.2.4 for a detailed description.  
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Figure 5.5. Enlarged from Figure 5.3 showing SUV’s of MLCCTLA inside an 
endosomal structure 
 
Notes. Refer to section 5.2.4 for a detailed description.  
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Figure 5.6. CLSM image of intracellular localization of LCCTLA in 
endolysosomes 
 
Notes. Refer to section 5.2.5 for a detailed description.  
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Figure 5.7. Effect of LCCTLA particles on expression of hallmark apoptotic and 
oncogenic proteins 
 
Notes. (A) Effect of LCCTLA on expression of caspase-3, pAKT, c-myc and pJNK, and 
(B) Western blot results for the expression patterns post LCCTLA treatment for 3 time 
points, 2, 4 and 6 hours. Refer to section 5.2.6 for a detailed description of the result.   
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dependent increase in the concentration of caspase 3 as depicted in Figure 5.7B, which is 
a hallmark of cell death via apoptosis. There is a possibility for AD 198 to activate 
caspase-3 by other pathways but these are not well understood yet.  
 
 Protein kinase B also known as Akt is a serine threonine specific protein kinase 
which plays a key role in multiple process in the cell such as cell proliferation, 
transcription and apoptosis. It is capable of initiating cell survival via growth factor 
dependent and independent pathways (Nicholson and Anderson, 2002). Phosphorylated 
Akt is the activated form of Akt which is necessary for it to activate or deactivate its 
substrates (Sarbassov et al., 2005, Edwards et al., 2013). In Figure 5.7B, we can see the 
expression of pAKT going down in a time dependent manner compared to the control 
which means that LCCTLA also inhibited cell proliferation via suppression of pAKT.  
 
 JNK’s or c-Jun N-terminal kinases are master protein kinases that regulate many 
processes in the cell such as inflammation, cell proliferation and differentiation and 
apoptosis. They belong to the mitogen-activated protein kinase family. Their active role 
in cancer development is now well-established (Bubici and Papa, 2014). JNK is activated 
by phosphorylation (pJNK). pJNK in turn phosphorylates multiple protein depending on 
its isoform. Figure 5.7B shows a time dependent suppression of pJNK by treatment of 
Daudi cells with LCCTLA, thus proving that cell proliferation is also inhibited by 
suppression of pJNK. 
 
 
5.3. Summary and Conclusions 
 
 Studies to verify the in vitro pathways undertaken and mechanisms employed by 
the LCCTLA to enter, release drug and eradicate the malignant cells were performed. It 
was observed that the uptake pathway of LCCTLA was primarily energy dependent. 
However, the known mechanisms of uptake such as the clathrin or caveolin dependent 
pathways were possibly not the pathways for uptake of the LCCTLA. Results suggest a 
relatively newer method for uptake called the clathrin- and caveolae-independent 
pathway. This pathway functioned independently of the proteins required for the 
conventional endocytotic pathways. Little is currently known about this pathway. What is 
known is that this pathway works by recruiting proteins such as Arf6, Cdc42, Rhoa and 
dynamin.  
 
 The intracellular localization of LCCTLA was determined by CLSM and TEM. 
By TEM we established that the LCCTLA were located in endosomes. However, using 
LysoTracker® deep red under the CLSM, it was understood that the endosomes were 
more specifically endolysosomes. Once the liposomes were intracellularly located in the 
endolysosomes, the low pH would break down the bilayer formation of the LCCTLA, 
releasing the AD 198 load.  
 
 The expression of specific proteins in the cells are markers for specific processes 
and pathways proceeding in the cell. Expression profiles of proteins engaged in processes 
such as apoptosis and cell proliferation were successfully monitored. Post-LCCTLA 
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treatment in Daudi cells, caspase-3 expression, an apoptotic protein, increased in a time 
dependent manner. Conversely, the expression of certain proteins which aid in cell 
proliferation, such as c-myc, pJNK and pAKT was significantly lowered.  
 
 These results suggest that CD22 targeted drug delivery system is successfully 
delivering the AD 198 cargo inside the malignant cells. The uptake mechanism works 
differently from the well documented pathways but efficiently delivers LCCTLA inside 
the cells. The drug is released due to the fusion of endosomes with the lysosomes and 
works well in comparison with the free AD 198 solution drug (Edwards et al., 2013).  
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CHAPTER 6.    LYOPHILIZATION OF LCCTLA TO ENHANCE LONG TERM 
STABILITY  
 
 
 Results from studies conducted earlier in this dissertation have shown the 
potential efficacy and specificity of LCCTLA in the treatment of B cell malignancies. 
However, one of the limitations in using dispersed liposomal systems for therapeutic 
purposes is their physical instability due to aggregation, particle fusion and drug leakage 
from the bilayer (van Winden, 2003) when they are in the dispersed liquid form. This 
instability is because of non-elastic collisions and the fluid behavior of the lipid bilayer 
resulting in drug leakage from the particles.  
 
 One of the ways to address this limitation is to remove the water from the 
nanoparticulate dispersion which limits both the Brownian motion nanoparticles in the 
dispersion and the fluidity of the lipid bilayer. However, water constitutes an essential 
component of the liposome superstructure. If removed it could result in collapse of the 
liposome structure. Therefore certain additives need to be added to the liposomal 
dispersion to ensure that the removal of water does not negatively impact the stability of 
the dispersion (Abdelwahed et al., 2006b).  
 
 Removal of water to prolong the stability of the dispersion can be done by a 
process known as lyophilization. Removal of water is achieved by freezing the dispersion 
and subliming away the ice by exposing the frozen dispersion to a relatively lower partial 
pressure of water vapor. This process exerts stresses on the nanoparticulate dispersion 
especially the stress of freezing and dehydration. Stress from freezing is due to the 
crystallization of ice which causes separation of phases into ice and the cryo-concentrated 
phase (composed of the nanoparticles and other components such as buffering salts). This 
greatly increases the tonicity of the cryo-concentrated phase which may potentially 
impact the formulation negatively (Abdelwahed et al., 2006b, Abdelwahed et al., 2006a). 
Stress from drying is due to the fact that water interacts with the hydrophilic phosphate 
head groups which plays a key role in the formation of liposomes. Removal of this water 
will result in a complete collapse of the system (van Winden, 2003). Although 
rehydration with water may result in the reformation of the vesicles, yet the complete 
process could increase drug leakage. To address this issue, lyo and cryoprotectants are 
utilized to reduce or eliminate the stresses due to freezing (cryoprotectants) and drying 
(lyoprotectant).  
 
 As water freezes, the cryo-concentrated phase gets pushed into smaller and 
smaller pockets as the ice crystals get larger. Cryoprotectants function by dissolving and 
lowering the melting point of water. This process is known as vitrification. By allowing 
salts and other molecules to remain undisturbed in their natural locations, vitrification 
avoids the damage caused by freezing.  Cryoprotectants increase the size of the pockets 
of the cryo-concentrated phase to an extent that damage due to phase separation becomes 
negligible.  
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 Lyoprotectants on the other hand work by the theory of replacement. As specified, 
the hydrophilic phosphate head groups require water to maintain the liposomal structure 
and removal of water could cause them to collapse. Non-reactive disaccharides such as 
sucrose function as lyoprotectants. It is hypothesized that the sugar molecules form 
hydrogen bonds with the polar head groups during the drying process (Abdelwahed et al., 
2006b). Therefore it is assumed that the sugar molecules serve as substitutes for water. 
Inclusion of lyoprotectant can form an amorphous matrix around the vesicles and protect 
the vesicles from fusion and prevent rupture of the vesicles due to crystallization of ice 
(Koster et al., 1994). 
 
 Trehalose is another disaccharide that is widely used as a lyoprotectant for the 
stabilization of liposomes (Crowe et al., 1984, Crowe et al., 1985). In preliminary studies 
performed, trehalose did not show a significant difference from sucrose for AD 198 
retention or particle size and charge maintenance (data not presented in the present text). 
Sucrose in effect gave marginally better results compared to trehalose. This may be 
attributed to the fact that trehalose demonstrates crystallization during the dehydration 
process which may contribute to some degree of vesicle rupture (Sundaramurthi and 
Suryanarayanan, 2009). In the following sections, studies performed to determine the 
appropriate concentration of sucrose required to efficiently stabilize lyophilized 
liposomes is discussed. Also presented are results for a stability comparison of 
lyophilized LCCTLA and dispersed LCCTLA.  
 
 
6.1. Materials and Methods 
 
 
6.1.1. Materials  
 
 Ultrapure sucrose was purchased from Thermo Fisher Scientific, Waltham, MA, 
USA and T-Zero aluminum pans were purchased from TA Instruments, New Castle, DE, 
USA. 
 
 
6.1.2. Determination of Tg 
 
 The Tg of maximally freeze concentrated amorphous phase of mixture of 
liposomes and sucrose was determined by DSC. About 10-20 μL of the liposome mixture 
prior to lyophilization was placed in T-Zero aluminum pans and hermetically sealed. An 
empty pan prepared in a similar manner was used as reference. The samples were 
equilibrated at 25°C and then cooled at 5°C/min to -70°C. After equilibration, the 
samples were heated at the rate of 10°C/min to 25°C. 
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6.1.3. Preparation of lyophilized LCCTLA (Lyo-LCCTLA)  
 
 The liposomes were prepared in the same method as previously specified in 
Chapter 2 section 2.1.2. However, for including lyoprotectants in the hydrophilic core of 
the liposome, sucrose was dissolved in the 1x PBS that was used for hydrating the dry 
lipid film. The lyoprotectant for the external phase was added after conjugation of the 
Fab’ and removal of unconjugated fragments. Volume was made up to the batch size (if 
necessary) after all the sucrose was dissolved.  
 
 
6.1.4. Lyophilization formulation optimization 
 
 500 μL’s of the final LCCTLA along with the dissolved sucrose was loaded into 2 
mL pharmaceutical amber glass vials. The vials were appropriately labelled and covered 
with lyophilization rubber closures. The rubber closures had a small vent that remained 
open during lyophilization for water vapor to be extracted. The vials were then loaded 
into the lyophilizer (Virtis Advantage 2.0) and the cycle was started. The cycle was as 
follows: Thermal treatment included ramping the temperature down to -45°C over a 
period of 180 minutes. The samples were then held at -45°C for 240 minutes to make 
sure the sample was frozen evenly throughout. Following this the drying phase was 
started. The drying was divided into two phases; the primary drying phase and the 
secondary drying phase. For the primary drying phase the temperature was ramped up 
from -45°C to -35°C in 30 minutes. The vacuum was pulled down to 100 mTorr 
(millitorr). This condition was maintained for 720 minutes to aid maximum drying. 
Following this the secondary drying was started where the temperature was ramped up to 
10°C over a period of two hours. Vacuum was maintained at 100 mTorr. This condition 
was maintained for 240 minutes. The end of secondary drying completed the 
lyophilization cycle and samples were overlaid with ultrapure nitrogen and crimp sealed 
with flip-off caps. The formulations containing the various lipid:sucrose ratios were then 
examined for their moisture content, drug retention, particle size and ζ-potential.  
 
 To determine AD 198 retention, lyophilized LCCTLA were reconstituted with 
500 μL of HPLC grade water and free AD 198 removed by gel chromatography using 
G25 sephadex gel. Samples were prepared and the AD 198 content in the eluate was 
determined by HPLC as specified in Chapter 2, determination of encapsulated AD 198. 
The gel chromatography eluate was also used to determine the size and ζ-potential. 
Moisture content of the lyophilized LCCTLA cake was determined by Karl Fischer 
titration (Scholz, 1984).  
 
 
6.1.5. Retention of Fab´ activity post-lyophilization 
 
 Lyophilization is a process that exerts stress on the weaker molecular bonds of 
certain molecules such as hydrogen bonding in proteins. Thus it is important to confirm 
the activity of an antibody post-lyophilization. Cellular uptake studies in Daudi cells were 
performed to confirm the activity of the Fab´ in the LCCTLA and compared to the uptake 
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of non-lyophilized dispersed LCCTLA. The protocol followed was the same as in 4.1.2, 
cellular uptake of LCLA and LCCTLA by flow cytometry.  
 
 
6.1.6. Stability study  
 
 A four week stability study was conducted on the lyophilized samples and 
compared with liquid liposomal dispersion samples. Lyo-LCCTLA samples were 
prepared in the procedure described above. Liquid liposomal dispersion stability samples 
were prepared in the same method as used for preparing LCCTLA. The liquid samples 
were also loaded into the same vials and sealed using the same container closure system 
used for preparing Lyo-LCCTLA samples for stability. Both formulations were tested for 
stability at two temperatures, 5°C ± 3°C, and 25°C ± 3°C. Each formulation was tested at 
5 time points; 0, 7, 14, 21 and 31 days (1 month). Parameters tested at each time point 
were drug retention, liposome size and ζ-potential. Moisture content was tested twice, 
once at 0 time and once at 31 days.  
 
 
6.2. Results and Discussion 
 
 
6.2.1. The Tg values for sucrose-LCCTLA formulation increased with an increase 
in sucrose concentration 
 
 The lyophilization cycle was designed based on the Tg of the liposome sucrose 
mixtures as determined by DSC. The heating profiles for mixtures of liposomes 
containing increasing concentrations of sucrose is shown in Figure 6.1. The Tg of these 
mixtures containing 2x to 8x sucrose of the total lipid content was between -34 and -
39°C. Consequently, for the lyophilization cycle, the liposome sucrose mixtures were 
frozen to -45°C and held for 240 minutes and the rest of the drying cycle begun as stated 
earlier.  
 
 
6.2.2. 8x sucrose proved to be optimum for lyo-LCCTLA 
 
 At the selected parameters for the lyophilization cycle (Figure 6.2), the results for 
the optimization of sucrose concentration are presented in Figure 6.3. The sucrose 
concentration for the internal core of the liposome was observed to be optimum at 
approximately 84 mM or 67 mg/mL (results not presented in the study). Keeping the 
internal sucrose concentration constant at 84 mM, the external sucrose concentration was 
increased such that the total sucrose concentration was between 2x and 8x of the total 
lipid concentration. The control for the study was a formulation with no sucrose (internal 
and external). It was observed that as the sucrose concentration was increased from 0x to 
8x, the AD 198 retention post lyophilization increased from 23% to 98%. There was 
almost a direct correlation between the sucrose concentration and drug retention. Size and 
ζ-potential conversely were not significantly affected beyond 2x sucrose concentration.  
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Figure 6.1. Effect of sucrose concentration on Tg 
 
Notes. The Tg of these mixtures containing 2x to 8x sucrose of the total lipid content was 
between -34 and -39°C. Consequently, for the lyophilization cycle, the liposome sucrose 
mixtures were frozen to -45°C and held for 240 minutes and the rest of the drying cycle 
begun as stated earlier.  
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Figure 6.2. Phases of a lyophilization cycle for LCCTLA 
 
Notes. The temperature was reduced to -45°C over a period of 180 minutes. The samples 
were then held at -45°C for 240 minutes to make sure the sample was frozen evenly 
throughout (freezing phase in blue). Following this the drying phase was started. The 
drying was divided into two phases; the primary drying phase (green phase) and the 
secondary drying phase (red phase). For the primary drying phase the temperature was 
ramped up from -45°C to -35°C in 30 minutes. This temperature was maintained for 720 
minutes to aid maximum drying. Following this the secondary drying was started where 
the temperature was ramped up to 10°C over a period of two hours. This temperature was 
maintained for 240 minutes.  
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Figure 6.3. Effect of increasing sucrose concentration on post-lyophilization size 
and drug retention (n=3) 
 
Notes. The sucrose concentration for the internal core of the liposome was observed to be 
optimum at approximately 84 mM or 67 mg/mL (results not presented in the study). 
Keeping the internal sucrose concentration constant at 84 mM, the external sucrose 
concentration was increased such that the total sucrose concentration was between 2x and 
8x of the total lipid concentration. The control for the study was a formulation with no 
sucrose (internal and external). It was observed that as the sucrose concentration was 
increased from 0x to 8x, the AD 198 retention post lyophilization increased from 23% to 
98%. There was almost a direct correlation between the sucrose concentration and drug 
retention. Size and ζ-potential conversely were not significantly affected beyond 2x 
sucrose concentration. The size also decreased at the 6x and 8x concentration of sucrose. 
Error bars represent standard deviation around the mean. This study gives the impression 
that 8x sucrose concentration was optimum for lyophilization of LCCTLA to retain AD 
198 in the lipid bilayer and also preserve the size and charge of the liposomes.  
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The size also decreased at the 6x and 8x concentration of sucrose. This study gives the 
impression that 8x sucrose concentration was optimum for lyophilization of LCCTLA to 
retain AD 198 in the lipid bilayer and also preserve the size and charge of the liposomes. 
 
 Moisture content is a critical parameter to maintain the stability of lyophilized 
drug products.  As per the US FDA (United States Food and Drug Administration), the 
residual moisture content in a lyophilized product with protein must be between less than 
1% to 5% (FDA, 1990). The moisture content for the lyo-LCCTLA was approximately 
1.48% immediately after lyophilization.  
 
 
6.2.3. Activity of Fab´ was retained post-lyophilization 
 
 Activity of the anti-CD22 Fab´ was confirmed by cellular uptake studies in Daudi 
cells to ensure that the targeting ligand was behaving in the same manner after 
lyophilization compared to the un-lyophilized product. The result is represented in 
Figure 6.4. By cell cytometry, it was observed that the cellular uptake of the lyo-
LCCTLA was not significantly different compared to uptake by un-lyophilized 
LCCTLA.  
 
 
6.2.4. Lyo-LCCTLA are more stable than liquid LCCTLA for one month  
 
 A stability comparison was done between the Lyo-LCCTLA and liquid LCCTLA 
at two temperatures, 5°C and 25°C. The results in Figure 6.5 represent the % AD 198 
retention on every stability time point. It was observed that the Lyo-LCCTLA were most 
stable at 5°C compared to other temperatures and other formulations. Lyophilized 
formulation performed far better at both temperatures (5°C and 25°C) compared to the 
liquid LCCTLA formulation. On day 28 of the study, Lyo-LCCTLA had a 102% AD 198 
retention at 5°C and 96% at 25°C, whereas the liquid LCCTLA formulation had a 69% 
AD 198 retention at 5°C and 55% at 25°C. Size and ζ-potential were not affected for both 
formulations stored at either temperature. The liquid formulations were additionally 
stored in an inverted position, to maximize the container closure interaction, for the 14 
day and 28 day time point. These inverted samples also did not show a significantly 
different AD 198 retention or liposomal size and ζ-potential compared to the upright 
samples of the same formulation at the same temperature. Moisture content on day 0 was 
1.48% whereas at 5°C and 25°C on day 28 it was 1.08% and 1.34%.  
 
 These results suggest that the lyophilized liposomal formulations are more stable 
compared to liquid liposomal formulations. One possible justification for this may be that 
the lipids tend to get oxidized in the presence of water as explained by Winden et al (van 
Winden, 2003). Once the water was removed (almost completely) by lyophilization, the 
potential for degradation by oxidation was reduced.  
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Figure 6.4. Fab´ activity before and after lyophilization (n=3) 
 
Notes. The cellular uptake of the lyo-LCCTLA was not significantly different compared 
to uptake by un-lyophilized LCCTLA (p<0.05).  Error bars represent standard deviation 
around the mean.  
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Figure 6.5. LCCTLA stability comparison for liquid and lyophilized formulations 
at 5°C and 25°C (n=3) 
 
Notes. The Lyo-LCCTLA were most stable at 5°C compared to other temperatures and 
other formulations. Lyophilized formulation performed far better at both temperatures 
(5°C and 25°C) compared to the liquid LCCTLA formulation. On day 28 of the study, 
Lyo-LCCTLA had a 102% AD 198 retention at 5°C and 96% at 25°C, whereas the liquid 
LCCTLA formulation had a 69% AD 198 retention at 5°C and 55% at 25°C. Size and ζ-
potential were not affected for both formulations stored at either temperature. The liquid 
formulations were additionally stored in an inverted position, to maximize the container 
closure interaction, for the 14 day and 28 day time point. These inverted samples also did 
not show a significantly different AD 198 retention or liposomal size and ζ-potential 
compared to the upright samples of the same formulation at the same temperature. 
Moisture content on day 0 was 1.48% whereas at 5°C and 25°C on day 28 it was 1.08% 
and 1.34%. These results suggest that the lyophilized liposomal formulations are more 
stable compared to liquid liposomal formulations. One possible justification for this may 
be that the lipids tend to get oxidized in the presence of water as explained by Winden et 
al (van Winden, 2003). Once the water was removed (almost completely) by 
lyophilization, the potential for degradation by oxidation was reduced. Error bars 
represent standard deviation around the mean. 
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6.3. Summary and Conclusions 
 
 Liposomes for lyophilization were successfully processed by including the 
appropriate amount of sucrose in the aqueous core of the LCCTLA and in the external 
phase. Based on the results for the thermal analysis of the sucrose liposome mixtures, the 
optimum freezing temperature was determined to be -45°C. Thus the liposomes were 
frozen at -45°C. The lyophilization cycle is depicted in Figure 6.2. A sucrose 
concentration of 8 times the lipid concentration was determined to be optimum. Of the 8x 
sugar concentration 84 mM or approximately 67 mg/mL sucrose was optimum for the 
internal aqueous core. Post-lyophilization, the moisture content was determined to be 
approximately 1.48%, which was within the acceptable limits as specified by the FDA 
(FDA, 1990). Activity of the anti-CD22 Fab´ was retained post lyophilization which was 
determined by a comparable cellular uptake of the LCCTLA in Daudi cells before and 
after lyophilization.  
 
 Stability studies of the liquid and lyophilized formulation concluded that 
lyophilized liposomes were evidently more stable compared to the liquid dispersed 
formulations. This lead to the conclusion that while water is an integral part of the 
liposomal structure, its presence was detrimental to their long term stability. Thus, it is 
necessary to store these formulations in the dehydrated form. Also they must be stored at 
5°C to avoid degradation of the drug substance in the formulations.  
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CHAPTER 7.    SUMMARY AND CONCLUSIONS 
 
 
 B cell malignancies are a serious health concern killing almost 44,000 people in 
the United States every year. CHOP is the standard of therapy. DOX is a part of CHOP 
therapy that displays dose related cardiotoxicity which is one of the reasons many 
patients need to opt out of CHOP. AD 198 is an analogue of DOX which is superior to 
DOX in murine cancer models and has novel biochemical pathways and pharmacological 
properties. One of the common drawbacks of chemotherapeutic agents is depletion of the 
healthy population of neutrophils and thrombocytes. This is also displayed by AD 198. 
Cytopenias are mainly due to non-specific interactions of the drug with healthy cells of 
the body. Thus, a targeted long circulating AD 198 loaded drug delivery system that 
would impart specificity to the drug action and reduce adverse effects was sought. 
Nanotechnology has been actively pursued as a means of providing alternative drug 
delivery systems for disease targeted therapy. Liposomes, a specific type of nanoparticle 
comprising of lipid bilayers turned out to be an attractive option due to its biocompatible 
nature of excipients and its ability to accommodate drugs of a wide range of physico-
chemical characteristics. In addition, an active targeting approach could be applied to 
liposomes which offer a wide repertoire of surface modification options to choose from. 
A targeting ligand such as an antibody could be conjugated to a specific functional group 
built into the liposomal structure. The main objective of this dissertation work was to 
design, develop, characterize and test long circulating AD 198 loaded targeted liposomes 
that would be cytotoxic specifically to malignant B cells.  
 
 A prototype formulation of AD 198 loaded liposomes (LCLA) was developed that 
would be able to encapsulate maximum AD 198 and have optimum parameters for 
effective delivery of the encapsulated drug. The optimized composition of LCLA was as 
follows. HSPC was the lipid of choice and was used at 75 mole %, mPEG2000-DSPE 2 
mole %, cholesterol 10 mole % and AD 198 2 mg/mL. The physicochemical parameters 
of the optimized formulation were as follows; size 115-145 nm, ζ-potential -8 to -15 mV, 
AD 198 encapsulation 1000-1500 μg/mL and dissolution of not more than 30% AD 198 
occurred for 72 hours. The size of the LCLA as per TEM was found be in the range of 
80-90 nm. TEM micrographs indicated a roughly spherical morphology of the liposomes. 
It was calculated that the number of HSPC molecules per liposome were approximately 
117,196 and the number of AD 198 molecules were approximately 3790 per liposome.  
 
 To achieve an active targeting approach it was necessary to conjugate a ligand for 
a specific receptor on the surface of the malignant B cells. For this purpose, CD22 was 
selected as the receptor to be targeted on the malignant B cells. CD22 was selected due to 
its property of receptor mediated endocytosis upon interaction with the ligand and also 
because it was overexpressed on malignant B cells. The anti-CD22 monoclonal antibody, 
RFB4, was selected as the targeting ligand. Since earlier studies by other research groups 
had proven that the circulating half-life of targeted liposomal systems was higher if 
targeted using just the Fab´ conjugated to the liposomes rather than the whole antibody, 
only the anti-CD22 Fab´ conjugation was optimized. Numerous methods for conjugating 
a ligand to the liposome exist. The one selected for conjugating the anti-CD22 Fab´ to the 
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LCLA was with the thioether bond. The reason for selecting this strategy was its 
minimum use of harsh reagents and provision of a strong covalent chemical bond 
ensuring stability of the targeted liposomal system. Proof of conjugation by the thioether 
bonding was provided by a western blot of the targeted liposomes which evidently 
portrayed a band at the 50 kD region which is be the molecular weight of the anti-CD22 
Fab´. It was calculated that every liposome displayed an average of approximately 13 
anti-CD22 Fab´ molecules.  
 
 Whether or not the 13 anti-CD22 Fab´ molecules were sufficient to effectively 
target and deliver the liposomal AD 198 to the malignant B cells was determined by 
testing the long-circulating CD22 targeted liposomal AD 198 (LCCTLA), in vitro in 
CD22 overexpressing Daudi cells and comparing this result with non-CD22 expressing 
Jurkat cells. It was seen that Daudi cells had a significantly higher uptake of the 
LCCTLA compared to Jurkat cells, which confirmed specificity of the delivery system. 
The MTT assay results for cell cytotoxicity suggested a delay in cell kill for Daudi cells 
treated with LCCTLA, but this could be explained by the method of endocytosis that they 
underwent which would take more time compared to the diffusion mechanism for LCLA 
and solution AD 198. Nevertheless, cytotoxicity by the LCCTLA in Daudi cells was 
highest for a 24 hour study. However, the results from the 48 hour study warranted 
studies in animals in which unbound drug would be cleared such that clinical settings 
could better be mimicked.  
 
 The functioning of the LCCTLA after cellular was explained by the several 
studies performed in vitro. Cellular association studies determined that the endocytotic 
mechanism was an energy dependent mechanism and it was further ascertained that the 
mechanism of endocytosis was a clathrin- and caveolin-independent pathway. This 
pathway has not been fully understood yet particularly the later stages. However, it was 
successfully determined that after endocytosis, the liposomes were localized in 
endolysosomes. This result deduced that the drug release would take place due to 
liposomal breakdown by the low lysosomal pH. Once the drug was released into the 
cytosol, it functioned via the activation of apoptotic proteins such as caspase-3 and the 
suppression of oncoproteins such as c-myc. These verifications were deduced by protein 
expression studies performed in Daudi cells post-LCCTLA treatment.  
 
 Since the long term storage of liposomes was an issue due to lipid degradation by 
oxidation, water was removed by the process of lyophilization. The lyophilization cycle 
parameters were successfully optimized and the formulations of the liposomes were also 
optimized so that they would not collapse during dehydration. It was determined that a 
lipid:sucrose ratio of 1:8 was required to retain maximum AD 198 post lyophilization. 
Via a short term stability study it was also ascertained that the lyophilized formulation 
was most stable at 5°C and was more robust than the liquid liposomal dispersions.  
 
 In conclusion, targeted drug delivery with AD 198 was more potent and specific 
compared to other untargeted formulations and the main hypothesis of the dissertation 
was accepted. Further studies in small animal models are necessary to ascertain the 
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efficacy of the system in more clinically relevant models. The stability of LCCTLA was 
improved by dehydrating them in a temperature and pressure controlled environment.  
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APPENDIX. BUFFERS FOR WESTERN BLOTTING 
 
 
1x Electrode running buffer (2L) 
 Glycine   28.8 G 
 Tris base   6.04 G 
 SDS    2.0 G 
 Water    q.s. 
 
Transfer buffer (1L) 
 Tris Base   3.03 G 
 Glycine   14.4 G 
 Methanol   200 mL 
 Water    q.s. 
 
10x TBS (Tris buffered saline) 
 Tris HCl   500 mM 
 NaCl    1500 mM 
 
1x TBST  
 10x TBS   100 mL 
 Tween 20 (10%)  10 mL 
 Water    890 mL 
 
Stripping buffer (100 mL) 
 SDS 10%   20 mL 
 Tris HCl   12.5 mL 
 β-mercaptoethanol  0.8 mL 
 Water    q.s. 
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